{"DataElement":{"publicId":"6161764","version":"1","preferredName":"Therapeutic Procedure Administered Name","preferredDefinition":"The name of the therapeutic agent administered that is intended to alter or stop a pathologic process","longName":"TRT_NAM","context":"CCTG","contextVersion":"1","DataElementConcept":{"publicId":"2763211","version":"1","preferredName":"Therapeutic Procedure Administered","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._The act of having given something (e.g., a medication or test).","longName":"THERAP_PRO_ADMST","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2512834","version":"1","preferredName":"Therapeutic Procedure","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B89860A-B9D6-3798-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-21","endDate":null,"createdBy":"UMLLOADER_AGNIS","dateCreated":"2006-08-21","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"51828FAE-F5A7-38E9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-07-08","endDate":null,"createdBy":"STURGILLJ","dateCreated":"2008-07-08","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6148599","version":"1","preferredName":"Therapeutic Procedure Name","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._The words or language units by which a thing is known.","longName":"6148599v1.0","context":"CCTG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Denosumab Prolia Xgeva","valueDescription":"Denosumab","ValueMeaning":{"publicId":"3241060","version":"1","preferredName":"Denosumab","longName":"3241060","preferredDefinition":"A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity. Denosumab specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces, resulting in inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Denosumab","conceptCode":"C61313","definition":"A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity. Denosumab specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces, resulting in inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A443510D-A108-C5AF-E040-BB89AD435D96","latestVersionIndicator":"Yes","beginDate":"2011-05-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683BBF84-4D7B-03E0-E053-F662850A5325","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Denileukin diftitox ONTAK","valueDescription":"Denileukin Diftitox","ValueMeaning":{"publicId":"2577847","version":"1","preferredName":"Denileukin Diftitox","longName":"2577847","preferredDefinition":"A cytotoxic recombinant protein consisting of interleukin-2 (IL-2) protein sequences fused to diphtheria toxin. The IL-2 protein sequence moiety of denileukin difitox directs the cytocidal action of diphtheria toxin to cells that express IL-2 receptors. After the toxin moiety is internalized into target IL-2 receptor-expressing cells, its catalytic domain catalyzes the transfer of the ADP-ribose moiety of NAD to a posttranslationally modified histidine residue of elongation factor 2 (EF-2), called diphthamine. This covalent modification inactivates EF-2 and disrupts polypeptide chain elongation, resulting in cell death. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Denileukin Diftitox","conceptCode":"C1476","definition":"A cytotoxic recombinant fusion protein consisting of the human cytokine interleukin-2 (IL-2) fused to diphtheria toxin fragments A and B, containing both the catalytic and translocation domains, with potential antineoplastic activity. Upon administration, the IL-2 moiety of denileukin difitox targets and binds to IL-2 receptors. After internalization by IL-2 receptor-expressing cells via endocytosis, denileukin difitox is proteolytically cleaved. This releases the catalytic domain of the toxin moiety, which catalyzes the transfer of the ADP-ribose moiety of NAD to a diphthamide residue of elongation factor 2 (EF-2). This covalent modification inactivates EF-2 and disrupts polypeptide chain elongation, resulting in an inhibition of translation and cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD24-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683BBF84-4D8F-03E0-E053-F662850A5325","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Degarelix Firmagon","valueDescription":"Degarelix","ValueMeaning":{"publicId":"3240855","version":"1","preferredName":"Degarelix","longName":"3240855","preferredDefinition":"A long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing testosterone production by interstitial (Leydig) cells in the testes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Degarelix","conceptCode":"C48385","definition":"A long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing testosterone production by interstitial (Leydig) cells in the testes.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A4302120-6A24-B554-E040-BB89AD4307C7","latestVersionIndicator":"Yes","beginDate":"2011-05-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-26","modifiedBy":"COOPERM","dateModified":"2019-03-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683BBF84-4DA3-03E0-E053-F662850A5325","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Decitabine, Dacogen","valueDescription":"Decitabine","ValueMeaning":{"publicId":"2577852","version":"1","preferredName":"Decitabine","longName":"2577852","preferredDefinition":"A cytidine antimetabolite analogue with potential antineoplastic activity. Decitabine incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Decitabine","conceptCode":"C981","definition":"A cytidine antimetabolite analogue with potential antineoplastic activity. Decitabine incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD29-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683BBF84-4DB7-03E0-E053-F662850A5325","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Daunorubicin Cerubidine Rubidomycin Daunomycin DNR","valueDescription":"Daunorubicin Hydrochloride","ValueMeaning":{"publicId":"6148661","version":"1","preferredName":"Daunorubicin Hydrochloride","longName":"6148661","preferredDefinition":"The hydrochloride salt of an anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin.  Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Daunorubicin Hydrochloride","conceptCode":"C1583","definition":"The hydrochloride salt of an anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin.  Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"683BBF84-4DC3-03E0-E053-F662850A5325","latestVersionIndicator":"Yes","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683BBF84-4DDC-03E0-E053-F662850A5325","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Daratumumab Darzalex","valueDescription":"Daratumumab","ValueMeaning":{"publicId":"5621727","version":"1","preferredName":"Daratumumab","longName":"5621727","preferredDefinition":"A fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. The binding of anti-CD38 monoclonal antibody to natural killer (NK) cells mimics the normal CD38-CD31 interaction on the NK cell surface. CD38 is also present on multiple myeloma (MM) cells and plasma leukemia cells; this agent may preferentially bind these cells, triggering antitumoral antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). CD38, a cell surface glycoprotein, is present on various immune cells and has been shown to regulate the cytotoxic response of activated NK cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Daratumumab","conceptCode":"C74007","definition":"A human immunoglobulin G1-kappa (IgG1k) monoclonal antibody directed against the cell surface glycoprotein CD38, with immunomodulating and antineoplastic activities. Upon administration, daratumumab targets and binds to CD38 expressed on tumor cells. This triggers direct cell killing, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cell mediated phagocytosis (ADCP) and antibody-mediated complement dependent cytotoxicity (CDC) in CD38-expressing tumor cells. In addition, binding to CD38 by daratumumab depletes CD38-expressing immunosuppressive regulatory T- and B-cells and myeloid-derived suppressor cells (MDSCs). CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AECAE5-BC32-28A7-E053-F662850AD609","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683BBF84-4DF0-03E0-E053-F662850A5325","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Dactinomycin Cosmegen Actinomycin-D","valueDescription":"Dactinomycin","ValueMeaning":{"publicId":"3378914","version":"1","preferredName":"Dactinomycin","longName":"3378914","preferredDefinition":"A chromopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces parvulus.  Dactinomycin intercalates between adjacent guanine-cytosine base pairs, blocking the transcription of DNA by RNA polymerase; it also causes single-strand DNA breaks, possibly via a free-radical intermediate or an interaction with topoisomerase II. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dactinomycin","conceptCode":"C412","definition":"A chromopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces parvulus.  Dactinomycin intercalates between adjacent guanine-cytosine base pairs, blocking the transcription of DNA by RNA polymerase; it also causes single-strand DNA breaks, possibly via a free-radical intermediate or an interaction with topoisomerase II. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9078B1E-F71D-89BB-E040-BB89AD432908","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683BBF84-4E04-03E0-E053-F662850A5325","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Dacarbazine DTIC","valueDescription":"Dacarbazine","ValueMeaning":{"publicId":"3378938","version":"1","preferredName":"Dacarbazine","longName":"3378938","preferredDefinition":"A triazene derivative with antineoplastic activity. Dacarbazine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dacarbazine","conceptCode":"C411","definition":"A triazene derivative with antineoplastic activity. Dacarbazine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B907F9D9-CD6D-F916-E040-BB89AD435222","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683BBF84-4E18-03E0-E053-F662850A5325","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Dabrafenib Tafinlar GSK211 8436","valueDescription":"Dabrafenib","ValueMeaning":{"publicId":"4539014","version":"1","preferredName":"Dabrafenib","longName":"4539014","preferredDefinition":"An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dabrafenib","conceptCode":"C82386","definition":"An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"059E8F71-D4FF-7062-E050-BB89AD435032","latestVersionIndicator":"Yes","beginDate":"2014-10-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-10-17","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683BBF84-4E2C-03E0-E053-F662850A5325","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Cyproterone acetate Androcur","valueDescription":"Cyproterone Acetate","ValueMeaning":{"publicId":"6148663","version":"1","preferredName":"Cyproterone Acetate","longName":"6148663","preferredDefinition":"The acetate salt of a synthetic steroidal antiandrogen with weak progestational and antineoplastic activities. Cyproterone binds the androgen receptor (AR), thereby preventing androgen-induced receptor activation in target tissues and inhibiting the growth of testosterone-sensitive tumor cells. This agent also exerts progestational agonist properties at the level of the pituitary that reduce luteinizing hormone (LH), resulting in reductions in testicular androgen secretion and serum testosterone levels. Treatment with cyproterone alone results in incomplete suppression of serum testosterone levels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyproterone Acetate","conceptCode":"C1059","definition":"The acetate salt of a synthetic steroidal antiandrogen with weak progestational and antineoplastic activities. Cyproterone binds the androgen receptor (AR), thereby preventing androgen-induced receptor activation in target tissues and inhibiting the growth of testosterone-sensitive tumor cells. This agent also exerts progestational agonist properties at the level of the pituitary that reduce luteinizing hormone (LH), resulting in reductions in testicular androgen secretion and serum testosterone levels. Treatment with cyproterone alone results in incomplete suppression of serum testosterone levels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"683BBF84-4E39-03E0-E053-F662850A5325","latestVersionIndicator":"Yes","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683BBF84-4E52-03E0-E053-F662850A5325","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Cyclophosphamide Cytoxan Procytox CTX endoxan Neosar","valueDescription":"Cyclophosphamide","ValueMeaning":{"publicId":"5127394","version":"1","preferredName":"Cyclophosphamide","longName":"5127394","preferredDefinition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-F9F9-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683BBF84-4E66-03E0-E053-F662850A5325","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Crizotinib Xalkori","valueDescription":"Crizotinib","ValueMeaning":{"publicId":"3377031","version":"1","preferredName":"Crizotinib","longName":"3377031","preferredDefinition":"An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Crizotinib","conceptCode":"C74061","definition":"An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B89EC9E2-49F5-54C4-E040-BB89AD432648","latestVersionIndicator":"Yes","beginDate":"2012-02-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683BBF84-4E7B-03E0-E053-F662850A5325","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"CPT-11 Camptosar Irinotecan hydrochloride","valueDescription":"Irinotecan Hydrochloride","ValueMeaning":{"publicId":"2579326","version":"1","preferredName":"Irinotecan Hydrochloride","longName":"2579326","preferredDefinition":"The hydrochloride salt of a semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata.  Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme.  One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death.  Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Irinotecan Hydrochloride","conceptCode":"C1381","definition":"The hydrochloride salt of a semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata.  Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme.  One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death.  Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-02EB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-05-18","modifiedBy":"ONEDATA","dateModified":"2006-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683BBF84-4E8F-03E0-E053-F662850A5325","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Copanlisib BAY80-6946","valueDescription":"Copanlisib","ValueMeaning":{"publicId":"5982159","version":"1","preferredName":"Copanlisib","longName":"5982159","preferredDefinition":"A phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Copanlisib","conceptCode":"C96796","definition":"A phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"59A3C36F-85B0-32C0-E053-F662850ABBC1","latestVersionIndicator":"Yes","beginDate":"2017-09-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683BBF84-4EA3-03E0-E053-F662850A5325","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Bicalutamide Casodex","valueDescription":"Bicalutamide","ValueMeaning":{"publicId":"2573403","version":"1","preferredName":"Bicalutamide","longName":"2573403","preferredDefinition":"A synthetic, nonsteroidal antiandrogen.  Bicalutamide competitively binds to cytosolic androgen receptors in target tissues, thereby inhibiting the receptor binding of androgens. This agent does not bind to most mutated forms of androgen receptors. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bicalutamide","conceptCode":"C1599","definition":"A synthetic, nonsteroidal antiandrogen.  Bicalutamide competitively binds to cytosolic androgen receptors in target tissues, thereby inhibiting the receptor binding of androgens. This agent does not bind to most mutated forms of androgen receptors. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EBC8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-11","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-4223-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Bexarotene Targretin","valueDescription":"Bexarotene","ValueMeaning":{"publicId":"2567420","version":"1","preferredName":"Bexarotene","longName":"2567420","preferredDefinition":"A synthetic retinoic acid agent with potential antineoplastic, chemopreventive, teratogenic and embryotoxic properties.  Bexarotene selectively binds to and activates retinoid X receptors (RXRs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, apoptosis of some cancer cell types, and tumor regression. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bexarotene","conceptCode":"C1635","definition":"A synthetic retinoic acid agent with potential antineoplastic, chemopreventive, teratogenic and embryotoxic properties.  Bexarotene selectively binds to and activates retinoid X receptors (RXRs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, apoptosis of some cancer cell types, and tumor regression. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D469-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"COOPERM","dateModified":"2017-12-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-4237-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Bevacizumab Avastin Rhumab VEGF","valueDescription":"Bevacizumab","ValueMeaning":{"publicId":"4916311","version":"1","preferredName":"Bevacizumab","longName":"4916311","preferredDefinition":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bevacizumab","conceptCode":"C2039","definition":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B693509-9093-B947-E050-BB89AD43520F","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ZHANGWE","dateModified":"2021-09-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-424B-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Belinostat PXD-101","valueDescription":"Belinostat","ValueMeaning":{"publicId":"3378157","version":"1","preferredName":"Belinostat","longName":"3378157","preferredDefinition":"A novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Belinostat","conceptCode":"C48812","definition":"A novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90390BA-6CDB-6B71-E040-BB89AD432BAA","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-425F-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"BCH-4556 Troxacitabine","valueDescription":"Troxacitabine","ValueMeaning":{"publicId":"6148642","version":"1","preferredName":"Troxacitabine","longName":"6148642","preferredDefinition":"A dioxolane derivative and a novel L-configuration deoxycytidine analogue with potent antineoplastic activity. When incorporated into growing chain during DNA replication, troxacitabine stops DNA polymerization due to its unnatural L-configuration, in contrast to the normal nucleotides with D-configuration. As a result, this agent terminates DNA synthesis upon incorporated into DNA molecules, and consequently interrupts tumor cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Troxacitabine","conceptCode":"C1438","definition":"A dioxolane derivative and a novel L-configuration deoxycytidine analogue with potent antineoplastic activity. When incorporated into growing chain during DNA replication, troxacitabine stops DNA polymerization due to its unnatural L-configuration, in contrast to the normal nucleotides with D-configuration. As a result, this agent terminates DNA synthesis upon incorporated into DNA molecules, and consequently interrupts tumor cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682E2DE8-426C-2546-E053-F662850A0E58","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-4285-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"BBI608","valueDescription":"Napabucasin","ValueMeaning":{"publicId":"6148644","version":"1","preferredName":"Napabucasin","longName":"6148644","preferredDefinition":"An orally available cancer cell stemness inhibitor with potential antineoplastic activity. Even though the exact target has yet to be fully elucidated, napabucasin appears to target and inhibit multiple pathways involved in cancer cell stemness. This may ultimately inhibit cancer stemness cell (CSC) growth as well as heterogeneous cancer cell growth. CSCs, self-replicating cells that are able to differentiate into heterogeneous cancer cells, appear to be responsible for the malignant growth, recurrence and resistance to conventional chemotherapies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Napabucasin","conceptCode":"C96429","definition":"An orally available cancer cell stemness inhibitor with potential antineoplastic activity. Even though the exact target has yet to be fully elucidated, napabucasin appears to target and inhibit multiple pathways involved in cancer cell stemness. This may ultimately inhibit cancer stemness cell (CSC) growth as well as heterogeneous cancer cell growth. CSCs, self-replicating cells that are able to differentiate into heterogeneous cancer cells, appear to be responsible for the malignant growth, recurrence and resistance to conventional chemotherapies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682E2DE8-4292-2546-E053-F662850A0E58","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-42AB-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"BBI503","valueDescription":"Cancer Stemness Kinase Inhibitor BBI503","ValueMeaning":{"publicId":"6148646","version":"1","preferredName":"Cancer Stemness Kinase Inhibitor BBI503","longName":"6148646","preferredDefinition":"An orally available cancer cell stemness kinase inhibitor with potential antineoplastic activity. Even though the exact target has not been fully elucidated, BBI503 targets and inhibits one or more pathways involved in cancer stem cell survival. As a result, cancer stem cell (CSC) growth as well as heterogeneous cancer cell growth is inhibited. CSCs, self-replicating cells able to differentiate into heterogeneous cancer cells, appear to be responsible for both tumor relapse and metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amcasertib","conceptCode":"C104745","definition":"An orally available cancer cell stemness kinase inhibitor with potential antineoplastic activity. Even though the exact target has not been fully elucidated, amcasertib targets and inhibits one or more pathways involved in cancer stem cell survival. As a result, cancer stem cell (CSC) growth as well as heterogeneous cancer cell growth is inhibited. CSCs, self-replicating cells able to differentiate into heterogeneous cancer cells, appear to be responsible for both tumor relapse and metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682E2DE8-42B8-2546-E053-F662850A0E58","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-42D1-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"BB2516 Marimastat oral","valueDescription":"Marimastat","ValueMeaning":{"publicId":"6148648","version":"1","preferredName":"Marimastat","longName":"6148648","preferredDefinition":"An orally-active synthetic hydroxamate with potential antineoplastic activity.  Marimastat covalently binds to the zinc(II) ion in the active site of matrix metalloproteinases (MMPs), thereby inhibiting the action of MMPs, inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.  This agent may also inhibit tumor necrosis factor-alpha converting enzyme (TACE), an enzyme involved in tumor necrosis factor alpha (TNF-alpha) production that may play a role in some malignancies as well as in the development of arthritis and sepsis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Marimastat","conceptCode":"C1652","definition":"An orally-active synthetic hydroxamate with potential antineoplastic activity.  Marimastat covalently binds to the zinc(II) ion in the active site of matrix metalloproteinases (MMPs), thereby inhibiting the action of MMPs, inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.  This agent may also inhibit tumor necrosis factor-alpha converting enzyme (TACE), an enzyme involved in tumor necrosis factor alpha (TNF-alpha) production that may play a role in some malignancies as well as in the development of arthritis and sepsis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682E2DE8-42DE-2546-E053-F662850A0E58","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-42F7-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"BAY43-9006 Sorafenib Nexavar","valueDescription":"Sorafenib","ValueMeaning":{"publicId":"3380164","version":"1","preferredName":"Sorafenib","longName":"3380164","preferredDefinition":"A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sorafenib","conceptCode":"C61948","definition":"A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A2A6B-9613-1351-E040-BB89AD432684","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-430B-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"ODM-201 Darolutamide","valueDescription":"AR Antagonist ODM-201","ValueMeaning":{"publicId":"6159883","version":"1","preferredName":"Darolutamide","longName":"6159883v1.00","preferredDefinition":"A formulation containing an androgen receptor (AR) antagonist with potential antineoplastic activity. Darolutamide binds to ARs in target tissues; subsequently, inhibiting androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes that regulate prostate cancer cell proliferation. This ultimately leads to an inhibition of growth in AR-expressing prostate cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Darolutamide","conceptCode":"C104748","definition":"A formulation containing an androgen receptor (AR) antagonist with potential antineoplastic activity. Darolutamide binds to ARs in target tissues; subsequently, inhibiting androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes that regulate prostate cancer cell proliferation. This ultimately leads to an inhibition of growth in AR-expressing prostate cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A540C7-4B98-0CA2-E053-F662850A07D0","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"KUMMEROA","dateModified":"2022-08-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A540C7-4BB1-0CA2-E053-F662850A07D0","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Obinutuzumab Gazyva","valueDescription":"Obinutuzumab","ValueMeaning":{"publicId":"5096860","version":"1","preferredName":"Obinutuzumab","longName":"5096860","preferredDefinition":"A glycoengineered, humanized IgG1 monoclonal antibody with potential antineoplastic activity. Afutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells. The Fc region carbohydrates of the antibody, enriched in bisected non-fucosylated glycosylation variants, contribute to its higher binding affinity for human FcgammaRIII receptors compared to non-glycoengineered antibodies, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) and caspase-independent apoptosis. In addition, modification of elbow hinge sequences within the antibody variable framework regions may account for the strong apoptosis-inducing activity of R7159 upon binding to CD20 on target cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Obinutuzumab","conceptCode":"C70741","definition":"A glycoengineered, humanized IgG1 monoclonal antibody with potential antineoplastic activity. Obinutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells. The Fc region carbohydrates of the antibody, enriched in bisected non-fucosylated glycosylation variants, contribute to its higher binding affinity for human FcgammaRIII receptors compared to non-glycoengineered antibodies, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) and caspase-independent apoptosis. In addition, modification of elbow hinge sequences within the antibody variable framework regions may account for the strong apoptosis-inducing activity of R7159 upon binding to CD20 on target cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28ACEAFB-4750-6667-E050-BB89AD432DA7","latestVersionIndicator":"Yes","beginDate":"2016-01-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-01-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A540C7-4BC5-0CA2-E053-F662850A07D0","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"NX-211 Liposomal lurtotecan","valueDescription":"Lurtotecan Liposome","ValueMeaning":{"publicId":"6159885","version":"1","preferredName":"Lurtotecan Liposome","longName":"6159885","preferredDefinition":"A liposome-encapsulated formulation of lurtotecan with antineoplastic activity. Lurtotecan, a semisynthetic analogue of camptothecin, selectively stabilizes the topoisomerase I-DNA covalent complex and forms an enzyme-drug-DNA ternary complex during S phase of the cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-stranded DNA breaks. This ultimately results in an inhibition of DNA replication, inducing double-stranded DNA breakages, obstruction of RNA and protein synthesis and triggering apoptosis. Furthermore, this agent also stimulates degradation of topoisomerase I, likely mediated through ubiquitin-proteasomal pathway. Liposomal delivery of lurtotecan improves its penetration and delivery into tumors while lowering systemic side effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lurtotecan Liposome","conceptCode":"C1876","definition":"A liposome-encapsulated formulation of lurtotecan with antineoplastic activity. Lurtotecan, a semisynthetic analogue of camptothecin, selectively stabilizes the topoisomerase I-DNA covalent complex and forms an enzyme-drug-DNA ternary complex during S phase of the cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-stranded DNA breaks. This ultimately results in an inhibition of DNA replication, inducing double-stranded DNA breakages, obstruction of RNA and protein synthesis and triggering apoptosis. Furthermore, this agent also stimulates degradation of topoisomerase I, likely mediated through ubiquitin-proteasomal pathway. Liposomal delivery of lurtotecan improves its penetration and delivery into tumors while lowering systemic side effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A540C7-4BD2-0CA2-E053-F662850A07D0","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A540C7-4BEB-0CA2-E053-F662850A07D0","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Not Applicable","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"5043360","version":"1","preferredName":"Not Applicable","longName":"5043360","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2421E11B-65A6-151D-E050-BB89AD4378BB","latestVersionIndicator":"Yes","beginDate":"2015-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-11-09","modifiedBy":"DWARZEL","dateModified":"2018-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A540C7-4C1A-0CA2-E053-F662850A07D0","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Norvasc Amlodipine besylate","valueDescription":"Amlodipine Besylate","ValueMeaning":{"publicId":"2576922","version":"1","preferredName":"Amlodipine Besylate","longName":"2576922","preferredDefinition":"A dihydropyridine calcium channel blocking agent. Amlodipine besylate inhibits the influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility.  This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in some multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. Amlodipine besylate exhibits a longer half-life in vivo compared to other dihydropyridine calcium channel blocking agents. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amlodipine Besylate","conceptCode":"C28820","definition":"The besylate salt of amlodipine, a synthetic dihydropyridine with antihypertensive and antianginal effects. Amlodipine inhibits the influx of extracellular calcium ions into myocardial and peripheral vascular smooth muscle cells, thereby preventing vascular and myocardial contraction. This results in a dilatation of the main coronary and systemic arteries, decreased myocardial contractility, increased blood flow and oxygen delivery to the myocardial tissue, and decreased total peripheral resistance. This agent may also modulate multi-drug resistance (MDR) activity through inhibition of the p-glycoprotein efflux pump.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F987-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A540C7-4C2F-0CA2-E053-F662850A07D0","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"N-Methylformamide","valueDescription":"N-Methylformamide","ValueMeaning":{"publicId":"6159888","version":"1","preferredName":"N-Methylformamide","longName":"6159888","preferredDefinition":"A water-soluble organic solvent.  As an adjuvant antineoplastic agent, N-methylformamide depletes cellular glutathione, a key molecule involved in the antioxidation of reactive oxygen species (ROS) and other free radicals, thereby enhancing ionizing radiation-induced DNA cross-linking in and terminal differentiation of tumor cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"N-Methylformamide","conceptCode":"C1163","definition":"A water-soluble organic solvent.  As an adjuvant antineoplastic agent, N-methylformamide depletes cellular glutathione, a key molecule involved in the antioxidation of reactive oxygen species (ROS) and other free radicals, thereby enhancing ionizing radiation-induced DNA cross-linking in and terminal differentiation of tumor cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A540C7-4C3D-0CA2-E053-F662850A07D0","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A540C7-4C56-0CA2-E053-F662850A07D0","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Nizatidine Axid","valueDescription":"Nizatidine","ValueMeaning":{"publicId":"3335136","version":"1","preferredName":"Nizatidine","longName":"3335136","preferredDefinition":"A competitive and reversible histamine H2-receptor antagonist with antacid activity. Nizatidine inhibits the histamine H2-receptors located on the basolateral membrane of the gastric parietal cell, thereby reducing basal and nocturnal gastric acid secretion, resulting in a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nizatidine","conceptCode":"C29295","definition":"A competitive and reversible histamine H2-receptor antagonist with antacid activity. Nizatidine inhibits the histamine H2-receptors located on the basolateral membrane of the gastric parietal cell, thereby reducing basal and nocturnal gastric acid secretion, resulting in a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B43BE7C1-ECEA-6A5C-E040-BB89AD437808","latestVersionIndicator":"Yes","beginDate":"2011-12-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A540C7-4C6A-0CA2-E053-F662850A07D0","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Nivolumab, Opdivo, ONO-4538, MDX-1106, BMS-936558","valueDescription":"Nivolumab","ValueMeaning":{"publicId":"5076694","version":"1","preferredName":"Nivolumab","longName":"5076694","preferredDefinition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nivolumab","conceptCode":"C68814","definition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2653AD7D-EBB8-5B33-E050-BB89AD437FF5","latestVersionIndicator":"Yes","beginDate":"2015-12-07","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A540C7-4C7E-0CA2-E053-F662850A07D0","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Nitrosourea","valueDescription":"Nitrosourea Compound","ValueMeaning":{"publicId":"2829938","version":"1","preferredName":"Nitrosourea Compound","longName":"2829938","preferredDefinition":"A group of anticancer drugs that can cross the blood-brain barrier. Carmustine (BCNU) and lomustine (CCNU) are nitrosoureas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nitrosourea Compound","conceptCode":"C699","definition":"Any of a class of alkylating agents that contain both a nitroso group and a urea. They are lipophilic and can cross the blood-brain barrier.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"618DC679-B127-32DD-E040-BB89AD43461A","latestVersionIndicator":"Yes","beginDate":"2009-01-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-01-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A540C7-4C88-0CA2-E053-F662850A07D0","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Nitrogen mustard Mustargen Mechlorethamine HCL Mustine","valueDescription":"Mechlorethamine","ValueMeaning":{"publicId":"5044413","version":"1","preferredName":"Mechlorethamine","longName":"5044413","preferredDefinition":"A synthetic agent related to sulphur mustard with antineoplastic and immunosuppressive properties. Nitrogen mustard (a member of a family of chemotherapy agents including cyclophosphamide and chlorambucil) is an irritant and carcinogenic agent metabolized to a highly reactive ethylene immonium derivative; the ethylene immonium derivative alkylates DNA and inhibits DNA replication. This agent also exhibits lympholytic properties. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mechlorethamine","conceptCode":"C62056","definition":"A synthetic agent related to sulphur mustard with antineoplastic and immunosuppressive properties. Nitrogen mustard (a member of a family of chemotherapy agents including cyclophosphamide and chlorambucil) is an irritant and carcinogenic agent metabolized to a highly reactive ethylene immonium derivative; the ethylene immonium derivative alkylates DNA and inhibits DNA replication. This agent also exhibits lympholytic properties. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"245B5ACF-1BCF-A2B9-E050-BB89AD43722C","latestVersionIndicator":"Yes","beginDate":"2015-11-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2015-11-12","modifiedBy":"COLBERTM","dateModified":"2023-06-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A540C7-4C9C-0CA2-E053-F662850A07D0","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Oxaliplatin Eloxatin","valueDescription":"Oxaliplatin","ValueMeaning":{"publicId":"2579327","version":"1","preferredName":"Oxaliplatin","longName":"2579327","preferredDefinition":"An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oxaliplatin","conceptCode":"C1181","definition":"An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-02EC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-02","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-02","modifiedBy":"REEVESD","dateModified":"2006-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AD0C15-A3B2-3AF6-E053-F662850A4C6F","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Ovarex Oregovomab","valueDescription":"Oregovomab","ValueMeaning":{"publicId":"6159890","version":"1","preferredName":"Oregovomab","longName":"6159890","preferredDefinition":"A murine monoclonal antibody that attaches to the tumor-associated antigen CA125. Vaccination with monoclonal antibody B43.13 may stimulate a host cytotoxic immune response against tumor cells that express CA125. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oregovomab","conceptCode":"C1784","definition":"A murine monoclonal antibody that attaches to the tumor-associated antigen CA125. Vaccination with monoclonal antibody B43.13 may stimulate a host cytotoxic immune response against tumor cells that express CA125. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68AD0C15-A3BF-3AF6-E053-F662850A4C6F","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AD0C15-A3D8-3AF6-E053-F662850A4C6F","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2946060","version":"1","preferredName":"Other","longName":"2946060","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"746A8063-D650-3C9D-E040-BB89AD437A9B","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-25","modifiedBy":"GDEEN","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":"1/25/23 added alt name for ticket number CADSR0001948 for CCTG cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AD0C15-A3E2-3AF6-E053-F662850A4C6F","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Osimertinib Tagrisso","valueDescription":"Osimertinib","ValueMeaning":{"publicId":"5305951","version":"1","preferredName":"Osimertinib","longName":"5305951","preferredDefinition":"A third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, osimertinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. AZD9291 preferentially inhibits mutated forms of EGFR including T790M, a secondarily-acquired resistance mutation, and may have enhanced anti-tumor effects in tumors with T790M-mediated resistance when compared to other EGFR tyrosine kinase inhibitors. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Osimertinib","conceptCode":"C116377","definition":"A third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, osimertinib covalently binds to and inhibits the activity of numerous mutant forms of EGFR, including the secondarily-acquired resistance mutation T790M, L858R, and exon 19 deletions, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"35DFF1EC-FEBB-8034-E050-BB89AD435383","latestVersionIndicator":"Yes","beginDate":"2016-06-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-06-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AD0C15-A3F6-3AF6-E053-F662850A4C6F","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"OSI-774 NSC 718781 Erlotinib Tarceva","valueDescription":"Erlotinib Hydrochloride","ValueMeaning":{"publicId":"5709521","version":"1","preferredName":"Erlotinib Hydrochloride","longName":"5709521","preferredDefinition":"The hydrochloride salt of a quinazoline derivative with antineoplastic properties.  Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Erlotinib Hydrochloride","conceptCode":"C2693","definition":"The hydrochloride salt of a quinazoline derivative with antineoplastic properties.  Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AA01C0C-6D12-2061-E053-F662850A2D37","latestVersionIndicator":"Yes","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AD0C15-A40A-3AF6-E053-F662850A4C6F","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"BAY 59-8862 Ortataxel","valueDescription":"Ortataxel","ValueMeaning":{"publicId":"6148650","version":"1","preferredName":"Ortataxel","longName":"6148650","preferredDefinition":"A semisynthetic, second-generation taxane derivative with potential antineoplastic activity. Ortataxel binds to and stabilizes tubulin molecules, thereby interfering with the dynamics of microtubule assembly/disassembly. This results in the inhibition of cell division and cellular proliferation. As it represents a poor substrate for P-glycoprotein (P-gp), multi-drug resistance protein (MRP-1) and breast cancer resistance protein (BCRP) mediated efflux, ortataxel modulates multi-drug resistance mechanisms and may be useful for treating multi-drug resistant tumors that express Pgp, MRP-1 and BCRP.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ortataxel","conceptCode":"C1867","definition":"A semisynthetic, second-generation taxane derivative with potential antineoplastic activity. Ortataxel binds to and stabilizes tubulin molecules, thereby interfering with the dynamics of microtubule assembly/disassembly. This results in the inhibition of cell division and cellular proliferation. As it represents a poor substrate for P-glycoprotein (P-gp), multi-drug resistance protein (MRP-1) and breast cancer resistance protein (BCRP) mediated efflux, ortataxel modulates multi-drug resistance mechanisms and may be useful for treating multi-drug resistant tumors that express Pgp, MRP-1 and BCRP.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682E2DE8-4318-2546-E053-F662850A0E58","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-4331-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"BAY 38-3441","valueDescription":"BAY 56-3722","ValueMeaning":{"publicId":"6148652","version":"1","preferredName":"BAY 56-3722","longName":"6148652","preferredDefinition":"A water-soluble camptothecin derivative conjugated to a carbohydrate moiety exhibiting antineoplastic activity. BAY 56-3722 stabilizes the topoisomerase I-DNA covalent complex and forms an enzyme-drug-DNA ternary complex. As a consequence of the formation of this complex, both the initial cleavage reaction and religation steps are inhibited and subsequent collision of the replication fork with the cleaved strand of DNA results in inhibition of DNA replication, double strand DNA breakage and triggering of apoptosis. The peptide carbohydrate moiety of this agent stabilizes the lactone form of camptothecin in blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Afeletecan Hydrochloride","conceptCode":"C1886","definition":"The hydrochloride salt form of afeletecan, a water-soluble camptothecin derivative conjugated to a carbohydrate moiety exhibiting antineoplastic activity. Afeletecan stabilizes the topoisomerase I-DNA covalent complex and forms an enzyme-drug-DNA ternary complex. As a consequence of the formation of this complex, both the initial cleavage reaction and religation steps are inhibited and subsequent collision of the replication fork with the cleaved strand of DNA results in inhibition of DNA replication, double strand DNA breakage and triggering of apoptosis. The peptide carbohydrate moiety of this agent stabilizes the lactone form of camptothecin in blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682E2DE8-433E-2546-E053-F662850A0E58","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-4357-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"BAY 12-9566 Tanomastat","valueDescription":"Tanomastat","ValueMeaning":{"publicId":"6148654","version":"1","preferredName":"Tanomastat","longName":"6148654","preferredDefinition":"A biphenyl matrix metalloproteinase (MMP) inhibitor (MMPI) with potential antineoplastic activity. Tanomastat inhibits MMP-2, MMP-3, and MMP-9, inhibiting extracellular matrix degradation and potentially inhibiting angiogenesis, tumor growth and invasion, and metastasis. MMPs consist of at least 18 zinc-containing endo-proteinases that are capable of degrading collagen and proteoglycan.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tanomastat","conceptCode":"C1705","definition":"A biphenyl matrix metalloproteinase (MMP) inhibitor (MMPI) with potential antineoplastic activity. Tanomastat inhibits MMP-2, MMP-3, and MMP-9, inhibiting extracellular matrix degradation and potentially inhibiting angiogenesis, tumor growth and invasion, and metastasis. MMPs consist of at least 18 zinc-containing endo-proteinases that are capable of degrading collagen and proteoglycan.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682E2DE8-4364-2546-E053-F662850A0E58","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-437D-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Bacillus calmette-guerin Immucyst BCG Oncotice","valueDescription":"BCG Vaccine","ValueMeaning":{"publicId":"5654664","version":"1","preferredName":"BCG Vaccine","longName":"5654664","preferredDefinition":"A vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BCG Vaccine","conceptCode":"C298","definition":"A vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"47E22FDA-53D4-0E13-E053-F662850AD9C8","latestVersionIndicator":"Yes","beginDate":"2017-02-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-02-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-4391-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"AZQ Diaziquone","valueDescription":"Diaziquone","ValueMeaning":{"publicId":"3378918","version":"1","preferredName":"Diaziquone","longName":"3378918","preferredDefinition":"A water-soluble, synthetic aziridinylbenzoquinone with potential antineoplastic activity. Bioactivation of aziridinylbenzoquinone RH1 occurs through the two-electron reduction of the quinone to the hydroquinone by the two-electron quinone reductase DT-diaphorase (DTD). The resultant hydroquinone selectively alkylates and cross-links DNA at the 5'-GNC-3' sequence, inihibiting DNA replication, inducing apoptosis, and inhibiting tumor cell proliferation. DTD is over-expressed in many tumors relative to normal tissue, including lung, colon, breast and liver tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diaziquone","conceptCode":"C1363","definition":"A water-soluble, synthetic aziridinylbenzoquinone with potential antineoplastic activity. Bioactivation of aziridinylbenzoquinone RH1 occurs through the two-electron reduction of the quinone to the hydroquinone by the two-electron quinone reductase DT-diaphorase (DTD). The resultant hydroquinone selectively alkylates and cross-links DNA at the 5'-GNC-3' sequence, inihibiting DNA replication, inducing apoptosis, and inhibiting tumor cell proliferation. DTD is over-expressed in many tumors relative to normal tissue, including lung, colon, breast and liver tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9078B1E-F7A5-89BB-E040-BB89AD432908","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-43A5-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"AZD6094 Savolitinib Volitinib","valueDescription":"Volitinib","ValueMeaning":{"publicId":"6148656","version":"1","preferredName":"Volitinib","longName":"6148656","preferredDefinition":"An orally bioavailable inhibitor of the c-Met receptor tyrosine kinase with potential antineoplastic activity. Volitinib selectively binds to and inhibits the activation of c-Met in an ATP-competitive manner, and disrupts c-Met signal transduction pathways. This may result in cell growth inhibition in tumors that overexpress the c-Met protein. C-Met encodes the hepatocyte growth factor receptor tyrosine kinase and plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis; this protein is overexpressed or mutated in a variety of cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Savolitinib","conceptCode":"C104732","definition":"An orally bioavailable inhibitor of the c-Met receptor tyrosine kinase with potential antineoplastic activity. Savolitinib selectively binds to and inhibits the activation of c-Met in an ATP-competitive manner, and disrupts c-Met signal transduction pathways. This may result in cell growth inhibition in tumors that overexpress the c-Met protein. C-Met encodes the hepatocyte growth factor receptor tyrosine kinase and plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis; this protein is overexpressed or mutated in a variety of cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682E2DE8-43B2-2546-E053-F662850A0E58","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-43CB-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Conjugated estrogens Premarin","valueDescription":"Estrogens, Conjugated","ValueMeaning":{"publicId":"6148658","version":"1","preferredName":"Estrogens, Conjugated","longName":"6148658","preferredDefinition":"Purified orally bioavailable female sex hormones isolated from pregnant mare urine or synthetically derived from plant materials and primarily conjugated as sulfate esters. Estrogen binds to and activates specific nuclear receptors, which, in turn, bind to estrogen response elements (EREs) in target genes, resulting in histone acetylation, alteration of chromatin conformation, and initiation of transcription. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Estrogens, Conjugated","conceptCode":"C482","definition":"Purified orally bioavailable female sex hormones isolated from pregnant mare urine or synthetically derived from plant materials and primarily conjugated as sulfate esters. Estrogen binds to and activates specific nuclear receptors, which, in turn, bind to estrogen response elements (EREs) in target genes, resulting in histone acetylation, alteration of chromatin conformation, and initiation of transcription. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"683B72D8-17EC-2741-E053-F662850AA7F3","latestVersionIndicator":"Yes","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683B72D8-1805-2741-E053-F662850AA7F3","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Cobimetinib Cotellic","valueDescription":"MEK inhibitor GDC-0973","ValueMeaning":{"publicId":"3653958","version":"1","preferredName":"MEK inhibitor GDC-0973","longName":"3653958","preferredDefinition":"An orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity. MEK inhibitor GDC-0973 specifically binds to and inhibits the catalytic activity of MEK1, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation and activation and decreased tumor cell proliferation. Preclinical studies have demonstrated that this agent is effective in inhibiting the growth of tumor cells bearing a B-RAF mutation, which has been found to be associated with many tumor types. A threonine-tyrosine kinase and a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors, MEK1 is required for the transmission of growth-promoting signals from numerous receptor tyrosine kinases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cobimetinib","conceptCode":"C68923","definition":"An orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity. Cobimetinib specifically binds to and inhibits the catalytic activity of MEK1, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation and activation and decreased tumor cell proliferation. Preclinical studies have demonstrated that this agent is effective in inhibiting the growth of tumor cells bearing a B-RAF mutation, which has been found to be associated with many tumor types. A threonine-tyrosine kinase and a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors, MEK1 is required for the transmission of growth-promoting signals from numerous receptor tyrosine kinases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D3E1EFE4-45EB-52B6-E040-BB89AD431E3D","latestVersionIndicator":"Yes","beginDate":"2013-01-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-01-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683B72D8-1819-2741-E053-F662850AA7F3","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Cladribine Leustatin","valueDescription":"Cladribine","ValueMeaning":{"publicId":"2829877","version":"1","preferredName":"Cladribine","longName":"2829877","preferredDefinition":"A purine nucleoside antimetabolite analogue. Cladribine triphosphate, a phosphorylated metabolite of cladribine, incorporates into DNA, resulting in single-strand breaks in DNA, depletion of nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP), and apoptosis.  Because this agent is resistant to adenosine deaminase, an enzyme that inactivates some antineoplastic agents, it is selectively toxic to lymphocytes and monocytes which exhibit little deoxynucleotide deaminase activity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cladribine","conceptCode":"C1336","definition":"A purine nucleoside antimetabolite analogue. Cladribine triphosphate, a phosphorylated metabolite of cladribine, incorporates into DNA, resulting in single-strand breaks in DNA, depletion of nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP), and apoptosis.  Because this agent is resistant to adenosine deaminase, an enzyme that inactivates some antineoplastic agents, it is selectively toxic to lymphocytes and monocytes which exhibit little deoxynucleotide deaminase activity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"617A04FE-518F-3582-E040-BB89AD432071","latestVersionIndicator":"Yes","beginDate":"2009-01-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-01-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683B72D8-182D-2741-E053-F662850AA7F3","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Cimetidine Tagamet","valueDescription":"Cimetidine","ValueMeaning":{"publicId":"2577816","version":"1","preferredName":"Cimetidine","longName":"2577816","preferredDefinition":"A histamine H(2)-receptor antagonist.  Enhancing anti-tumor cell-mediated responses, cimetidine blocks histamine's ability to stimulate suppressor T lymphocyte activity and to inhibit natural killer (NK) cell activity and interleukin-2 production.  Cimetidine also may inhibit tumor growth by suppressing histamine's growth-factor activity and blocking histamine-induced stimulation of vascular endothelial growth factor (VEGF), a pro-angiogenic growth factor. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cimetidine","conceptCode":"C374","definition":"A histamine H(2)-receptor antagonist.  Enhancing anti-tumor cell-mediated responses, cimetidine blocks histamine's ability to stimulate suppressor T lymphocyte activity and to inhibit natural killer (NK) cell activity and interleukin-2 production.  Cimetidine also may inhibit tumor growth by suppressing histamine's growth-factor activity and blocking histamine-induced stimulation of vascular endothelial growth factor (VEGF), a pro-angiogenic growth factor. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD05-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683B72D8-1841-2741-E053-F662850AA7F3","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Chlorambucil Leukeran","valueDescription":"Chlorambucil","ValueMeaning":{"publicId":"2577804","version":"1","preferredName":"Chlorambucil","longName":"2577804","preferredDefinition":"An orally-active antineoplastic aromatic nitrogen mustard. Chlorambucil alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chlorambucil","conceptCode":"C362","definition":"An orally-active antineoplastic aromatic nitrogen mustard. Chlorambucil alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCF9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683B72D8-1855-2741-E053-F662850AA7F3","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"CFG920","valueDescription":"CYP17 Inhibitor CFG920","ValueMeaning":{"publicId":"6148660","version":"1","preferredName":"CYP17 Inhibitor CFG920","longName":"6148660","preferredDefinition":"An orally available inhibitor of the steroid 17-alpha-hydroxylase/C17,20 lyase (CYP17A1 or CYP17), with potential antiandrogen and antineoplastic activities. Upon oral administration, CYP17 inhibitor CFG920 inhibits the enzymatic activity of CYP17A1 in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen-dependent growth signaling and may inhibit cell proliferation of androgen-dependent tumor cells. The cytochrome P450 enzyme CYP17A1, localized to the endoplasmic reticulum, exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces steroidal hormones.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CYP17/CYP11B2 Inhibitor LAE001","conceptCode":"C102855","definition":"An orally bioavailable, non-steroidal, potent, reversible, dual inhibitor of cytochrome P450 17 (CYP17 or CYP17A1) and CYP11B2, with potential antiandrogen and antineoplastic activities. Upon oral administration, LAE001 inhibits the enzymatic activity of CYP17A1 in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen-dependent growth signaling and may inhibit cell proliferation of androgen-dependent tumor cells. LAE001 also inhibits the enzymatic activity of CYP11B2, thereby inhibiting aldosterone production. This may reduce the elevated aldosterone levels resulting from CYP17 inhibition and androgen deprivation, leading to a reduction in mineralocorticoid side effects including cardiovascular complications. The cytochrome P450 enzyme CYP17A1, localized to the endoplasmic reticulum, exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces steroidal hormones. The cytochrome P450 enzyme CYP11B2, aldosterone synthase, is an enzyme that plays a key role in aldosterone biosynthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"683B72D8-1862-2741-E053-F662850AA7F3","latestVersionIndicator":"Yes","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683B72D8-187B-2741-E053-F662850AA7F3","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Cetuximab Erbitux C225","valueDescription":"Cetuximab","ValueMeaning":{"publicId":"2574309","version":"1","preferredName":"Cetuximab","longName":"2574309","preferredDefinition":"A monoclonal antibody specific for the epidermal growth factor receptor (EGFR), a tyrosine kinase that triggers cell division.  Cetuximab binds to and inhibits EGFRs, which are overexpressed on the cell surfaces of many types of tumors.  This agent blocks the tumor growth, invasion, and metastasis associated with the overexpression of cell-surface EGFRs. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cetuximab","conceptCode":"C1723","definition":"A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EF52-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-02","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-02","modifiedBy":"REEVESD","dateModified":"2006-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683B72D8-188F-2741-E053-F662850AA7F3","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Ceritinib Zykadia","valueDescription":"Ceritinib","ValueMeaning":{"publicId":"4369572","version":"1","preferredName":"Ceritinib","longName":"4369572","preferredDefinition":"An orally available inhibitor of the receptor tyrosine kinase activity of anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, ceritinib binds to and inhibits wild-type ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to both the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a variety of tumor cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ceritinib","conceptCode":"C115112","definition":"An orally available inhibitor of the receptor tyrosine kinase activity of anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, ceritinib binds to and inhibits wild-type ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to both the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a variety of tumor cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCC29A29-1614-A1F3-E040-BB89AD433071","latestVersionIndicator":"Yes","beginDate":"2014-06-26","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2014-06-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683B72D8-18A3-2741-E053-F662850AA7F3","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"CCNU Lomustine NSC79037 CEENU","valueDescription":"Lomustine","ValueMeaning":{"publicId":"2739549","version":"1","preferredName":"Lomustine","longName":"2739549","preferredDefinition":"A nitrosourea with antineoplastic activity. Lomustine alkylates and crosslinks DNA, thereby inhibiting DNA and RNA synthesis.  This agent also carbamoylates DNA and proteins, resulting in inhibition of DNA and RNA synthesis and disruption of RNA processing.  Lomustine is lipophilic and crosses the blood-brain barrier. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lomustine","conceptCode":"C617","definition":"A nitrosourea with antineoplastic activity. Lomustine alkylates and crosslinks DNA, thereby inhibiting DNA and RNA synthesis.  This agent also carbamoylates DNA and proteins, resulting in inhibition of DNA and RNA synthesis and disruption of RNA processing.  Lomustine is lipophilic and crosses the blood-brain barrier. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A7528ED-01D9-5EF5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683B72D8-18B7-2741-E053-F662850AA7F3","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Carmustine BCNU","valueDescription":"Carmustine","ValueMeaning":{"publicId":"3378823","version":"1","preferredName":"Carmustine","longName":"3378823","preferredDefinition":"An antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  This agent also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carmustine","conceptCode":"C349","definition":"An antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  This agent also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-158F-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683B72D8-18CB-2741-E053-F662850AA7F3","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Carfilzomib Kyprolis","valueDescription":"Carfilzomib","ValueMeaning":{"publicId":"3378843","version":"1","preferredName":"Carfilzomib","longName":"3378843","preferredDefinition":"An epoxomicin derivate with potential antineoplastic activity. Carfilzomib irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S catalytic core subunit of the proteasome, a protease complex responsible for degrading a large variety of cellular proteins. Inhibition of proteasome-mediated proteolysis results in an accumulation of polyubiquinated proteins, which may lead to cell cycle arrest, induction of apoptosis, and inhibition of tumor growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carfilzomib","conceptCode":"C52196","definition":"An epoxomicin derivate with potential antineoplastic activity. Carfilzomib irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S catalytic core subunit of the proteasome, a protease complex responsible for degrading a large variety of cellular proteins. Inhibition of proteasome-mediated proteolysis results in an accumulation of polyubiquinated proteins, which may lead to cell cycle arrest, induction of apoptosis, and inhibition of tumor growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-17EC-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683B72D8-18DF-2741-E053-F662850AA7F3","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Carboplatin Paraplatin","valueDescription":"Carboplatin","ValueMeaning":{"publicId":"3378841","version":"1","preferredName":"Carboplatin","longName":"3378841","preferredDefinition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-17C6-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683B72D8-18F3-2741-E053-F662850AA7F3","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Cisplatin CDDP Cisplatinum Platinol-AQ","valueDescription":"Cisplatin","ValueMeaning":{"publicId":"5544728","version":"1","preferredName":"Cisplatin","longName":"5544728","preferredDefinition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3FCC725E-178D-054A-E053-F662850A831B","latestVersionIndicator":"Yes","beginDate":"2016-10-26","endDate":null,"createdBy":"ZHANGW","dateCreated":"2016-10-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683B72D8-1907-2741-E053-F662850AA7F3","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Orteronel TAK-700","valueDescription":"Steroid 17alpha-monooxygenase TAK-700","ValueMeaning":{"publicId":"3259298","version":"1","preferredName":"Steroid 17alpha-monooxygenase TAK-700","longName":"3259298","preferredDefinition":"An orally bioavailable non-steroidal androgen synthesis inhibitor of steroid 17alpha-monooxygenase (17,20 lyase) with potential antiandrogen activity. TAK-700 binds to and inhibits the steroid 17alpha-monooxygenase in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen-dependent growth signaling and may inhibit cell proliferation of androgen-dependent tumor cells. The cytochrome P450 enzyme CYP17A1 (P450C17), localized to the endoplasmic reticulum (ER), exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces steroidal hormones, such as progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Orteronel","conceptCode":"C90582","definition":"An orally bioavailable non-steroidal androgen synthesis inhibitor of steroid 17alpha-monooxygenase (17,20 lyase) with potential antiandrogen activity. TAK-700 binds to and inhibits the steroid 17alpha-monooxygenase in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen-dependent growth signaling and may inhibit cell proliferation of androgen-dependent tumor cells. The cytochrome P450 enzyme CYP17A1 (P450C17), localized to the endoplasmic reticulum (ER), exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces steroidal hormones, such as progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A939DA44-CB85-3822-E040-BB89AD432672","latestVersionIndicator":"Yes","beginDate":"2011-07-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AD0C15-A41E-3AF6-E053-F662850A4C6F","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Orimeten Aminoglutethimide Cytadren Elipten","valueDescription":"Aminoglutethimide","ValueMeaning":{"publicId":"2576921","version":"1","preferredName":"Aminoglutethimide","longName":"2576921","preferredDefinition":"A synthetic derivative of the sedative and anticonvulsant glutethimide with anti-steroid properties.  Originally used as an anticonvulsant, aminoglutethimide also blocks adrenal steroidogenesis by inhibiting the enzymatic conversion of cholesterol to pregnenolone.  In addition, this agent blocks the peripheral aromatization of androgenic precursors to estrogens.  Aminoglutethimide does not suppress ovarian estrogen production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aminoglutethimide","conceptCode":"C233","definition":"A synthetic derivative of the sedative and anticonvulsant glutethimide with anti-steroid properties.  Originally used as an anticonvulsant, aminoglutethimide also blocks adrenal steroidogenesis by inhibiting the enzymatic conversion of cholesterol to pregnenolone.  In addition, this agent blocks the peripheral aromatization of androgenic precursors to estrogens.  Aminoglutethimide does not suppress ovarian estrogen production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F986-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AD0C15-A432-3AF6-E053-F662850A4C6F","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Omeprazole Losec","valueDescription":"Omeprazole","ValueMeaning":{"publicId":"4640882","version":"1","preferredName":"Omeprazole","longName":"4640882","preferredDefinition":"A benzimidazole with selective and irreversible proton pump inhibition activity. Omeprazole forms a stable disulfide bond with the sulfhydryl group of the hydrogen-potassium (H+ - K+) ATPase found on the secretory surface of parietal cells, thereby inhibiting the final transport of hydrogen ions (via exchange with potassium ions) into the gastric lumen and suppressing gastric acid secretion. This agent exhibits no anticholinergic activities and does not antagonize histamine H2 receptors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Omeprazole","conceptCode":"C716","definition":"A benzimidazole with selective and irreversible proton pump inhibition activity. Omeprazole forms a stable disulfide bond with the sulfhydryl group of the hydrogen-potassium (H+ - K+) ATPase found on the secretory surface of parietal cells, thereby inhibiting the final transport of hydrogen ions (via exchange with potassium ions) into the gastric lumen and suppressing gastric acid secretion. This agent exhibits no anticholinergic activities and does not antagonize histamine H2 receptors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0A7E4D2D-36A2-F298-E050-BB89AD4309D6","latestVersionIndicator":"Yes","beginDate":"2014-12-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-12-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AD0C15-A446-3AF6-E053-F662850A4C6F","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Olaratumab Lartruvo","valueDescription":"Anti-PDGFR alpha Monoclonal Antibody IMC-3G3","ValueMeaning":{"publicId":"3178312","version":"1","preferredName":"Anti-PDGFR alpha Monoclonal Antibody IMC-3G3","longName":"3178312","preferredDefinition":"A fully human IgG1 monoclonal antibody directed against the platelet-derived growth factor receptor alpha (PDGFR alpha) with potential antineoplastic activity. Anti-PDGFR alpha monoclonal antibody IMC-3G3 selectively binds to PDGFR alpha, .blocking the binding of its ligand, PDGF; signal transduction downstream of PDGFR through the MAPK and PI3K pathways is inhibited, which may result in inhibition of angiogenesis and tumor cell proliferation. Overexpressed by various cancer cell types, PDGFR is a transmembrane protein tyrosine kinase receptor, consisting of isoforms A and B that is important in regulating cellular growth and differentiation and angiogenesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Olaratumab","conceptCode":"C79825","definition":"A fully human IgG1 monoclonal antibody directed against the platelet-derived growth factor receptor alpha (PDGFR alpha) with potential antineoplastic activity. Anti-PDGFR alpha monoclonal antibody IMC-3G3 selectively binds to PDGFR alpha, .blocking the binding of its ligand, PDGF; signal transduction downstream of PDGFR through the MAPK and PI3K pathways is inhibited, which may result in inhibition of angiogenesis and tumor cell proliferation. Overexpressed by various cancer cell types, PDGFR is a transmembrane protein tyrosine kinase receptor, consisting of isoforms A and B that is important in regulating cellular growth and differentiation and angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"985B5C8B-3348-E22D-E040-BB89AD432202","latestVersionIndicator":"Yes","beginDate":"2010-12-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AD0C15-A45A-3AF6-E053-F662850A4C6F","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"OGX-427 Apatorsen","valueDescription":"Apatorsen","ValueMeaning":{"publicId":"6159892","version":"1","preferredName":"Apatorsen","longName":"6159892","preferredDefinition":"A second-generation antisense oligonucleotide targeting heat shock protein 27 (Hsp27) with potential antitumor and chemosensitizing activities. Apatorsen suppresses tumor cell expression of Hsp27, which may induce tumor cell apoptosis and enhance tumor cell sensitivity to cytotoxic agents. Hsp27, a chaperone belonging to the small heat shock protein (sHsp) group of proteins, is a cytoprotective protein that supports cell survival under conditions of stress; it has been found to be over-expressed in a variety of human cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Apatorsen","conceptCode":"C71740","definition":"A second-generation antisense oligonucleotide targeting heat shock protein 27 (Hsp27) with potential antitumor and chemosensitizing activities. Apatorsen suppresses tumor cell expression of Hsp27, which may induce tumor cell apoptosis and enhance tumor cell sensitivity to cytotoxic agents. Hsp27, a chaperone belonging to the small heat shock protein (sHsp) group of proteins, is a cytoprotective protein that supports cell survival under conditions of stress; it has been found to be over-expressed in a variety of human cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68AD0C15-A467-3AF6-E053-F662850A4C6F","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AD0C15-A480-3AF6-E053-F662850A4C6F","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"OGX-011","valueDescription":"Custirsen Sodium","ValueMeaning":{"publicId":"6159894","version":"1","preferredName":"Custirsen Sodium","longName":"6159894","preferredDefinition":"The eicosasodium salt of a mixed-backbone antisense oligodeoxynucleotide with chemosensitizing properties. Custirsen inhibits testosterone-repressed prostate message-2 (TRPM-2). Administration of custirsen abrogates the anti-apoptotic effect of TRPM-2, thereby sensitizing cells to chemotherapy and resulting in tumor cell death. TRPM-2 is an anti-apoptotic clusterin that is overexpressed by prostate cancer cells and is associated with chemoresistance.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Custirsen Sodium","conceptCode":"C1055","definition":"The eicosasodium salt of a mixed-backbone antisense oligodeoxynucleotide with chemosensitizing properties. Custirsen inhibits testosterone-repressed prostate message-2 (TRPM-2). Administration of custirsen abrogates the anti-apoptotic effect of TRPM-2, thereby sensitizing cells to chemotherapy and resulting in tumor cell death. TRPM-2 is an anti-apoptotic clusterin that is overexpressed by prostate cancer cells and is associated with chemoresistance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68AD0C15-A48D-3AF6-E053-F662850A4C6F","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AD0C15-A4A6-3AF6-E053-F662850A4C6F","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Siltuximab Sylvant","valueDescription":"Siltuximab","ValueMeaning":{"publicId":"5621734","version":"1","preferredName":"Siltuximab","longName":"5621734","preferredDefinition":"A chimeric, human-murine, monoclonal antibody targeting the pro-inflammatory cytokine interleukin 6 (IL-6), with antitumor and anti-inflammatory activities. Upon intravenous administration of siltuximab, this agent targets and binds to IL-6. This inhibits the binding of IL-6 to the IL-6 receptor (IL-6R), which results in the blockade of the IL-6/IL-6R-mediated signal transduction pathway. This inhibits cancer cell growth in tumors overexpressing IL-6.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Siltuximab","conceptCode":"C61084","definition":"A chimeric, human-murine, monoclonal antibody targeting the pro-inflammatory cytokine interleukin 6 (IL-6), with antitumor and anti-inflammatory activities. Upon intravenous administration of siltuximab, this agent targets and binds to IL-6. This inhibits the binding of IL-6 to the IL-6 receptor (IL-6R), which results in the blockade of the IL-6/IL-6R-mediated signal transduction pathway. This inhibits cancer cell growth in tumors overexpressing IL-6.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AECAE5-BCF0-28A7-E053-F662850AD609","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68ADEF5B-1353-393D-E053-F662850A4BFD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Selumetinib AZD6244","valueDescription":"Selumetinib","ValueMeaning":{"publicId":"3238481","version":"1","preferredName":"Selumetinib","longName":"3238481","preferredDefinition":"An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) 1 and 2. MEK 1 and 2 are dual specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are often upregulated in various cancer cells, and are drivers of diverse cellular responses, including proliferation. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Selumetinib","conceptCode":"C66939","definition":"An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) 1 and 2. MEK 1 and 2 are dual specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are often upregulated in various cancer cells, and are drivers of diverse cellular responses, including proliferation. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A41DC8A8-EBA5-0F50-E040-BB89AD436610","latestVersionIndicator":"Yes","beginDate":"2011-05-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-25","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68ADEF5B-1367-393D-E053-F662850A4BFD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"SCH66336 Lonafarnib","valueDescription":"Lonafarnib","ValueMeaning":{"publicId":"3379207","version":"1","preferredName":"Lonafarnib","longName":"3379207","preferredDefinition":"A synthetic tricyclic derivative of carboxamide with antineoplastic properties.  Lonarfanib binds to and inhibits farnesyl transferase, an enzyme involved in the post-translational modification and activation of Ras proteins.  Ras proteins participate in numerous signalling pathways (proliferation, cytoskeletal organization), and play an important role in oncogenesis.  Mutated ras proteins have been found in a wide range of human cancers. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lonafarnib","conceptCode":"C1829","definition":"A synthetic tricyclic derivative of carboxamide with antineoplastic properties.  Lonarfanib binds to and inhibits farnesyl transferase, an enzyme involved in the post-translational modification and activation of Ras proteins.  Ras proteins participate in numerous signalling pathways (proliferation, cytoskeletal organization), and play an important role in oncogenesis.  Mutated ras proteins have been found in a wide range of human cancers. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B918227F-B26F-6EA7-E040-BB89AD434A76","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68ADEF5B-137B-393D-E053-F662850A4BFD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"SB939","valueDescription":"Pracinostat","ValueMeaning":{"publicId":"6159916","version":"1","preferredName":"Pracinostat","longName":"6159916","preferredDefinition":"An orally available, small-molecule histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Pracinostat inhibits HDACs, which may result in the accumulation of highly acetylated histones, followed by the induction of chromatin remodeling; the selective transcription of tumor suppressor genes; the tumor suppressor protein-mediated inhibition of tumor cell division; and, finally, the induction of tumor cell apoptosis. This agent may possess improved metabolic, pharmacokinetic and pharmacological properties compared to other HDAC inhibitors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pracinostat","conceptCode":"C71708","definition":"An orally available, small-molecule histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Pracinostat inhibits HDACs, which may result in the accumulation of highly acetylated histones, followed by the induction of chromatin remodeling; the selective transcription of tumor suppressor genes; the tumor suppressor protein-mediated inhibition of tumor cell division; and, finally, the induction of tumor cell apoptosis. This agent may possess improved metabolic, pharmacokinetic and pharmacological properties compared to other HDAC inhibitors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68ADEF5B-1388-393D-E053-F662850A4BFD","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68ADEF5B-13A1-393D-E053-F662850A4BFD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"SB-715992 Ispinesib","valueDescription":"Ispinesib","ValueMeaning":{"publicId":"3379089","version":"1","preferredName":"Ispinesib","longName":"3379089","preferredDefinition":"A synthetic small molecule, derived from quinazolinone, with antineoplastic properties. Ispinesib selectively inhibits the mitotic motor protein, kinesin spindle protein (KSP), resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest during the mitotic phase, and cell death in tumor cells that are actively dividing. Because KSP is not involved in nonmitotic processes, such as neuronal transport, ispinesib may be less likely to cause the peripheral neuropathy often associated with the tubulin-targeting agents.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ispinesib","conceptCode":"C38131","definition":"A synthetic small molecule, derived from quinazolinone, with antineoplastic properties. Ispinesib selectively inhibits the mitotic motor protein, kinesin spindle protein (KSP), resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest during the mitotic phase, and cell death in tumor cells that are actively dividing. Because KSP is not involved in nonmitotic processes, such as neuronal transport, ispinesib may be less likely to cause the peripheral neuropathy often associated with the tubulin-targeting agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B915D7F9-565E-D77C-E040-BB89AD4330BD","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68ADEF5B-13B5-393D-E053-F662850A4BFD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"SARCNU NSC364432 Sarcosinamide nitrosourea","valueDescription":"SarCNU","ValueMeaning":{"publicId":"6159918","version":"1","preferredName":"SarCNU","longName":"6159918","preferredDefinition":"An alkylating chloroethylnitrosourea with antineoplastic activity.  Selectively accumulating in some tumor cells, SarCNU forms covalent linkages with nucleophilic centers in DNA, causing depurination, base pair miscoding, strand scission, and DNA-DNA cross-linking, which may result in cytotoxicity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"SarCNU","conceptCode":"C963","definition":"An alkylating chloroethylnitrosourea with antineoplastic activity.  Selectively accumulating in some tumor cells, SarCNU forms covalent linkages with nucleophilic centers in DNA, causing depurination, base pair miscoding, strand scission, and DNA-DNA cross-linking, which may result in cytotoxicity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68ADEF5B-13C2-393D-E053-F662850A4BFD","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68ADEF5B-13DB-393D-E053-F662850A4BFD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"SAR245409 Voxtalisib","valueDescription":"Voxtalisib","ValueMeaning":{"publicId":"6159920","version":"1","preferredName":"Voxtalisib","longName":"6159920","preferredDefinition":"An orally bioavailable small molecule targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinases in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Voxtalisib inhibits both PI3K kinase and mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in susceptible tumor cell populations. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated in a PI3K-independent fashion in response to nutrient and energy deprivation. Accordingly, this agent maybe more potent compared to an agent that inhibits either PI3K kinase or mTOR kinase alone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Voxtalisib","conceptCode":"C71704","definition":"An orally bioavailable small molecule targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinases in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Voxtalisib inhibits both PI3K kinase and mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in susceptible tumor cell populations. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated in a PI3K-independent fashion in response to nutrient and energy deprivation. Accordingly, this agent maybe more potent compared to an agent that inhibits either PI3K kinase or mTOR kinase alone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68ADEF5B-13E8-393D-E053-F662850A4BFD","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68ADEF5B-1401-393D-E053-F662850A4BFD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"SAR245408 Pilaralisib","valueDescription":"Pilaralisib","ValueMeaning":{"publicId":"6159922","version":"1","preferredName":"Pilaralisib","longName":"6159922","preferredDefinition":"An orally bioavailable small molecule, targeting the class I phosphatidylinositol 3 kinase (PI3K) family of lipid kinases, with potential antineoplastic activity. Pilaralisib reversibly binds to class 1 PI3Ks in an ATP-competitive manner, inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K signaling pathway; this may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents including genotoxic agents and receptor tyrosine kinase inhibitors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pilaralisib","conceptCode":"C71705","definition":"An orally bioavailable small molecule, targeting the class I phosphatidylinositol 3 kinase (PI3K) family of lipid kinases, with potential antineoplastic activity. Pilaralisib reversibly binds to class 1 PI3Ks in an ATP-competitive manner, inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K signaling pathway; this may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents including genotoxic agents and receptor tyrosine kinase inhibitors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68ADEF5B-140E-393D-E053-F662850A4BFD","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68ADEF5B-1427-393D-E053-F662850A4BFD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Sandostatin Octreotide acetate","valueDescription":"Octreotide Acetate","ValueMeaning":{"publicId":"3919466","version":"1","preferredName":"Octreotide Acetate","longName":"3919466","preferredDefinition":"The acetate salt of a synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Octreotide is a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Similar to somatostatin, this agent also suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Octreotide Acetate","conceptCode":"C53447","definition":"The acetate salt of a synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Octreotide is a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Similar to somatostatin, this agent also suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E8CA7C7F-FF37-3690-E040-BB89AD43404F","latestVersionIndicator":"Yes","beginDate":"2013-10-15","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2013-10-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68ADEF5B-143B-393D-E053-F662850A4BFD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"S-1, TS-1, TS-ONE, tegafur-gimeracil-oteracil potassium","valueDescription":"Tegafur-gimeracil-oteracil Potassium","ValueMeaning":{"publicId":"6159923","version":"1","preferredName":"Tegafur-gimeracil-oteracil Potassium","longName":"6159923","preferredDefinition":"An orally bioavailable fluoropyrimidine antagonist composed of tegafur combined with two modulators of 5-fluorouracil (5-FU) activity, gimeracil and potassium oxonate, in a molar ratio of 1:0.4:1. Tegafur is a prodrug of 5-fluorouracil, an antimetabolite that inhibits thymidylate synthase, DNA synthesis and cell division, and competes with uridine triphosphate, thus inhibiting RNA and protein synthesis. Gimeracil is a reversible inhibitor of dihydropyrimidine dehydrogenase (DPD), the liver enzyme responsible for rapid catabolism of 5-FU into inactive metabolites. Potassium oxonate preferentially localizes in the gut and inhibits the enzyme orotate phosphoribosyl-transferase (OPRT), thereby decreasing activation of 5-FU in the gut and activated 5-FU-related gastrointestinal toxicity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tegafur-gimeracil-oteracil Potassium","conceptCode":"C1833","definition":"An orally bioavailable fluoropyrimidine antagonist composed of tegafur combined with two modulators of 5-fluorouracil (5-FU) activity, gimeracil and potassium oxonate, in a molar ratio of 1:0.4:1. Tegafur is a prodrug of 5-fluorouracil, an antimetabolite that inhibits thymidylate synthase, DNA synthesis and cell division, and competes with uridine triphosphate, thus inhibiting RNA and protein synthesis. Gimeracil is a reversible inhibitor of dihydropyrimidine dehydrogenase (DPD), the liver enzyme responsible for rapid catabolism of 5-FU into inactive metabolites. Potassium oxonate preferentially localizes in the gut and inhibits the enzyme orotate phosphoribosyl-transferase (OPRT), thereby decreasing activation of 5-FU in the gut and activated 5-FU-related gastrointestinal toxicity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68ADEF5B-1447-393D-E053-F662850A4BFD","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68ADEF5B-1460-393D-E053-F662850A4BFD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Ruxolitinib phosphate Jakafi","valueDescription":"Ruxolitinib Phosphate","ValueMeaning":{"publicId":"6159925","version":"1","preferredName":"Ruxolitinib Phosphate","longName":"6159925","preferredDefinition":"The phosphate salt form of ruxolitinib, an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ruxolitinib Phosphate","conceptCode":"C97937","definition":"The phosphate salt form of ruxolitinib, an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68ADEF5B-146D-393D-E053-F662850A4BFD","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68ADEF5B-1486-393D-E053-F662850A4BFD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Rucaparib, Rubraca","valueDescription":"Rucaparib Camsylate","ValueMeaning":{"publicId":"6159927","version":"1","preferredName":"Rucaparib Camsylate","longName":"6159927v1.00","preferredDefinition":"The camsylate salt form of rucaparib, an orally bioavailable tricyclic indole and inhibitor of poly(ADP-ribose) polymerases (PARPs) 1 (PARP1), 2 (PARP2) and 3 (PARP3), with potential chemo/radiosensitizing and antineoplastic activities. Upon administration, rucaparib selectively binds to PARP1, 2 and 3 and inhibits PARP-mediated DNA repair. This enhances the accumulation of DNA strand breaks, promotes genomic instability and induces cell cycle arrest and apoptosis. This may enhance the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapy and radiation therapy. PARPs are enzymes activated by single-strand DNA breaks that catalyze the post-translational ADP-ribosylation of nuclear proteins, which induces signaling and the recruitment of other proteins to repair damaged DNA. The PARP-mediated repair pathway plays a key role in DNA repair and is dysregulated in a variety of cancer cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rucaparib Camsylate","conceptCode":"C131178","definition":"The camsylate salt form of rucaparib, an orally bioavailable tricyclic indole and inhibitor of poly(ADP-ribose) polymerases (PARPs) 1 (PARP1), 2 (PARP2) and 3 (PARP3), with potential chemo/radiosensitizing and antineoplastic activities. Upon administration, rucaparib selectively binds to PARP1, 2 and 3 and inhibits PARP-mediated DNA repair. This enhances the accumulation of DNA strand breaks, promotes genomic instability and induces cell cycle arrest and apoptosis. This may enhance the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapy and radiation therapy. PARPs are enzymes activated by single-strand DNA breaks that catalyze the post-translational ADP-ribosylation of nuclear proteins, which induces signaling and the recruitment of other proteins to repair damaged DNA. The PARP-mediated repair pathway plays a key role in DNA repair and is dysregulated in a variety of cancer cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68ADEF5B-1493-393D-E053-F662850A4BFD","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"KUMMEROA","dateModified":"2023-08-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68ADEF5B-14AC-393D-E053-F662850A4BFD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Rubidazone Zorubicin","valueDescription":"Zorubicin","ValueMeaning":{"publicId":"6159929","version":"1","preferredName":"Zorubicin","longName":"6159929","preferredDefinition":"A benzoylhydrazone derivative of the anthracycline antineoplastic antibiotic daunorubicin. Zorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair as well as RNA and protein synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zorubicin","conceptCode":"C91365","definition":"A benzoylhydrazone derivative of the anthracycline antineoplastic antibiotic daunorubicin. Zorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair as well as RNA and protein synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68ADEF5B-14B9-393D-E053-F662850A4BFD","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68ADEF5B-14D1-393D-E053-F662850A4BFD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"RPR 109881A","valueDescription":"Larotaxel","ValueMeaning":{"publicId":"6159931","version":"1","preferredName":"Larotaxel","longName":"6159931","preferredDefinition":"A semi-synthetic derivative of the taxane 10-deacetylbaccatin III with potential antineoplastic activities. Larotaxel binds to tubulin, promoting microtubule assembly and stabilization and preventing microtubule depolymerization, thereby inhibiting cell proliferation. As it represents poor substrate for P-glycoprotein-related drug resistance mechanisms, this agent may be useful for treating multi-drug resistant tumors. Larotaxel penetrates the blood brain barrier.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Larotaxel","conceptCode":"C48427","definition":"A semi-synthetic derivative of the taxane 10-deacetylbaccatin III with potential antineoplastic activities. Larotaxel binds to tubulin, promoting microtubule assembly and stabilization and preventing microtubule depolymerization, thereby inhibiting cell proliferation. As it represents poor substrate for P-glycoprotein-related drug resistance mechanisms, this agent may be useful for treating multi-drug resistant tumors. Larotaxel penetrates the blood brain barrier.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68ADEF5B-14DF-393D-E053-F662850A4BFD","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68ADEF5B-14F8-393D-E053-F662850A4BFD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Romidepsin Istodax","valueDescription":"Romidepsin","ValueMeaning":{"publicId":"5342172","version":"1","preferredName":"Romidepsin","longName":"5342172","preferredDefinition":"A bicyclic depsipeptide antibiotic isolated from the bacterium Chromobacterium violaceum with antineoplastic activity. After intracellular activation, romidepsin binds to and inhibits histone deacetylase (HDAC), resulting in alterations in gene expression and the induction of cell differentiation, cell cycle arrest, and apoptosis. This agent also inhibits hypoxia-induced angiogenesis and depletes several heat shock protein 90 (Hsp90)-dependent oncoproteins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Romidepsin","conceptCode":"C1544","definition":"A bicyclic depsipeptide antibiotic isolated from the bacterium Chromobacterium violaceum with antineoplastic activity. After intracellular activation, romidepsin binds to and inhibits histone deacetylase (HDAC), resulting in alterations in gene expression and the induction of cell differentiation, cell cycle arrest, and apoptosis. This agent also inhibits hypoxia-induced angiogenesis and depletes several heat shock protein 90 (Hsp90)-dependent oncoproteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3765270F-39D0-8633-E050-BB89AD4330A5","latestVersionIndicator":"Yes","beginDate":"2016-07-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-07-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68ADEF5B-150C-393D-E053-F662850A4BFD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Rituximab Rituxan Mabthera","valueDescription":"Rituximab","ValueMeaning":{"publicId":"5127434","version":"1","preferredName":"Rituximab","longName":"5127434","preferredDefinition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rituximab","conceptCode":"C1702","definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FBA0-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68ADEF5B-1520-393D-E053-F662850A4BFD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Tegafur-uracil Uftoral Uft Ftorafur","valueDescription":"Tegafur-Uracil","ValueMeaning":{"publicId":"6159958","version":"1","preferredName":"Tegafur-Uracil","longName":"6159958","preferredDefinition":"A formulated therapeutic oral agent consisting of a combination of the 5-fluorouracil (5-FU) congener prodrug tegafur (tetrahydrofuranyl-5-fluorouracil) and uracil (1:4). The high concentration of uracil reversibly inhibits the uracil-reducing enzyme dihydropyrimidine dehydrogenase (DPD), thereby inhibiting first-pass DPD-mediated hepatic metabolism of the uracil analogue 5-FU and permitting administration of 5-FU as the orally bioavailable prodrug tegafur. Tegafur is bioactivated to 5-FU by liver microsomal cytochrome P450 enzymes. 5-FU is subsequently converted into its active metabolites 5-fluoro-deoxyuridine-monophosphate (FdUMP) and 5-fluorouridine-triphosphate (FUTP) intracellularly; these metabolites inhibit the enzyme thymidylate synthase and intercalate into RNA, resulting in decreased thymidine synthesis, reduced DNA synthesis, disrupted RNA function, and tumor cell cytotoxicity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tegafur-Uracil","conceptCode":"C9506","definition":"A formulated therapeutic oral agent consisting of a combination of the 5-fluorouracil (5-FU) congener prodrug tegafur (tetrahydrofuranyl-5-fluorouracil) and uracil (1:4). The high concentration of uracil reversibly inhibits the uracil-reducing enzyme dihydropyrimidine dehydrogenase (DPD), thereby inhibiting first-pass DPD-mediated hepatic metabolism of the uracil analogue 5-FU and permitting administration of 5-FU as the orally bioavailable prodrug tegafur. Tegafur is bioactivated to 5-FU by liver microsomal cytochrome P450 enzymes. 5-FU is subsequently converted into its active metabolites 5-fluoro-deoxyuridine-monophosphate (FdUMP) and 5-fluorouridine-triphosphate (FUTP) intracellularly; these metabolites inhibit the enzyme thymidylate synthase and intercalate into RNA, resulting in decreased thymidine synthesis, reduced DNA synthesis, disrupted RNA function, and tumor cell cytotoxicity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68D489E1-FF5B-7061-E053-F662850A5645","latestVersionIndicator":"Yes","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D489E1-FF74-7061-E053-F662850A5645","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"T-DM1, trastuzimab emtansine, Kadcyla","valueDescription":"Trastuzumab Emtansine","ValueMeaning":{"publicId":"4255113","version":"1","preferredName":"Trastuzumab Emtansine","longName":"4255113","preferredDefinition":"An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trastuzumab Emtansine","conceptCode":"C82492","definition":"An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5AA2DE6-BE47-4E55-E040-BB89AD43059A","latestVersionIndicator":"Yes","beginDate":"2014-03-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-03-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D489E1-FF88-7061-E053-F662850A5645","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Taxotere Docetaxel","valueDescription":"Docetaxel","ValueMeaning":{"publicId":"2576637","version":"1","preferredName":"Docetaxel","longName":"2576637","preferredDefinition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Docetaxel","conceptCode":"C1526","definition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F86A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D489E1-FF9C-7061-E053-F662850A5645","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Taxol Paclitaxel Onxal","valueDescription":"Paclitaxel","ValueMeaning":{"publicId":"2739551","version":"1","preferredName":"Paclitaxel","longName":"2739551","preferredDefinition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paclitaxel","conceptCode":"C1411","definition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A7528ED-0248-5EF5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D489E1-FFB0-7061-E053-F662850A5645","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Taselisib GDC0032 RO5537381","valueDescription":"Taselisib","ValueMeaning":{"publicId":"6159960","version":"1","preferredName":"Taselisib","longName":"6159960","preferredDefinition":"An orally bioavailable inhibitor of the class I phosphatidylinositol 3-kinase (PI3K) alpha isoform (PIK3CA), with potential antineoplastic activity. Taselisib selectively inhibits PIK3CA and its mutant forms in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PIK3CA-expressing tumor cells. By specifically targeting class I PI3K alpha, this agent may be more efficacious and less toxic than pan PI3K inhibitors. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and causes increased tumor cell growth, survival, and resistance to both chemotherapy and radiotherapy. PIK3CA, which encodes the p110-alpha catalytic subunit of the class I PI3K, is mutated in a variety of cancer cell types and plays a key role in cancer cell growth and invasion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Taselisib","conceptCode":"C116876","definition":"An orally bioavailable inhibitor of the class I phosphatidylinositol 3-kinase (PI3K) alpha isoform (PIK3CA), with potential antineoplastic activity. Taselisib selectively inhibits PIK3CA and its mutant forms in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PIK3CA-expressing tumor cells. By specifically targeting class I PI3K alpha, this agent may be more efficacious and less toxic than pan PI3K inhibitors. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and causes increased tumor cell growth, survival, and resistance to both chemotherapy and radiotherapy. PIK3CA, which encodes the p110-alpha catalytic subunit of the class I PI3K, is mutated in a variety of cancer cell types and plays a key role in cancer cell growth and invasion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68D489E1-FFBD-7061-E053-F662850A5645","latestVersionIndicator":"Yes","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D489E1-FFD6-7061-E053-F662850A5645","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"TAS-102 Tipiracil hydrochloride Lonsurf","valueDescription":"Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102","ValueMeaning":{"publicId":"5831612","version":"1","preferredName":"Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102","longName":"5831612","preferredDefinition":"An orally bioavailable combination agent composed of the cytotoxic pyrimidine analog trifluridine (5-trifluoro-2'-deoxythymidine or TFT) and a thymidine phosphorylase inhibitor (TPI) tipiracil hydrochloride, in a molar ratio of 1.0:0.5 (TFT:TPI), with potential antineoplastic activity. After oral administration of TAS-102, TFT is phosphorylated to the active monophosphate form TF-TMP, which binds covalently to the active site of thymidylate synthase, thereby reducing the nucleotide pool levels required for DNA replication. Furthermore, the triphosphate form TF-TTP can be incorporated into DNA, which induces DNA fragmentation and leads to the inhibition of tumor growth. TPI exhibits a dual effect: 1) an anti-angiogenic effect mediated through the inhibition of thymidine phosphorylase, which plays important role in nucleotide metabolism and a variety of development processes, including angiogenesis, 2) increased bioavailability of the normally short-lived antimetabolite TFT by preventing its degradation into the inactive form trifluorothymine (TF-Thy). The synergistic effect of the components in TAS-10 may demonstrate antitumor activity in 5-FU-resistant cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trifluridine and Tipiracil Hydrochloride","conceptCode":"C102554","definition":"An orally bioavailable combination agent composed of the cytotoxic pyrimidine analog trifluridine (5-trifluoro-2'-deoxythymidine or TFT) and a thymidine phosphorylase inhibitor (TPI) tipiracil hydrochloride, in a molar ratio of 1.0:0.5 (TFT:TPI), with potential antineoplastic activity. After oral administration of TAS-102, TFT is phosphorylated to the active monophosphate form TF-TMP, which binds covalently to the active site of thymidylate synthase, thereby reducing the nucleotide pool levels required for DNA replication. Furthermore, the triphosphate form TF-TTP can be incorporated into DNA, which induces DNA fragmentation and leads to the inhibition of tumor growth. TPI exhibits a dual effect: 1) an anti-angiogenic effect mediated through the inhibition of thymidine phosphorylase, which plays important role in nucleotide metabolism and a variety of development processes, including angiogenesis, 2) increased bioavailability of the normally short-lived antimetabolite TFT by preventing its degradation into the inactive form trifluorothymine (TF-Thy). The synergistic effect of the components in TAS-10 may demonstrate antitumor activity in 5-FU-resistant cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FBE47AA-07CE-1C05-E053-F662850AE460","latestVersionIndicator":"Yes","beginDate":"2017-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-05-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D489E1-FFEA-7061-E053-F662850A5645","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Tamoxifen citrate Nolvadex","valueDescription":"Tamoxifen Citrate","ValueMeaning":{"publicId":"5294355","version":"1","preferredName":"Tamoxifen Citrate","longName":"5294355","preferredDefinition":"The citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tamoxifen Citrate","conceptCode":"C855","definition":"The citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3557625D-6251-3A11-E050-BB89AD435F94","latestVersionIndicator":"Yes","beginDate":"2016-06-15","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-06-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D489E1-FFFE-7061-E053-F662850A5645","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Tallimustine","valueDescription":"Tallimustine","ValueMeaning":{"publicId":"6159962","version":"1","preferredName":"Tallimustine","longName":"6159962","preferredDefinition":"A benzoyl mustard derivative of the antiviral agent distamycin A with potential antineoplastic activity. Tallimustine selectively binds to A-T rich regions in the minor groove of DNA and alkylates at the N3 position of adenine in a highly sequence-specific manner. This prevents DNA replication, inhibits cellular proliferation and triggers apoptosis. Moreover, unlike other clinical nitrogen mustards, tallimustine does not carry out guanine-N7 alkylation in the major groove of DNA, which may lead to a high selectivity of action.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tallimustine","conceptCode":"C1603","definition":"A benzoyl mustard derivative of the antiviral agent distamycin A with potential antineoplastic activity. Tallimustine selectively binds to A-T rich regions in the minor groove of DNA and alkylates at the N3 position of adenine in a highly sequence-specific manner. This prevents DNA replication, inhibits cellular proliferation and triggers apoptosis. Moreover, unlike other clinical nitrogen mustards, tallimustine does not carry out guanine-N7 alkylation in the major groove of DNA, which may lead to a high selectivity of action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68D489E2-000B-7061-E053-F662850A5645","latestVersionIndicator":"Yes","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D489E2-0024-7061-E053-F662850A5645","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Talazoparib BMN673","valueDescription":"Talazoparib","ValueMeaning":{"publicId":"6159964","version":"1","preferredName":"Talazoparib","longName":"6159964","preferredDefinition":"An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. Talazoparib selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Talazoparib","conceptCode":"C95733","definition":"An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. Talazoparib selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68D489E2-0031-7061-E053-F662850A5645","latestVersionIndicator":"Yes","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D489E2-004A-7061-E053-F662850A5645","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Tace Chlorotrianisene","valueDescription":"Chlorotrianisene","ValueMeaning":{"publicId":"6159966","version":"1","preferredName":"Chlorotrianisene","longName":"6159966v1.00","preferredDefinition":"An orally bioavailable, highly lipophilic, synthetic triphenylethylene (TPE) derivative and selective estrogen receptor modulator (SERM), with predominantly estrogenic but also antiestrogenic activities. Upon administration, chlorotrianisene binds to estrogen receptors (ER) and, depending on the responsive target cells, either activates or blocks ER activity. This modulates the expression of ER-responsive genes in a tissue-specific manner. This agent may increase bone mineral density, modify the lipid profile and ameliorate vasomotor symptoms. Chlorotrianisene inhibits the pituitary secretion of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH) through a negative feedback mechanism.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chlorotrianisene","conceptCode":"C65320","definition":"An orally bioavailable, highly lipophilic, synthetic triphenylethylene (TPE) derivative and selective estrogen receptor modulator (SERM), with predominantly estrogenic but also antiestrogenic activities. Upon administration, chlorotrianisene binds to estrogen receptors (ER) and, depending on the responsive target cells, either activates or blocks ER activity. This modulates the expression of ER-responsive genes in a tissue-specific manner. This agent may increase bone mineral density, modify the lipid profile and ameliorate vasomotor symptoms. Chlorotrianisene inhibits the pituitary secretion of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH) through a negative feedback mechanism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68D489E2-0057-7061-E053-F662850A5645","latestVersionIndicator":"Yes","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"KUMMEROA","dateModified":"2023-09-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D489E2-0070-7061-E053-F662850A5645","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"T900607","valueDescription":"T900607","ValueMeaning":{"publicId":"6159968","version":"1","preferredName":"T900607","longName":"6159968","preferredDefinition":"A pentafluorophenylsulfonamide compound with potential antineoplastic activity. T900607 inhibits tubulin polymerization by binding irreversibly to colchicine binding sites, resulting in cell cycle arrest and apoptosis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T900607","conceptCode":"C26674","definition":"A pentafluorophenylsulfonamide compound with potential antineoplastic activity. T900607 inhibits tubulin polymerization by binding irreversibly to colchicine binding sites, resulting in cell cycle arrest and apoptosis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68D489E2-007D-7061-E053-F662850A5645","latestVersionIndicator":"Yes","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D489E2-0096-7061-E053-F662850A5645","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"T138067-Sodium","valueDescription":"Batabulin Sodium","ValueMeaning":{"publicId":"6159970","version":"1","preferredName":"Batabulin Sodium","longName":"6159970","preferredDefinition":"The sodium salt form of batabulin, a synthetic pentafluorophenylsulfonamide with potential antineoplastic activity. Batabulin covalently binds to and selectively modifies the beta 1, beta 2, beta 3, and beta 4 isotypes of beta tubulin at a conserved cysteine residue, resulting in disruption of microtubule polymerization, collapse of the cytoskeleton, an increase in chromosomal ploidy, cell cycle arrest, and tumor cell apoptosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Batabulin Sodium","conceptCode":"C1835","definition":"The sodium salt form of batabulin, a synthetic pentafluorophenylsulfonamide with potential antineoplastic activity. Batabulin covalently binds to and selectively modifies the beta 1, beta 2, beta 3, and beta 4 isotypes of beta tubulin at a conserved cysteine residue, resulting in disruption of microtubule polymerization, collapse of the cytoskeleton, an increase in chromosomal ploidy, cell cycle arrest, and tumor cell apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68D489E2-00A3-7061-E053-F662850A5645","latestVersionIndicator":"Yes","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D489E2-00BC-7061-E053-F662850A5645","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Sunitinib malate Sunitinib SU11248 SU011248 Sutent","valueDescription":"Sunitinib Malate","ValueMeaning":{"publicId":"2679054","version":"1","preferredName":"Sunitinib Malate","longName":"2679054","preferredDefinition":"The orally bioavailable malate salt of an indolinone-based tyrosine kinase inhibitor with potential antineoplastic activity.  Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.  This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sunitinib Malate","conceptCode":"C26673","definition":"The orally bioavailable malate salt of an indolinone-based tyrosine kinase inhibitor with potential antineoplastic activity.  Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.  This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"399116D7-83EA-5962-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-09-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D489E2-00D0-7061-E053-F662850A5645","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Sulofenur LY186641","valueDescription":"Sulofenur","ValueMeaning":{"publicId":"6159972","version":"1","preferredName":"Sulofenur","longName":"6159972","preferredDefinition":"A diarylsulfonylurea with potential antineoplastic activity. Sulofenur's antineoplastic mechanism of action is unknown. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sulofenur","conceptCode":"C1432","definition":"A diarylsulfonylurea with potential antineoplastic activity. Sulofenur's antineoplastic mechanism of action is unknown. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68D489E2-00DD-7061-E053-F662850A5645","latestVersionIndicator":"Yes","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D489E2-00F6-7061-E053-F662850A5645","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Suberoylanilide hydroxamic acid Vorinostat Zolinza","valueDescription":"Vorinostat","ValueMeaning":{"publicId":"3380298","version":"1","preferredName":"Vorinostat","longName":"3380298","preferredDefinition":"A synthetic hydroxamic acid derivative with antineoplastic activity. Vorinostat, a second generation polar-planar compound, binds to the catalytic domain of the histone deacetylases (HDACs). This allows the hydroxamic moiety to chelate zinc ion located in the catalytic pockets of HDAC, thereby inhibiting deacetylation and leading to an accumulation of both hyperacetylated histones and transcription factors. Hyperacetylation of histone proteins results in the upregulation of the cyclin-dependant kinase p21, followed by G1 arrest. Hyperacetylation of non-histone proteins such as tumor suppressor p53, alpha tubulin, and heat-shock protein 90 produces additional anti-proliferative effects. This agent also induces apoptosis and sensitizes tumor cells to cell death processes. Vorinostat crosses the blood-brain barrier.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vorinostat","conceptCode":"C1796","definition":"A synthetic hydroxamic acid derivative with antineoplastic activity. Vorinostat, a second generation polar-planar compound, binds to the catalytic domain of the histone deacetylases (HDACs). This allows the hydroxamic moiety to chelate zinc ion located in the catalytic pockets of HDAC, thereby inhibiting deacetylation and leading to an accumulation of both hyperacetylated histones and transcription factors. Hyperacetylation of histone proteins results in the upregulation of the cyclin-dependant kinase p21, followed by G1 arrest. Hyperacetylation of non-histone proteins such as tumor suppressor p53, alpha tubulin, and heat-shock protein 90 produces additional anti-proliferative effects. This agent also induces apoptosis and sensitizes tumor cells to cell death processes. Vorinostat crosses the blood-brain barrier.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A5B1-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D489E2-010A-7061-E053-F662850A5645","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Streptozocin Zanosar","valueDescription":"Streptozocin","ValueMeaning":{"publicId":"3380160","version":"1","preferredName":"Streptozocin","longName":"3380160","preferredDefinition":"A methylnitrosourea antineoplastic antibiotic isolated from the bacterium Streptomyces achromogenes.  Streptozocin alkylates DNA, forming inter-strand DNA cross-links and inhibiting DNA synthesis.  Due to its glucose moiety, this agent is readily taken up by pancreatic beta cells, inducing diabetes mellitus at high concentrations.  Unlike other nitrosoureas, streptozocin causes little myelosuppression. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Streptozocin","conceptCode":"C845","definition":"A methylnitrosourea antineoplastic antibiotic isolated from the bacterium Streptomyces achromogenes.  Streptozocin alkylates DNA, forming inter-strand DNA cross-links and inhibiting DNA synthesis.  Due to its glucose moiety, this agent is readily taken up by pancreatic beta cells, inducing diabetes mellitus at high concentrations.  Unlike other nitrosoureas, streptozocin causes little myelosuppression. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A2A6B-95A7-1351-E040-BB89AD432684","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D489E2-011E-7061-E053-F662850A5645","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"STI-571 Gleevec Imatinib","valueDescription":"Imatinib Mesylate","ValueMeaning":{"publicId":"2737465","version":"1","preferredName":"Imatinib Mesylate","longName":"2737465","preferredDefinition":"The mesylate salt of an antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that contain the Philadelphia chromosome.  Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF)/c-kit; the SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor (GIST).  This agent inhibits proliferation and induces apoptosis in cells that overexpress these oncoproteins. It is also known as Gleevec.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Imatinib Mesylate","conceptCode":"C1687","definition":"The mesylate salt of imatinib, a tyrosine kinase inhibitor with antineoplastic activity. Imatinib binds to an intracellular pocket located within tyrosine kinases (TK), thereby inhibiting ATP binding and preventing phosphorylation and the subsequent activation of growth receptors and their downstream signal transduction pathways. This agent inhibits TK encoded by the bcr-abl oncogene as well as receptor TKs encoded by the c-kit and platelet-derived growth factor receptor (PDGFR) oncogenes. Inhibition of the bcr-abl TK results in decreased proliferation and enhanced apoptosis in malignant cells of Philadelphia-positive (Ph+) hematological malignancies such as CML and ALL; effects on c-kit TK activity inhibit mast-cell and cellular proliferation in those diseases overexpressing c-kit, such as mastocytosis and gastrointestinal stromal tumor (GIST).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"497238FA-C337-26E6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D489E2-0132-7061-E053-F662850A5645","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"AZD4635 HTL-1071","valueDescription":"Adenosine A2A Receptor Antagonist AZD4635","ValueMeaning":{"publicId":"6161765","version":"1","preferredName":"Adenosine A2A Receptor Antagonist AZD4635","longName":"6161765","preferredDefinition":"An orally bioavailable antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon administration, A2AR antagonist AZD4635 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This blocks tumor-released adenosine from interacting with A2AR and prevents the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits T-cell proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Imaradenant","conceptCode":"C148039","definition":"An orally bioavailable antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon administration, imaradenant selectively binds to and inhibits A2AR expressed on T-lymphocytes. This blocks tumor-released adenosine from interacting with A2AR and prevents the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits T-cell proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"692F5CB3-427C-2049-E053-F662850A2011","latestVersionIndicator":"Yes","beginDate":"2018-04-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-06","modifiedBy":"ONEDATA","dateModified":"2018-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"692F5CB3-4295-2049-E053-F662850A2011","beginDate":"2018-04-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-06","modifiedBy":"ONEDATA","dateModified":"2018-04-06","deletedIndicator":"No"},{"value":"Betamethasone ","valueDescription":"Betamethasone","ValueMeaning":{"publicId":"2577761","version":"1","preferredName":"Betamethasone","longName":"2577761","preferredDefinition":"A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Betamethasone","conceptCode":"C303","definition":"A synthetic glucocorticoid with metabolic, immunosuppressive and anti-inflammatory activities. Betamethasone binds to specific intracellular glucocorticoid receptors and subsequently binds to DNA to modify gene expression. The synthesis of certain anti-inflammatory proteins is induced while the synthesis of certain inflammatory mediators is inhibited.  As a result, there is an overall reduction in chronic inflammation and autoimmune reactions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCCE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"692F5CB3-42A9-2049-E053-F662850A2011","beginDate":"2018-04-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-06","modifiedBy":"ONEDATA","dateModified":"2018-04-06","deletedIndicator":"No"},{"value":"Clodronate Bisphosphonate Bonefos","valueDescription":"Clodronate Disodium","ValueMeaning":{"publicId":"2597233","version":"1","preferredName":"Clodronate Disodium","longName":"2597233","preferredDefinition":"A drug used as treatment for hypercalcemia (abnormally high levels of calcium in the blood) and for cancer that has spread to the bone (bone metastases). It may decrease pain, the risk of fractures, and the development of new bone metastases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clodronate Disodium","conceptCode":"C1418","definition":"The disodium salt of a nitrogen-free bisphosphonate analog of naturally occurring pyrophosphate. Clodronate binds to calcium and inhibits osteoclastic bone resorption and hydroxyapatite crystal formation and dissolution, resulting in a reduction of bone turnover. This agent may control malignancy-associated hypercalcemia, inhibit osteolytic bone metastasis and decrease pain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"29750184-344E-0EED-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"692F5CB3-42BD-2049-E053-F662850A2011","beginDate":"2018-04-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-06","modifiedBy":"ONEDATA","dateModified":"2018-04-06","deletedIndicator":"No"},{"value":"Cortisone ","valueDescription":"Cortisone","ValueMeaning":{"publicId":"6161766","version":"1","preferredName":"Cortisone","longName":"6161766","preferredDefinition":"A steroid hormone synthesized and secreted by the adrenal gland and necessary for life. It is involved with maintaining cardiovascular function, blood glucose balance, regulating the inflammatory response and metabolism of proteins, carbohydrates, and fat.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cortisone","conceptCode":"C2291","definition":"A steroid hormone synthesized and secreted by the adrenal gland and necessary for life. It is involved with maintaining cardiovascular function, blood glucose balance, regulating the inflammatory response and metabolism of proteins, carbohydrates, and fat.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"692F5CB3-42C9-2049-E053-F662850A2011","latestVersionIndicator":"Yes","beginDate":"2018-04-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-06","modifiedBy":"ONEDATA","dateModified":"2018-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"692F5CB3-42E2-2049-E053-F662850A2011","beginDate":"2018-04-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-06","modifiedBy":"ONEDATA","dateModified":"2018-04-06","deletedIndicator":"No"},{"value":"Cytarabine Cytosar Arabinosylcytosine Ara-C","valueDescription":"Cytarabine","ValueMeaning":{"publicId":"3270479","version":"1","preferredName":"Cytarabine","longName":"3270479","preferredDefinition":"An anticancer drug that belongs to the family of drugs called antimetabolites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytarabine","conceptCode":"C408","definition":"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC7520C3-67D4-A135-E040-BB89AD436B61","latestVersionIndicator":"Yes","beginDate":"2011-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"692F5CB3-42F6-2049-E053-F662850A2011","beginDate":"2018-04-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-06","modifiedBy":"ONEDATA","dateModified":"2018-04-06","deletedIndicator":"No"},{"value":"DPPE","valueDescription":"Tesmilifene","ValueMeaning":{"publicId":"6161768","version":"1","preferredName":"Tesmilifene","longName":"6161768v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tesmilifene Hydrochloride","conceptCode":"C952","definition":"No value exists.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"692F5CB3-4303-2049-E053-F662850A2011","latestVersionIndicator":"Yes","beginDate":"2018-04-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"692F5CB3-431C-2049-E053-F662850A2011","beginDate":"2018-04-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-06","modifiedBy":"ONEDATA","dateModified":"2018-04-06","deletedIndicator":"No"},{"value":"Aclarubicin Aclacinomycine Aclacinon","valueDescription":"Affected by gastric pH","ValueMeaning":{"publicId":"2575518","version":"1","preferredName":"Affected by gastric pH","longName":"2575518v1.00","preferredDefinition":"An oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces galilaeus. Aclarubicin intercalates into DNA and interacts with topoisomerases I and II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine. This agent is less cardiotoxic than doxorubicin and daunorubicin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aclarubicin","conceptCode":"C202","definition":"An oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces galilaeus. Aclarubicin intercalates into DNA and interacts with topoisomerases I and II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine. This agent is less cardiotoxic than doxorubicin and daunorubicin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F40B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-06","endDate":null,"createdBy":"HARDINGR","dateCreated":"2005-07-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"692F5CB3-4331-2049-E053-F662850A2011","beginDate":"2018-04-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-06","modifiedBy":"ONEDATA","dateModified":"2018-04-06","deletedIndicator":"No"},{"value":"Actonel Risedronate","valueDescription":"Risedronate Sodium","ValueMeaning":{"publicId":"5709611","version":"1","preferredName":"Risedronate Sodium","longName":"5709611","preferredDefinition":"The sodium salt of risedronic acid, a synthetic pyridinyl bisphosphonate. Risedronic acid binds to hydroxyapatite crystals in bone and inhibits osteoclast-dependent bone resorption.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Risedronate Sodium","conceptCode":"C1528","definition":"The sodium salt of risedronic acid, a synthetic pyridinyl bisphosphonate. Risedronic acid binds to hydroxyapatite crystals in bone and inhibits osteoclast-dependent bone resorption.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AA0A7DB-1CE4-7C8E-E053-F662850A3136","latestVersionIndicator":"Yes","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"ZHANGWE","dateModified":"2021-09-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"692F5CB3-4346-2049-E053-F662850A2011","beginDate":"2018-04-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-06","modifiedBy":"ONEDATA","dateModified":"2018-04-06","deletedIndicator":"No"},{"value":"Midostaurin Rydapt","valueDescription":"Midostaurin","ValueMeaning":{"publicId":"5805895","version":"1","preferredName":"Midostaurin","longName":"5805895","preferredDefinition":"A synthetic indolocarbazole multikinase inhibitor with potential antiangiogenic and antineoplastic activities. Midostaurin inhibits protein kinase C alpha (PKCalpha), vascular endothelial growth factor receptor 2 (VEGFR2), c-kit, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase 3 (FLT3) tyrosine kinases, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Midostaurin","conceptCode":"C1872","definition":"A synthetic indolocarbazole multikinase inhibitor with potential antiangiogenic and antineoplastic activities. Midostaurin inhibits protein kinase C alpha (PKCalpha), vascular endothelial growth factor receptor 2 (VEGFR2), c-kit, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase 3 (FLT3) tyrosine kinases, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4EA05B60-4464-1133-E053-F662850AB1AF","latestVersionIndicator":"Yes","beginDate":"2017-05-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-03","modifiedBy":"COOPERM","dateModified":"2020-04-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AC54BB-F2A4-3A69-E053-F662850AF0F9","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"MG98 Methylgene","valueDescription":"MG 98","ValueMeaning":{"publicId":"6159873","version":"1","preferredName":"MG 98","longName":"6159873","preferredDefinition":"A second-generation, mixed-backbone, phosphorothioate antisense oligonucleotide (ODN) with potential antitumor activity. MG 98 is a highly specific inhibitor of translation of the mRNA for human DNA (cytosine-5-)-methyltransferase 1 (DNMT1), hybridizing to the 3' un-translated region of DNMT1 mRNA. The silencing of DNMT1 translation by MG 98 may result in the prevention or reversal of abnormal methylation of tumor suppressor genes and ultimately in tumor growth inhibition or tumor regression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"DNMT1 Mixed-Backbone Antisense Oligonucleotide MG 98","conceptCode":"C2530","definition":"A second-generation, mixed-backbone, phosphorothioate antisense oligonucleotide (ODN) with potential antitumor activity. MG 98 is a highly specific inhibitor of translation of the mRNA for human DNA (cytosine-5-)-methyltransferase 1 (DNMT1), hybridizing to the 3' un-translated region of DNMT1 mRNA. The silencing of DNMT1 translation by MG 98 may result in the prevention or reversal of abnormal methylation of tumor suppressor genes and ultimately in tumor growth inhibition or tumor regression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68AC54BB-F2B1-3A69-E053-F662850AF0F9","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AC54BB-F2CA-3A69-E053-F662850AF0F9","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"MG1MA3","valueDescription":"Genetically-modified MAGE-A3-expressing MG1 Maraba Virus Vaccine","ValueMeaning":{"publicId":"6159875","version":"1","preferredName":"Genetically-modified MAGE-A3-expressing MG1 Maraba Virus Vaccine","longName":"6159875","preferredDefinition":"A vaccine consisting of the attenuated, genetically-modified, oncolytic form of the Maraba virus, MG1, which has been engineered to express a gene encoding the cancer testis antigen melanoma antigen family A3 (MAGE-A3), with potential antineoplastic activity. Upon administration of genetically-modified MAGE-A3-expressing MG1 Maraba virus vaccine, the attenuated Maraba virus selectively and rapidly replicates in cancer cells; however, it is unable to replicate in normal, healthy cells. This induces a selective Maraba virus-mediated cytotoxicity in those cancer cells, and leads to cancer cell lysis. In addition, the expression of MAGE-A3 further stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing MAGE-A3. The tumor-associated antigen MAGE-A3 is overexpressed by a variety of cancer cell types. The attenuated virus is a double mutant strain with single amino acid substitutions occurring in both G protein (Q242R) and M protein (L123W).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Genetically-modified MAGE-A3-expressing MG1 Maraba Virus Vaccine","conceptCode":"C118973","definition":"A vaccine consisting of the attenuated, genetically-modified, oncolytic form of the Maraba virus, MG1, which has been engineered to express a gene encoding the cancer testis antigen melanoma antigen family A3 (MAGE-A3), with potential antineoplastic activity. Upon administration of genetically-modified MAGE-A3-expressing MG1 Maraba virus vaccine, the attenuated Maraba virus selectively and rapidly replicates in cancer cells; however, it is unable to replicate in normal, healthy cells. This induces a selective Maraba virus-mediated cytotoxicity in those cancer cells, and leads to cancer cell lysis. In addition, the expression of MAGE-A3 further stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing MAGE-A3. The tumor-associated antigen MAGE-A3 is overexpressed by a variety of cancer cell types. The attenuated virus is a double mutant strain with single amino acid substitutions occurring in both G protein (Q242R) and M protein (L123W).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68AC54BB-F2D7-3A69-E053-F662850AF0F9","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AC54BB-F2F0-3A69-E053-F662850AF0F9","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Methyl-CCNU Semustine","valueDescription":"Semustine","ValueMeaning":{"publicId":"6159877","version":"1","preferredName":"Semustine","longName":"6159877","preferredDefinition":"A methylated derivative of carmustine with antineoplastic activity. As an alkylating agent, semustine forms covalent linkages with nucleophilic centers in DNA, causing depurination, base-pair miscoding, strand scission, and DNA-DNA cross-linking, which may result in cytotoxicity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Semustine","conceptCode":"C827","definition":"A methylated derivative of carmustine with antineoplastic activity. As an alkylating agent, semustine forms covalent linkages with nucleophilic centers in DNA, causing depurination, base-pair miscoding, strand scission, and DNA-DNA cross-linking, which may result in cytotoxicity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68AC54BB-F2FD-3A69-E053-F662850AF0F9","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AC54BB-F316-3A69-E053-F662850AF0F9","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Methotrexate Amethopterin Mexate MTX Folex Trexall Rheumatrex","valueDescription":"Methotrexate","ValueMeaning":{"publicId":"5127393","version":"1","preferredName":"Methotrexate","longName":"5127393","preferredDefinition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methotrexate","conceptCode":"C642","definition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-F9D7-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"MAESKEB","dateModified":"2022-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AC54BB-F32A-3A69-E053-F662850AF0F9","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Metformin hydrochlodide APO-Metformin","valueDescription":"Metformin Hydrochloride","ValueMeaning":{"publicId":"2578288","version":"1","preferredName":"Metformin Hydrochloride","longName":"2578288","preferredDefinition":"The hydrochloride salt form of metformin, a biguanide with antihyperglycemic activity. Metformin hydrochloride exerts its action by improving hepatic sensitivity to insulin, thereby suppressing hepatic glucose production and increasing hepatic glycogen stores. In addition, metformin hydrochloride increases the number and/or affinity of insulin receptors on cell surface membranes in muscle and adipose tissue, thereby increasing the sensitivity to insulin at receptor and post-receptor binding sites and increasing glucose uptake peripherally.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metformin Hydrochloride","conceptCode":"C29251","definition":"The hydrochloride salt of the biguanide metformin with antihyperglycemic and potential antineoplastic activities. Metformin inhibits complex I (NADPH:ubiquinone oxidoreductase) of the mitochondrial respiratory chain, thereby increasing the cellular AMP to ATP ratio and leading to activation of AMP-activated protein kinase (AMPK) and regulating AMPK-mediated transcription of target genes. This eventually prevents hepatic gluconeogenesis, enhances insulin sensitivity and fatty acid oxidation and ultimately leads to a decrease in glucose levels. Metformin may exert antineoplastic effects through AMPK-mediated or AMPK-independent inhibition of mammalian target of rapamycin (mTOR), which is up-regulated in many cancer tissues. Furthermore, this agent also inhibits tumor cell migration and invasion by inhibiting matrix metalloproteinase-9 (MMP-9) expression which is mediated through the suppression of transcription activator protein-1 (AP-1) activation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEDD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AC54BB-F33E-3A69-E053-F662850AF0F9","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Metaiodobenzylguanidine, MIBG, IOBENGUANE","valueDescription":"Iobenguane","ValueMeaning":{"publicId":"4916471","version":"1","preferredName":"Iobenguane","longName":"4916471","preferredDefinition":"A synthetic, aralkylguanidine analogue of the adrenergic neurotransmitter norepinephrine (NE) and adrenergic neuron blocking agent with potential diagnostic imaging or antineoplastic activity when radiolabeled. Iobenguane, also known as metaiodobenzylguanidine (MIBG), is taken up and accumulates in the granules of adrenal medullary chromaffin cells and in the pre-synaptic granules of adrenergic neurons in a manner almost identical with that of NE. In radiolabeled forms, iobenguane may be used to image or eradicate neuroendocrine tissues and tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Iobenguane","conceptCode":"C87757","definition":"A synthetic, aralkylguanidine analogue of the adrenergic neurotransmitter norepinephrine (NE) and adrenergic neuron blocking agent with potential diagnostic imaging or antineoplastic activity when radiolabeled. Iobenguane, also known as metaiodobenzylguanidine (MIBG), is taken up and accumulates in the granules of adrenal medullary chromaffin cells and in the pre-synaptic granules of adrenergic neurons in a manner almost identical with that of NE. In radiolabeled forms, iobenguane may be used to image or eradicate neuroendocrine tissues and tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B69FCD0-9A2F-6D22-E050-BB89AD433F78","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AC54BB-F352-3A69-E053-F662850AF0F9","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Mesna Uromitexan Mesnum Mesnex","valueDescription":"Mesna","ValueMeaning":{"publicId":"2578266","version":"1","preferredName":"Mesna","longName":"2578266","preferredDefinition":"A sulfhydryl compound that is used to reduce the incidence of hemorrhagic cystitis associated with certain chemotherapeutic agents.  Mesna is converted to a free thiol compound in the kidney, where it binds to and inactivates acrolein and other urotoxic metabolites of ifosfamide and cyclophosphamide, thereby reducing their toxic effects on the urinary tract during urinary excretion. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mesna","conceptCode":"C192","definition":"A sulfhydryl compound that is used to reduce the incidence of hemorrhagic cystitis associated with certain chemotherapeutic agents.  Mesna is converted to a free thiol compound in the kidney, where it binds to and inactivates acrolein and other urotoxic metabolites of ifosfamide and cyclophosphamide, thereby reducing their toxic effects on the urinary tract during urinary excretion. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEC7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AC54BB-F366-3A69-E053-F662850AF0F9","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Zyloprim Allopurinol Lopurin","valueDescription":"Allopurinol Sodium","ValueMeaning":{"publicId":"6159988","version":"1","preferredName":"Allopurinol Sodium","longName":"6159988","preferredDefinition":"The sodium form of allopurinol, which is a structural isomer of hypoxanthine. Allopurinol inhibits xanthine oxidase, an enzyme that converts oxypurines to uric acid. By blocking the production of uric acid, this agent decreases serum and urine concentrations of uric acid, thereby providing protection against uric acid-mediated end organ damage in conditions associated with excessive production of uric acid, i.e. the massive cell lysis associated with the treatment of some malignancies. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Allopurinol Sodium","conceptCode":"C2564","definition":"The sodium form of allopurinol, which is a structural isomer of hypoxanthine. Allopurinol inhibits xanthine oxidase, an enzyme that converts oxypurines to uric acid. By blocking the production of uric acid, this agent decreases serum and urine concentrations of uric acid, thereby providing protection against uric acid-mediated end organ damage in conditions associated with excessive production of uric acid, i.e. the massive cell lysis associated with the treatment of some malignancies. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68D66961-4467-7716-E053-F662850AE3D1","latestVersionIndicator":"Yes","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D66961-4480-7716-E053-F662850AE3D1","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Zibotentan ZD4054","valueDescription":"Zibotentan","ValueMeaning":{"publicId":"6159990","version":"1","preferredName":"Zibotentan","longName":"6159990","preferredDefinition":"An orally available selective antagonist of the endothelin-A (ET-A) receptor with potential antineoplastic activity. Zibotentan binds selectively to the ET-A receptor, thereby inhibiting endothelin-mediated mechanisms that promote tumor cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zibotentan","conceptCode":"C48430","definition":"An orally available selective antagonist of the endothelin-A (ET-A) receptor with potential antineoplastic activity. Zibotentan binds selectively to the ET-A receptor, thereby inhibiting endothelin-mediated mechanisms that promote tumor cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68D66961-44A1-7716-E053-F662850AE3D1","latestVersionIndicator":"Yes","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D66961-44BA-7716-E053-F662850AE3D1","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"ZD6474 Zactima Vandetanib","valueDescription":"Vandetanib","ValueMeaning":{"publicId":"3380803","version":"1","preferredName":"Vandetanib","longName":"3380803","preferredDefinition":"An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vandetanib","conceptCode":"C2737","definition":"An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B980D66E-5D67-FB86-E040-BB89AD43770B","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D66961-44CE-7716-E053-F662850AE3D1","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"ZD1839 Iressa A37 Gefitinib","valueDescription":"Gefitinib","ValueMeaning":{"publicId":"3237466","version":"1","preferredName":"Gefitinib","longName":"3237466","preferredDefinition":"An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gefitinib","conceptCode":"C1855","definition":"An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis. (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3F78E39-65BC-13D6-E040-BB89AD432B2B","latestVersionIndicator":"Yes","beginDate":"2011-05-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-05-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D66961-44E2-7716-E053-F662850AE3D1","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"ZD0473","valueDescription":"Picoplatin","ValueMeaning":{"publicId":"6159992","version":"1","preferredName":"Picoplatin","longName":"6159992","preferredDefinition":"A new generation organic platinum analog with an extended spectrum of antineoplastic activity. Designed to overcome platinum drug resistance, picoplatin alkylates DNA, forming both inter- and intra-strand cross-linkages, resulting in inhibition of DNA replication and transcription, and the induction of apoptosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Picoplatin","conceptCode":"C48416","definition":"A new generation organic platinum analog with an extended spectrum of antineoplastic activity. Designed to overcome platinum drug resistance, picoplatin alkylates DNA, forming both inter- and intra-strand cross-linkages, resulting in inhibition of DNA replication and transcription, and the induction of apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68D66961-44EF-7716-E053-F662850AE3D1","latestVersionIndicator":"Yes","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D66961-4508-7716-E053-F662850AE3D1","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"WR2721 Amifostine Ethyol","valueDescription":"Amifostine","ValueMeaning":{"publicId":"3380282","version":"1","preferredName":"Amifostine","longName":"3380282","preferredDefinition":"A phosphorylated aminosulfhydryl compound. After dephosphorylation by alkaline phosphatase to an active free sulfhydryl (thiol) metabolite, amifostine binds to and detoxifies cytotoxic platinum-containing metabolites of cisplatin and scavenges free radicals induced by cisplatin and ionizing radiation. The elevated activity of this agent in normal tissues results from both the relative abundance of alkaline phosphatase in normal tissues and the greater vascularity of normal tissues compared to tumor tissues. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amifostine","conceptCode":"C488","definition":"The trihydrate form of a phosphorylated aminosulfhydryl compound. After dephosphorylation of amifostine by alkaline phosphatase to an active free sulfhydryl (thiol) metabolite, the thiol metabolite binds to and detoxifies cytotoxic platinum-containing metabolites of cisplatin and scavenges free radicals induced by cisplatin and ionizing radiation. The elevated activity of this agent in normal tissues results from both the relative abundance of alkaline phosphatase in normal tissues and the greater vascularity of normal tissues compared to tumor tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A3FA-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D66961-451C-7716-E053-F662850AE3D1","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Vorozole","valueDescription":"Vorozole","ValueMeaning":{"publicId":"6159994","version":"1","preferredName":"Vorozole","longName":"6159994","preferredDefinition":"A hormone therapy drug used to decrease the production of estrogen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vorozole","conceptCode":"C1601","definition":"A hormone therapy drug used to decrease the production of estrogen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68D66961-4529-7716-E053-F662850AE3D1","latestVersionIndicator":"Yes","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D66961-4542-7716-E053-F662850AE3D1","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Virilon Methyltestosterone Testred Android","valueDescription":"Methyltestosterone","ValueMeaning":{"publicId":"2578270","version":"1","preferredName":"Methyltestosterone","longName":"2578270","preferredDefinition":"A methylated synthetic androgen receptor agonist with anabolic effects. Methyltestosterone, mimicking testosterone, binds to cytosolic androgen receptors, and the subsequent nuclear transfer of the ligand-receptor complex induces transcription initiation of androgen responsive genes. The gene products are responsible for normal growth and development of male sex organs and secondary sex characteristics. The agent also causes retention of nitrogen, sodium, potassium, phosphorus, as well as calcium.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methyltestosterone","conceptCode":"C648","definition":"A methylated synthetic androgen receptor agonist with anabolic effects. Methyltestosterone, mimicking testosterone, binds to cytosolic androgen receptors, and the subsequent nuclear transfer of the ligand-receptor complex induces transcription initiation of androgen responsive genes. The gene products are responsible for normal growth and development of male sex organs and secondary sex characteristics. The agent also causes retention of nitrogen, sodium, potassium, phosphorus, as well as calcium.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FECB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D66961-4556-7716-E053-F662850AE3D1","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Vinflunine Javlor","valueDescription":"Vinflunine Ditartrate","ValueMeaning":{"publicId":"6159996","version":"1","preferredName":"Vinflunine Ditartrate","longName":"6159996","preferredDefinition":"The ditartrate salt of vinflunine, a bi-fluorinated derivative of the semisynthetic vinca alkaloid vinorelbine with potential antimitotic and antineoplastic activities. Vinflunine binds to tubulin and inhibits tubulin assembly and disrupts microtubule assembly dynamics. This results in cell cycle arrest in mitosis and an induction of apoptosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vinflunine Ditartrate","conceptCode":"C76266","definition":"The ditartrate salt of vinflunine, a bi-fluorinated derivative of the semisynthetic vinca alkaloid vinorelbine with potential antimitotic and antineoplastic activities. Vinflunine binds to tubulin and inhibits tubulin assembly and disrupts microtubule assembly dynamics. This results in cell cycle arrest in mitosis and an induction of apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68D66961-4563-7716-E053-F662850AE3D1","latestVersionIndicator":"Yes","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D66961-457C-7716-E053-F662850AE3D1","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"LY294002","valueDescription":"PI3K/BET Inhibitor LY294002","ValueMeaning":{"publicId":"6161756","version":"1","preferredName":"PI3K/BET Inhibitor LY294002","longName":"6161756","preferredDefinition":"A morpholine-based inhibitor of phosphatidylinositol 3-kinase (PI3K) and the bromodomain and extra-terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, the PI3K/BET inhibitor LY294002 specifically targets and binds to both PI3K and the acetylated lysine recognition motifs in the bromodomains of BET proteins. Inhibition of PI3K activity inhibits the PI3K/AKT kinase signaling pathway. This may result in inhibition of growth and survival for tumor cells in which the PI3K-mediated signaling pathway is overactivated. Inhibition of BET proteins prevents their interaction with acetylated histones, disrupts chromatin remodeling and inhibits the expression of oncogenic drivers that are important for cell proliferation and survival, which together may lead to an inhibition of proliferation in BET-overexpressing tumor cells. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators and play an important role during development and cellular growth. In tumor cells, BET proteins play a key role in the regulation of oncogene transcription and tumor cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"PI3K/BET Inhibitor LY294002","conceptCode":"C148229","definition":"A morpholine-based inhibitor of phosphatidylinositol 3-kinase (PI3K) and the bromodomain and extra-terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, the PI3K/BET inhibitor LY294002 specifically targets and binds to both PI3K and the acetylated lysine recognition motifs in the bromodomains of BET proteins. Inhibition of PI3K activity inhibits the PI3K/AKT kinase signaling pathway. This may result in inhibition of growth and survival for tumor cells in which the PI3K-mediated signaling pathway is overactivated. Inhibition of BET proteins prevents their interaction with acetylated histones, disrupts chromatin remodeling and inhibits the expression of oncogenic drivers that are important for cell proliferation and survival, which together may lead to an inhibition of proliferation in BET-overexpressing tumor cells. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators and play an important role during development and cellular growth. In tumor cells, BET proteins play a key role in the regulation of oncogene transcription and tumor cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"692E7DA2-B47B-5D82-E053-F662850A72F6","latestVersionIndicator":"Yes","beginDate":"2018-04-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-06","modifiedBy":"ONEDATA","dateModified":"2018-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"692E7DA2-B494-5D82-E053-F662850A72F6","beginDate":"2018-04-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-06","modifiedBy":"ONEDATA","dateModified":"2018-04-06","deletedIndicator":"No"},{"value":"Mercaptopurine Purinethol","valueDescription":"Mercaptopurine","ValueMeaning":{"publicId":"3379290","version":"1","preferredName":"Mercaptopurine","longName":"3379290","preferredDefinition":"A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mercaptopurine","conceptCode":"C195","definition":"A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-C80B-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AC3EB1-CB69-43A6-E053-F662850AD41E","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Menogaril","valueDescription":"Menogaril","ValueMeaning":{"publicId":"6159867","version":"1","preferredName":"Menogaril","longName":"6159867","preferredDefinition":"A semisynthetic derivative of the anthracycline antineoplastic antibiotic nogalamycin.  Menogaril intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent is less cardiotoxic than doxorubicin. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Menogaril","conceptCode":"C1389","definition":"A semisynthetic derivative of the anthracycline antineoplastic antibiotic nogalamycin.  Menogaril intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent is less cardiotoxic than doxorubicin. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68AC3EB1-CB76-43A6-E053-F662850AD41E","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AC3EB1-CB8F-43A6-E053-F662850AD41E","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Melacine","valueDescription":"Melanoma Theraccine","ValueMeaning":{"publicId":"6159869","version":"1","preferredName":"Melanoma Theraccine","longName":"6159869","preferredDefinition":"A synthetic allogeneic cancer vaccine.  Melanoma theraccine typically consists of lysed melanoma cells obtained from several melanoma cell lines combined with an adjuvant (such as DETOX or RIBI).  This agent may be combined with immunomodulatory cytokines such as interferon alpha.  Melanoma theraccine may induce a rise in the level of cytotoxic T-lymphocyte precursors. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melanoma Theraccine","conceptCode":"C1830","definition":"A synthetic allogeneic cancer vaccine.  Melanoma theraccine typically consists of lysed melanoma cells obtained from several melanoma cell lines combined with an adjuvant (such as DETOX or RIBI).  This agent may be combined with immunomodulatory cytokines such as interferon alpha.  Melanoma theraccine may induce a rise in the level of cytotoxic T-lymphocyte precursors. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68AC3EB1-CB9C-43A6-E053-F662850AD41E","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AC3EB1-CBB5-43A6-E053-F662850AD41E","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Megestrol acetate Megace","valueDescription":"Megestrol Acetate","ValueMeaning":{"publicId":"3379278","version":"1","preferredName":"Megestrol Acetate","longName":"3379278","preferredDefinition":"The acetate salt form of megestrol, a synthetic derivative of the naturally occurring female sex hormone progesterone with anti-estrogenic activity and used in breast cancer treatment. Mimicking the action of progesterone, megestrol acetate binds to and activates nuclear progesterone receptors in the reproductive system, and causes the ligand-receptor complex to be translocated to the nucleus where it binds to and promotes expression of target genes. This leads to an alteration in protein synthesis, which modulates cell growth of reproductive tissues. Due to the negative feedback mechanism seen with progesterone, megestrol also blocks luteinizing hormone (LH) release from the pituitary gland, thereby leading to an inhibition of ovulation and an alteration in the cervical mucus and endometrium. Furthermore, without stimulation of LH, estrogen release from the ovaries is stopped, hence impedes the growth of estrogen-sensitive tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Megestrol Acetate","conceptCode":"C1156","definition":"The acetate salt form of megestrol, a synthetic derivative of the naturally occurring female sex hormone progesterone with potential anti-estrogenic and antineoplastic activity. Mimicking the action of progesterone, megestrol acetate binds to and activates nuclear progesterone receptors in the reproductive system, and causes the ligand-receptor complex to be translocated to the nucleus where it binds to and promotes expression of target genes. This leads to an alteration in protein synthesis, which modulates cell growth of reproductive tissues. Due to the negative feedback mechanism seen with progesterone, megestrol also blocks luteinizing hormone (LH) release from the pituitary gland, thereby leading to an inhibition of ovulation and an alteration in the cervical mucus and endometrium. Furthermore, without stimulation of LH, estrogen release from the ovaries is stopped, hence impedes the growth of estrogen-sensitive tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-C5F5-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AC3EB1-CBC9-43A6-E053-F662850AD41E","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Medroxyprogesterone acetate Provera Clinovir Cycrin","valueDescription":"Medroxyprogesterone 17-Acetate","ValueMeaning":{"publicId":"2578283","version":"1","preferredName":"Medroxyprogesterone 17-Acetate","longName":"2578283","preferredDefinition":"A synthetic, acetate derivative of the sex hormone progesterone.  Medroxyprogesterone 17-acetate (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Medroxyprogesterone Acetate","conceptCode":"C1155","definition":"A synthetic, acetate derivative of the sex hormone progesterone.  Medroxyprogesterone 17-acetate (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FED8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AC3EB1-CBDD-43A6-E053-F662850AD41E","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"MEDI4736 Durvalumab","valueDescription":"Durvalumab","ValueMeaning":{"publicId":"5755432","version":"1","preferredName":"Durvalumab","longName":"5755432","preferredDefinition":"A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Durvalumab","conceptCode":"C103194","definition":"A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4CFD0718-5F32-7D12-E053-F662850AD37E","latestVersionIndicator":"Yes","beginDate":"2017-04-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-04-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AC3EB1-CBF1-43A6-E053-F662850AD41E","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"MDV3100 Enzalutamide","valueDescription":"Enzalutamide","ValueMeaning":{"publicId":"5424693","version":"1","preferredName":"Enzalutamide","longName":"5424693","preferredDefinition":"An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Enzalutamide","conceptCode":"C71744","definition":"An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A6CD4EC-B2B3-871B-E050-BB89AD435B24","latestVersionIndicator":"Yes","beginDate":"2016-08-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AC3EB1-CC05-43A6-E053-F662850AD41E","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"M-AMSA Amsacrine Amsidine","valueDescription":"Amsacrine","ValueMeaning":{"publicId":"6159871","version":"1","preferredName":"Amsacrine","longName":"6159871","preferredDefinition":"An aminoacridine derivative with potential antineoplastic activity. Although its mechanism of action is incompletely defined, amsacrine may intercalate into DNA and inhibit topoisomerase II, resulting in DNA double-strand breaks, arrest of the S/G2 phase of the cell cycle, and cell death. This agent's cytotoxicity is maximal during the S phase of the cell cycle when topoisomerase levels are greatest. In addition, amsacrine may induce transcription of tumor promoter p53 protein and block p53 ubiquitination and proteasomal degradation, resulting in p53-dependent tumor cell apoptosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amsacrine","conceptCode":"C240","definition":"An aminoacridine derivative with potential antineoplastic activity. Although its mechanism of action is incompletely defined, amsacrine may intercalate into DNA and inhibit topoisomerase II, resulting in DNA double-strand breaks, arrest of the S/G2 phase of the cell cycle, and cell death. This agent's cytotoxicity is maximal during the S phase of the cell cycle when topoisomerase levels are greatest. In addition, amsacrine may induce transcription of tumor promoter p53 protein and block p53 ubiquitination and proteasomal degradation, resulting in p53-dependent tumor cell apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68AC3EB1-CC12-43A6-E053-F662850AD41E","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AC3EB1-CC2B-43A6-E053-F662850AD41E","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Lysodren Mitotane","valueDescription":"Mitotane","ValueMeaning":{"publicId":"2578300","version":"1","preferredName":"Mitotane","longName":"2578300","preferredDefinition":"A synthetic derivative of the insecticide dichlorodiphenyl trichloroethane (DDT) with anti-adrenocorticoid properties.  Following its metabolism in the adrenal cortex to a reactive acyl chloride intermediate, mitotane covalently binds to adrenal proteins, specifically inhibiting adrenal cortical hormone production. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mitotane","conceptCode":"C664","definition":"A synthetic derivative of the insecticide dichlorodiphenyl trichloroethane (DDT) with anti-adrenocorticoid properties.  Following its metabolism in the adrenal cortex to a reactive acyl chloride intermediate, mitotane covalently binds to adrenal proteins, specifically inhibiting adrenal cortical hormone production. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEE9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AC3EB1-CC3F-43A6-E053-F662850AD41E","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Estramustine phosphate sodium EMCYT","valueDescription":"Estramustine Phosphate Sodium","ValueMeaning":{"publicId":"6153879","version":"1","preferredName":"Estramustine Phosphate Sodium","longName":"6153879","preferredDefinition":"The orally available disodium salt, monohydrate, of estramustine phosphate, a synthetic molecule that combines estradiol and nornitrogen mustard through a carbamate link. Estramustine and its major metabolite estramustine bind to microtubule-associated proteins (MAPs) and tubulin, thereby inhibiting microtubule dynamics and leading to anaphase arrest in a dose-dependent fashion. This agent also exhibits anti-androgenic effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Estramustine Phosphate Sodium","conceptCode":"C480","definition":"The orally available disodium salt, monohydrate, of estramustine phosphate, a synthetic molecule that combines estradiol and nornitrogen mustard through a carbamate link. Estramustine and its major metabolite estramustine bind to microtubule-associated proteins (MAPs) and tubulin, thereby inhibiting microtubule dynamics and leading to anaphase arrest in a dose-dependent fashion. This agent also exhibits anti-androgenic effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"685806D8-C56A-1B13-E053-F662850A5637","latestVersionIndicator":"Yes","beginDate":"2018-03-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"685806D8-C583-1B13-E053-F662850A5637","beginDate":"2018-03-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"Estinyl Ethinyl estradiol","valueDescription":"Ethinyl Estradiol","ValueMeaning":{"publicId":"2576830","version":"1","preferredName":"Ethinyl Estradiol","longName":"2576830","preferredDefinition":"A semisynthetic estrogen. Ethinyl estradiol binds to the estrogen receptor complex and enters the nucleus, activating DNA transcription of genes involved in estrogenic cellular responses. This agent also inhibits 5-alpha reductase in epididymal tissue, which lowers testosterone levels and may delay progression of prostatic cancer. In addition to its antineoplastic effects, ethinyl estradiol protects against osteoporosis. In animal models, short-term therapy with this agent has been shown to provide long-term protection against breast cancer, mimicking the antitumor effects of pregnancy. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ethinyl Estradiol","conceptCode":"C486","definition":"A semisynthetic estrogen. Ethinyl estradiol binds to the estrogen receptor complex and enters the nucleus, activating DNA transcription of genes involved in estrogenic cellular responses. This agent also inhibits 5-alpha reductase in epididymal tissue, which lowers testosterone levels and may delay progression of prostatic cancer. In addition to its antineoplastic effects, ethinyl estradiol protects against osteoporosis. In animal models, short-term therapy with this agent has been shown to provide long-term protection against breast cancer, mimicking the antitumor effects of pregnancy. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F92B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"685806D8-C597-1B13-E053-F662850A5637","beginDate":"2018-03-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"Esperamycin Esperamicin","valueDescription":"Esperamicin Antibiotic","ValueMeaning":{"publicId":"6153880","version":"1","preferredName":"Esperamicin Antibiotic","longName":"6153880","preferredDefinition":"Any agent belonging to the esperamicins, a class of bacterium-derived chromoprotein enediyne antibiotics with antineoplastic activity. Esperamicins bind to the minor groove of DNA, cleave DNA and induce apoptosis of tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Esperamicin Antibiotic","conceptCode":"C148123","definition":"Any agent belonging to the esperamicins, a class of bacterium-derived chromoprotein enediyne antibiotics with antineoplastic activity. Esperamicins bind to the minor groove of DNA, cleave DNA and induce apoptosis of tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"685806D8-C5A3-1B13-E053-F662850A5637","latestVersionIndicator":"Yes","beginDate":"2018-03-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"685806D8-C5BC-1B13-E053-F662850A5637","beginDate":"2018-03-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"Eribulin mesylate Halaven","valueDescription":"Eribulin Mesylate","ValueMeaning":{"publicId":"3241058","version":"1","preferredName":"Eribulin Mesylate","longName":"3241058","preferredDefinition":"The mesylate salt of a synthetic analogue of halichondrin B, a substance derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eribulin Mesylate","conceptCode":"C26644","definition":"The mesylate salt of a synthetic analogue of halichondrin B, a substance derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A443510D-A0E2-C5AF-E040-BB89AD435D96","latestVersionIndicator":"Yes","beginDate":"2011-05-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"685806D8-C5D0-1B13-E053-F662850A5637","beginDate":"2018-03-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"EpothiloneB EPO906 Patupilone","valueDescription":"Epothilone B","ValueMeaning":{"publicId":"3013195","version":"1","preferredName":"Epothilone B","longName":"3013195","preferredDefinition":"A compound isolated from the myxobacterium Sorangium cellulosum.  Similar to paclitaxel, epothilone B induces microtubule polymerization and stabilizes microtubules against depolymerization conditions.  In addition to promoting tubulin polymerization and stabilization of microtubules, this agent is cytotoxic for cells overexpressing P-glycoprotein, a characteristic that distinguishes it from the taxanes.  Epothilone B may cause complete cell-cycle arrest. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patupilone","conceptCode":"C1623","definition":"A compound isolated from the myxobacterium Sorangium cellulosum.  Similar to paclitaxel, patupilone induces microtubule polymerization and stabilizes microtubules against depolymerization conditions.  In addition to promoting tubulin polymerization and stabilization of microtubules, this agent is cytotoxic for cells overexpressing P-glycoprotein, a characteristic that distinguishes it from the taxanes.  Patupilone may cause complete cell-cycle arrest.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7FF9397D-42B1-21AE-E040-BB89AD436688","latestVersionIndicator":"Yes","beginDate":"2010-02-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-02-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"685806D8-C5E4-1B13-E053-F662850A5637","beginDate":"2018-03-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"Epirubicin Pharmorubicin","valueDescription":"Epirubicin Hydrochloride","ValueMeaning":{"publicId":"2576634","version":"1","preferredName":"Epirubicin Hydrochloride","longName":"2576634","preferredDefinition":"The 4'-epi-isomer of the anthracycline antineoplastic antibiotic doxorubicin.  Epirubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epirubicin Hydrochloride","conceptCode":"C474","definition":"The hydrochloride salt of the 4'-epi-isomer of the anthracycline antineoplastic antibiotic doxorubicin. Epirubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis. This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F867-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"685806D8-C5F8-1B13-E053-F662850A5637","beginDate":"2018-03-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"Enasidenib mesylate Idhifa","valueDescription":"Enasidenib Mesylate","ValueMeaning":{"publicId":"6153882","version":"1","preferredName":"Enasidenib Mesylate","longName":"6153882","preferredDefinition":"The mesylate salt form of enasidenib, an orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits various mutant forms of IDH2, including the IDH2 variants R140Q, R172S, and R172K, which inhibits the formation of 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH2-expressing tumor cells. IDH2, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by blocking differentiation and the production of the oncometabolite 2HG.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Enasidenib Mesylate","conceptCode":"C137825","definition":"The mesylate salt form of enasidenib, an orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits various mutant forms of IDH2, including the IDH2 variants R140Q, R172S, and R172K, which inhibits the formation of 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH2-expressing tumor cells. IDH2, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by blocking differentiation and the production of the oncometabolite 2HG.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"685806D8-C605-1B13-E053-F662850A5637","latestVersionIndicator":"Yes","beginDate":"2018-03-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"685806D8-C61E-1B13-E053-F662850A5637","beginDate":"2018-03-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"Elsamitrucin","valueDescription":"Elsamitrucin","ValueMeaning":{"publicId":"6153884","version":"1","preferredName":"Elsamitrucin","longName":"6153884","preferredDefinition":"An heterocyclic antineoplastic antibiotic isolated from the bacterium Actinomycete strain J907-21.  Elsamitrucin intercalates into DNA at guanine-cytosine (G-C)-rich sequences and inhibits topoisomerase I and II, resulting in single-strand breaks and inhibition of DNA replication. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Elsamitrucin","conceptCode":"C1080","definition":"An heterocyclic antineoplastic antibiotic isolated from the bacterium Actinomycete strain J907-21.  Elsamitrucin intercalates into DNA at guanine-cytosine (G-C)-rich sequences and inhibits topoisomerase I and II, resulting in single-strand breaks and inhibition of DNA replication. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"685806D8-C62B-1B13-E053-F662850A5637","latestVersionIndicator":"Yes","beginDate":"2018-03-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"685806D8-C644-1B13-E053-F662850A5637","beginDate":"2018-03-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"Elotuzumab Empliciti","valueDescription":"Elotuzumab","ValueMeaning":{"publicId":"5621728","version":"1","preferredName":"Elotuzumab","longName":"5621728","preferredDefinition":"A humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity. Elotuzumab binds to the CS1 antigen, which may trigger antibody-dependent cellular cytotoxicity (ADCC) in cells expressing CS1. CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is highly expressed by multiple myeloma cells, but minimally expressed by normal cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Elotuzumab","conceptCode":"C66982","definition":"A humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity. Elotuzumab binds to the CS1 antigen, which may trigger antibody-dependent cellular cytotoxicity (ADCC) in cells expressing CS1. CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is highly expressed by multiple myeloma cells, but minimally expressed by normal cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AECAE5-BC55-28A7-E053-F662850AD609","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"685806D8-C658-1B13-E053-F662850A5637","beginDate":"2018-03-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"Edrecolomab Panorex MOAB 17-1A  Monoclonal antibody 17-1A","valueDescription":"Edrecolomab","ValueMeaning":{"publicId":"6153886","version":"1","preferredName":"Edrecolomab","longName":"6153886","preferredDefinition":"A murine monoclonal IgG2a antibody to tumor-associated epithelial cell adhesion molecule (EpCAM, or 17-1A) antigen. Edrecolomab attaches to EpCAM, a human cell surface glycoprotein that is found on normal epithelial cells and some tumor cells, such as those of colon and breast carcinomas. Upon binding, this agent recruits the body's immune effector cells, which may exhibit antitumor cytotoxicity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Edrecolomab","conceptCode":"C1554","definition":"A murine monoclonal IgG2a antibody to tumor-associated epithelial cell adhesion molecule (EpCAM, or 17-1A) antigen. Edrecolomab attaches to EpCAM, a human cell surface glycoprotein that is found on normal epithelial cells and some tumor cells, such as those of colon and breast carcinomas. Upon binding, this agent recruits the body's immune effector cells, which may exhibit antitumor cytotoxicity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"685806D8-C665-1B13-E053-F662850A5637","latestVersionIndicator":"Yes","beginDate":"2018-03-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"685806D8-C67E-1B13-E053-F662850A5637","beginDate":"2018-03-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"Andro Testosterone Androstenedione","valueDescription":"Androstenedione Testosterone ","ValueMeaning":{"publicId":"6148610","version":"1","preferredName":"Androstenedione Testosterone ","longName":"6148610","preferredDefinition":"A steroid hormone synthesized by the adrenal glands and the gonads from either 17-alpha-hydroxyprogesterone or dehydroepiandrosterone and is a precursor of testosterone.: A hormone made mainly in the testes (part of the male reproductive system). It is needed to develop and maintain male sex characteristics, such as facial hair, deep voice, and muscle growth. Testosterone may also be made in the laboratory and is used to treat certain medical conditions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Androstenedione","conceptCode":"C2300","definition":"A steroid hormone synthesized by the adrenal glands and the gonads from either 17-alpha-hydroxyprogesterone or dehydroepiandrosterone and is a precursor of testosterone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Testosterone","conceptCode":"C2299","definition":"A hormone made mainly in the testes (part of the male reproductive system). It is needed to develop and maintain male sex characteristics, such as facial hair, deep voice, and muscle growth. Testosterone may also be made in the laboratory and is used to treat certain medical conditions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682E2DE8-3EFC-2546-E053-F662850A0E58","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"TAYLORT","dateModified":"2018-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-3F15-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Amonafide Xanafide","valueDescription":"Amonafide L-Malate","ValueMeaning":{"publicId":"6148612","version":"1","preferredName":"Amonafide L-Malate","longName":"6148612","preferredDefinition":"The malate salt of amonafide, an imide derivative of naphthalic acid, with potential antineoplastic activity. Amonafide intercalates into DNA and inhibits topoisomerase II, resulting in DNA double-strand breaks (DSB) and inhibition of DNA replication and RNA synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amonafide L-Malate","conceptCode":"C61306","definition":"The malate salt of amonafide, an imide derivative of naphthalic acid, with potential antineoplastic activity. Amonafide intercalates into DNA and inhibits topoisomerase II, resulting in DNA double-strand breaks (DSB) and inhibition of DNA replication and RNA synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682E2DE8-3F22-2546-E053-F662850A0E58","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-3F3B-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"AMG-706 Motesanib","valueDescription":"Motesanib","ValueMeaning":{"publicId":"6148614","version":"1","preferredName":"Motesanib","longName":"6148614","preferredDefinition":"An orally bioavailable receptor tyrosine kinase inhibitor with potential antineoplastic activity. AMG 706 selectively targets and inhibits vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGFR), Kit, and Ret receptors, thereby inhibiting angiogenesis and cellular proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Motesanib","conceptCode":"C71896","definition":"An orally bioavailable receptor tyrosine kinase inhibitor with potential antineoplastic activity. AMG 706 selectively targets and inhibits vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGFR), Kit, and Ret receptors, thereby inhibiting angiogenesis and cellular proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682E2DE8-3F48-2546-E053-F662850A0E58","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-3F61-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"AMG386, Trebananib","valueDescription":"Angiopoietin 1/2-Neutralizing Peptibody AMG 386","ValueMeaning":{"publicId":"3205720","version":"1","preferredName":"Angiopoietin 1/2-Neutralizing Peptibody AMG 386","longName":"3205720","preferredDefinition":"An angiopoietin (Ang) 1 and 2 neutralizing peptibody, with potential antiangiogenic activity. AMG 386 targets and binds to Ang1 and Ang2, thereby preventing the interaction of the angiopoietins with their target tie2 receptors. This may inhibit angiogenesis and may eventually lead to an inhibition of tumor cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trebananib","conceptCode":"C91711","definition":"An angiopoietin (Ang) 1 and 2 neutralizing peptibody, with potential antiangiogenic activity. AMG 386 targets and binds to Ang1 and Ang2, thereby preventing the interaction of the angiopoietins with their target tie2 receptors. This may inhibit angiogenesis and may eventually lead to an inhibition of tumor cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9EFD7B87-C0FE-51DF-E040-BB89AD436BE5","latestVersionIndicator":"Yes","beginDate":"2011-03-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-03-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-3F75-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"AMD3100 Plerixafor Mozobil JM 3100","valueDescription":"Plerixafor","ValueMeaning":{"publicId":"3631680","version":"1","preferredName":"Plerixafor","longName":"3631680","preferredDefinition":"A bicyclam with hematopoietic stem cell-mobilizing activity. Plerixafor blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plerixafor","conceptCode":"C1777","definition":"A bicyclam with hematopoietic stem cell-mobilizing activity. Plerixafor blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFB802C2-BC50-449B-E040-BB89AD4358D4","latestVersionIndicator":"Yes","beginDate":"2012-11-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-11-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-3F89-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Altocor Lovastatin Altoprev Mevacor","valueDescription":"Lovastatin","ValueMeaning":{"publicId":"3379209","version":"1","preferredName":"Lovastatin","longName":"3379209","preferredDefinition":"A lactone metabolite isolated from the fungus Aspergillus terreus with cholesterol-lowering activity and potential antineoplastic activity. Lovastatin is hydrolyszed to the active beta-hydroxyacid form, which competitively inhibits 3-hydroxyl-3-methylgutarylcoenzyme A (HMG-CoA) reductase, an enzyme involved in the cholesterol biosynthesis.  In addition, this agent may inhibit tumor cell proliferation and reduce tumor cell invasiveness, thereby decreasing tumor metastatic potential; induce tumor cell apoptosis, possibly by inhibiting protein geranylgeranylation and; arrest cells in the G1 phase of the cell cycle, an effect that sensitizes tumor cells to the cytotoxic effects of ionizing radiation.  (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lovastatin","conceptCode":"C620","definition":"A lactone metabolite isolated from the fungus Aspergillus terreus with cholesterol-lowering and potential antineoplastic activities. Lovastatin is hydrolyzed to the active beta-hydroxyacid form, which competitively inhibits 3-hydroxyl-3-methylgutarylcoenzyme A (HMG-CoA) reductase, an enzyme involved in cholesterol biosynthesis. In addition, this agent may induce tumor cell apoptosis and inhibit tumor cell invasiveness, possibly by inhibiting protein farnesylation and protein geranylgeranylation, and may arrest cells in the G1 phase of the cell cycle. The latter effect sensitizes tumor cells to the cytotoxic effects of ionizing radiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B918227F-B2D7-6EA7-E040-BB89AD434A76","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-3F9D-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"All-trans-retinoic acid Vesanoid Tretinoin","valueDescription":"Tretinoin","ValueMeaning":{"publicId":"5342173","version":"1","preferredName":"Tretinoin","longName":"5342173","preferredDefinition":"A naturally-occurring acid of retinol. Tretinoin binds to and activates retinoic acid receptors (RARs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, and inhibition of tumorigenesis.  This agent also inhibits telomerase, resulting in telomere shortening and eventual apoptosis of some tumor cell types.  The oral form of tretinoin has teratogenic and embryotoxic properties.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tretinoin","conceptCode":"C900","definition":"A naturally-occurring acid of retinol. Tretinoin binds to and activates retinoic acid receptors (RARs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, and inhibition of tumorigenesis.  This agent also inhibits telomerase, resulting in telomere shortening and eventual apoptosis of some tumor cell types.  The oral form of tretinoin has teratogenic and embryotoxic properties.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3765270F-3A61-8633-E050-BB89AD4330A5","latestVersionIndicator":"Yes","beginDate":"2016-07-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-07-11","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-3FB1-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Alizapride ","valueDescription":"Alizapride","ValueMeaning":{"publicId":"6148616","version":"1","preferredName":"Alizapride","longName":"6148616","preferredDefinition":"A substituted benzamide that acts as a dopamine receptor antagonist with antiemetic properties.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alizapride","conceptCode":"C995","definition":"A substituted benzamide that acts as a dopamine receptor antagonist with antiemetic properties.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682E2DE8-3FBE-2546-E053-F662850A0E58","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-3FD7-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Alemtuzumab Campath","valueDescription":"Alemtuzumab","ValueMeaning":{"publicId":"2577772","version":"1","preferredName":"Alemtuzumab","longName":"2577772","preferredDefinition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alemtuzumab","conceptCode":"C1681","definition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCD9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-20","modifiedBy":"ALEYR","dateModified":"2008-04-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-3FEB-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Alectinib Alecensa","valueDescription":"Alectinib","ValueMeaning":{"publicId":"4828189","version":"1","preferredName":"Alectinib","longName":"4828189","preferredDefinition":"An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, alectinib binds to and inhibits ALK kinase, ALK fusion proteins as well as the gatekeeper mutation ALKL1196M known as one of the mechanisms of acquired resistance to small-molecule kinase inhibitors. The inhibition leads to disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alectinib","conceptCode":"C101790","definition":"An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, alectinib binds to and inhibits ALK kinase, ALK fusion proteins as well as the gatekeeper mutation ALKL1196M known as one of the mechanisms of acquired resistance to small-molecule kinase inhibitors. The inhibition leads to disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"16717093-49DD-6644-E050-BB89AD434C5B","latestVersionIndicator":"Yes","beginDate":"2015-05-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-05-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-3FFF-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Aflibercept Eylea","valueDescription":"Aflibercept","ValueMeaning":{"publicId":"3880514","version":"1","preferredName":"Aflibercept","longName":"3880514v1.00","preferredDefinition":"A recombinant protein comprised of epitopes of the extracellular domains of human vascular endothelial growth factor receptors (VEGFR) fused to the constant region (Fc) of human IgG1 with potential antiangiogenic activity. Afilbercept, functioning as a soluble decoy receptor, binds to pro-angiogenic vascular endothelial growth factors (VEGFs), thereby preventing VEGFs from binding to their endogenous receptors. Disruption of the binding of VEGFs to their cellular receptors may result in the inhibition of tumor angiogenesis, metastasis, and ultimately tumor regression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ziv-Aflibercept","conceptCode":"C2682","definition":"A recombinant protein comprised of epitopes of the extracellular domains of human vascular endothelial growth factor receptors (VEGFR) fused to the constant region (Fc) of human IgG1 with potential antiangiogenic activity. Afilbercept, functioning as a soluble decoy receptor, binds to pro-angiogenic vascular endothelial growth factors (VEGFs), thereby preventing VEGFs from binding to their endogenous receptors. Disruption of the binding of VEGFs to their cellular receptors may result in the inhibition of tumor angiogenesis, metastasis, and ultimately tumor regression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5B6AC0C-2D46-A8F1-E040-BB89AD43573C","latestVersionIndicator":"Yes","beginDate":"2013-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-06","modifiedBy":"GDEEN","dateModified":"2023-05-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-4013-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Afatinib, Gilotrif, Tomtovok","valueDescription":"Afatinib Dimaleate","ValueMeaning":{"publicId":"6148617","version":"1","preferredName":"Afatinib Dimaleate","longName":"6148617","preferredDefinition":"The dimaleate salt form of afatinib, an orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity. Upon administration, afatinib selectively and irreversibly binds to and inhibits the epidermal growth factor receptors 1 (ErbB1; EGFR), 2 (ErbB2; HER2), and 4 (ErbB4; HER4), and certain EGFR mutants, including those caused by EGFR exon 19 deletion mutations or exon 21 (L858R) mutations. This may result in the inhibition of tumor growth and angiogenesis in tumor cells overexpressing these RTKs. Additionally, afatinib inhibits the EGFR T790M gatekeeper mutation which is resistant to treatment with first-generation EGFR inhibitors. EGFR, HER2 and HER4 are RTKs that belong to the EGFR superfamily; they play major roles in both tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Afatinib Dimaleate","conceptCode":"C97273","definition":"The dimaleate salt form of afatinib, an orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity. Upon administration, afatinib selectively and irreversibly binds to and inhibits the epidermal growth factor receptors 1 (ErbB1; EGFR), 2 (ErbB2; HER2), and 4 (ErbB4; HER4), and certain EGFR mutants, including those caused by EGFR exon 19 deletion mutations or exon 21 (L858R) mutations. This may result in the inhibition of tumor growth and angiogenesis in tumor cells overexpressing these RTKs. Additionally, afatinib inhibits the EGFR T790M gatekeeper mutation which is resistant to treatment with first-generation EGFR inhibitors. EGFR, HER2 and HER4 are RTKs that belong to the EGFR superfamily; they play major roles in both tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682E2DE8-401F-2546-E053-F662850A0E58","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-4038-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Capecitabine Xeloda","valueDescription":"Capecitabine","ValueMeaning":{"publicId":"2718478","version":"1","preferredName":"Capecitabine","longName":"2718478","preferredDefinition":"A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Capecitabine","conceptCode":"C1794","definition":"A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42D79B0B-217A-74F3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-01-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-404D-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Calcitonin Calcimar Miacalcin","valueDescription":"Calcitonin Salmon","ValueMeaning":{"publicId":"6148632","version":"1","preferredName":"Calcitonin Salmon","longName":"6148632","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Calcitonin Salmon","conceptCode":"C329","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682E2DE8-405A-2546-E053-F662850A0E58","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-4073-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Cabozantinib Cometriq XL184","valueDescription":"XL184 (Cabozantinib-S-malate)","ValueMeaning":{"publicId":"3134357","version":"1","preferredName":"XL184 (Cabozantinib-S-malate)","longName":"3134357","preferredDefinition":"The s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cabozantinib S-malate","conceptCode":"C97938","definition":"The s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F391D7A-EA3F-2C4D-E040-BB89AD4302AD","latestVersionIndicator":"Yes","beginDate":"2010-09-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-4087-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Cabazitaxel Jevtana XRP-6258","valueDescription":"Cabazitaxel","ValueMeaning":{"publicId":"3788422","version":"1","preferredName":"Cabazitaxel","longName":"3788422","preferredDefinition":"A semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel binds to and stabilizes tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, this agent is a poor substrate for the membrane-associated, multidrug resistance (MDR), P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors. In addition, cabazitaxel penetrates the blood-brain barrier (BBB).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cabazitaxel","conceptCode":"C66937","definition":"A semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel binds to and stabilizes tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, this agent is a poor substrate for the membrane-associated, multidrug resistance (MDR), P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors. In addition, cabazitaxel penetrates the blood-brain barrier (BBB).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF80A1B1-CB63-E6C9-E040-BB89AD4332B0","latestVersionIndicator":"Yes","beginDate":"2013-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-409B-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Busulfan Myleran","valueDescription":"Busulfan","ValueMeaning":{"publicId":"2739539","version":"1","preferredName":"Busulfan","longName":"2739539","preferredDefinition":"A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties.  Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA.  Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Busulfan","conceptCode":"C321","definition":"A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties.  Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA.  Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A728356-BBD0-71E4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-40AF-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Buserelin Suprefact","valueDescription":"Buserelin","ValueMeaning":{"publicId":"2576647","version":"1","preferredName":"Buserelin","longName":"2576647","preferredDefinition":"A synthetic analog of gonadotropin-releasing hormone (GnRH).  Buserelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors.  Prolonged administration of buserelin results in sustained inhibition of gonadotropin production, suppression of testicular and ovarian steroidogenesis, and reduced levels of circulating gonadotropin and gonadal steroids. Buserelin is more potent that GnRH. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Buserelin","conceptCode":"C320","definition":"A synthetic analog of gonadotropin-releasing hormone (GnRH).  Buserelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors.  Prolonged administration of buserelin results in sustained inhibition of gonadotropin production, suppression of testicular and ovarian steroidogenesis, and reduced levels of circulating gonadotropin and gonadal steroids. Buserelin is more potent that GnRH. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F874-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"COOPERM","dateModified":"2016-08-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-40C3-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Buparlisib BKM120","valueDescription":"PI3K Inhibitor BKM120","ValueMeaning":{"publicId":"3788416","version":"1","preferredName":"PI3K Inhibitor BKM120","longName":"3788416","preferredDefinition":"An orally bioavailable specific oral inhibitor of the pan-class I phosphatidylinositol 3-kinase (PI3K) family of lipid kinases with potential antineoplastic activity. Buparlisib specifically inhibits class I PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway in an ATP-competitive manner, thereby inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate and activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Buparlisib","conceptCode":"C90565","definition":"An orally bioavailable specific oral inhibitor of the pan-class I phosphatidylinositol 3-kinase (PI3K) family of lipid kinases with potential antineoplastic activity. Buparlisib specifically inhibits class I PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway in an ATP-competitive manner, thereby inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate and activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF80A1B1-CAD3-E6C9-E040-BB89AD4332B0","latestVersionIndicator":"Yes","beginDate":"2013-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-40D7-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Bryostatin","valueDescription":"Bryostatin 1","ValueMeaning":{"publicId":"6148634","version":"1","preferredName":"Bryostatin 1","longName":"6148634","preferredDefinition":"A macrocyclic lactone isolated from the bryozoan Bugula neritina with antineoplastic activity.  Bryostatin 1 binds to and inhibits the cell-signaling enzyme protein kinase C, resulting in the inhibition of tumor cell proliferation, the promotion of tumor cell differentiation, and the induction of tumor cell apoptosis. This agent may act synergistically with other chemotherapeutic agents. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bryostatin 1","conceptCode":"C1026","definition":"A macrocyclic lactone isolated from the bryozoan Bugula neritina with antineoplastic activity.  Bryostatin 1 binds to and inhibits the cell-signaling enzyme protein kinase C, resulting in the inhibition of tumor cell proliferation, the promotion of tumor cell differentiation, and the induction of tumor cell apoptosis. This agent may act synergistically with other chemotherapeutic agents. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682E2DE8-40E4-2546-E053-F662850A0E58","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-40FD-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Brivanib alaninate BMS582664","valueDescription":"Brivanib Alaninate","ValueMeaning":{"publicId":"3378161","version":"1","preferredName":"Brivanib Alaninate","longName":"3378161","preferredDefinition":"The alaninate salt of a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity. Brivanib strongly binds to and inhibits VEGFR2, a tyrosine kinase receptor expressed almost exclusively on vascular endothelial cells; inhibition of VEGFR2 may result in inhibition of tumor angiogenesis, inhibition of tumor cell growth, and tumor regression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brivanib Alaninate","conceptCode":"C53397","definition":"The alaninate salt of a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity. Brivanib strongly binds to and inhibits VEGFR2, a tyrosine kinase receptor expressed almost exclusively on vascular endothelial cells; inhibition of VEGFR2 may result in inhibition of tumor angiogenesis, inhibition of tumor cell growth, and tumor regression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90390BA-6D59-6B71-E040-BB89AD432BAA","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-4111-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Brigatinib Alunbrig","valueDescription":"Brigatinib","ValueMeaning":{"publicId":"6117828","version":"1","preferredName":"Brigatinib","longName":"6117828","preferredDefinition":"An orally available inhibitor of receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Brigatinib binds to and inhibits ALK kinase and ALK fusion proteins as well as EGFR and mutant forms. This leads to the inhibition of ALK kinase and EGFR kinase, disrupts their signaling pathways and eventually inhibits tumor cell growth in susceptible tumor cells. In addition, AP26113 appears to overcome mutation-based resistance. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. EGFR is overexpressed in a variety of cancer cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brigatinib","conceptCode":"C98831","definition":"An orally available inhibitor of receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Brigatinib binds to and inhibits ALK kinase and ALK fusion proteins as well as EGFR and mutant forms. This leads to the inhibition of ALK kinase and EGFR kinase, disrupts their signaling pathways and eventually inhibits tumor cell growth in susceptible tumor cells. In addition, AP26113 appears to overcome mutation-based resistance. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. EGFR is overexpressed in a variety of cancer cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"66EA6EE2-D4A8-1BC0-E053-F662850AA277","latestVersionIndicator":"Yes","beginDate":"2018-03-08","endDate":null,"createdBy":"PATELV","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-4125-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Brentuximab vedotin Adcetris","valueDescription":"Brentuximab Vedotin","ValueMeaning":{"publicId":"3228385","version":"1","preferredName":"Brentuximab Vedotin","longName":"3228385","preferredDefinition":"An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the humanized anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brentuximab Vedotin","conceptCode":"C66944","definition":"An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the chimeric anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A16046E6-D6A0-1B8D-E040-BB89AD434ADA","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-20","modifiedBy":"KUMMEROA","dateModified":"2023-03-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-4139-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"BR96-Doxorubicin","valueDescription":"Doxorubicin","ValueMeaning":{"publicId":"2561008","version":"1","preferredName":"Doxorubicin","longName":"2561008","preferredDefinition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxorubicin","conceptCode":"C456","definition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BB5D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-04-11","endDate":null,"createdBy":"JASUR","dateCreated":"2002-04-11","modifiedBy":"CLOHNES","dateModified":"2022-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-414D-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Bosutinib Bosulif","valueDescription":"Bosutinib","ValueMeaning":{"publicId":"3379565","version":"1","preferredName":"Bosutinib","longName":"3379565","preferredDefinition":"A synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bosutinib","conceptCode":"C60809","definition":"A synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-371C-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-4161-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"BMS354825 Dasatinib Sprycel","valueDescription":"Dasatinib","ValueMeaning":{"publicId":"2737464","version":"1","preferredName":"Dasatinib","longName":"2737464","preferredDefinition":"An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases.  Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dasatinib","conceptCode":"C38713","definition":"An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases.  Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with a variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"497238FA-C312-26E6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-4175-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"BMS275291","valueDescription":"Rebimastat","ValueMeaning":{"publicId":"6148636","version":"1","preferredName":"Rebimastat","longName":"6148636","preferredDefinition":"A sulfhydryl-based second-generation matrix metalloproteinase (MMP) inhibitor with potential antineoplastic activity. Rebimastat selectively inhibits several MMPs (MMP 1, 2, 8, 9, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rebimastat","conceptCode":"C1875","definition":"A sulfhydryl-based second-generation matrix metalloproteinase (MMP) inhibitor with potential antineoplastic activity. Rebimastat selectively inhibits several MMPs (MMP 1, 2, 8, 9, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682E2DE8-4182-2546-E053-F662850A0E58","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-419B-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"BMS275183","valueDescription":"BMS-275183","ValueMeaning":{"publicId":"6148638","version":"1","preferredName":"BMS-275183","longName":"6148638","preferredDefinition":"An orally available, C-4 methyl carbonate analog of paclitaxel with potential antineoplastic activity. Like paclitaxel, BMS-275183 binds to tubulin and stabilizes microtubules, thereby inhibiting microtubule disassembly which results in cell-cycle arrest at the G2/M phase and an induction of apoptosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BMS-275183","conceptCode":"C62639","definition":"An orally available, C-4 methyl carbonate analog of paclitaxel with potential antineoplastic activity. Like paclitaxel, BMS-275183 binds to tubulin and stabilizes microtubules, thereby inhibiting microtubule disassembly which results in cell-cycle arrest at the G2/M phase and an induction of apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682E2DE8-41A8-2546-E053-F662850A0E58","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-41C1-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"BMK120, Buparlisib","valueDescription":"PI3K Inhibitor BKM120","ValueMeaning":{"publicId":"3788416","version":"1","preferredName":"PI3K Inhibitor BKM120","longName":"3788416","preferredDefinition":"An orally bioavailable specific oral inhibitor of the pan-class I phosphatidylinositol 3-kinase (PI3K) family of lipid kinases with potential antineoplastic activity. Buparlisib specifically inhibits class I PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway in an ATP-competitive manner, thereby inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate and activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Buparlisib","conceptCode":"C90565","definition":"An orally bioavailable specific oral inhibitor of the pan-class I phosphatidylinositol 3-kinase (PI3K) family of lipid kinases with potential antineoplastic activity. Buparlisib specifically inhibits class I PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway in an ATP-competitive manner, thereby inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate and activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF80A1B1-CAD3-E6C9-E040-BB89AD4332B0","latestVersionIndicator":"Yes","beginDate":"2013-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-41D5-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Blinatumomab Blincyto","valueDescription":"Blinatumomab","ValueMeaning":{"publicId":"3690103","version":"1","preferredName":"Blinatumomab","longName":"3690103","preferredDefinition":"A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blinatumomab","conceptCode":"C62528","definition":"A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D68C2697-3E36-5AFE-E040-BB89AD431E18","latestVersionIndicator":"Yes","beginDate":"2013-02-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-02-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-41E9-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Bleomycin sulfate Blenoxane","valueDescription":"Bleomycin Sulfate","ValueMeaning":{"publicId":"6148640","version":"1","preferredName":"Bleomycin Sulfate","longName":"6148640","preferredDefinition":"A mixture of the sulfate salts of basic glycopeptide antineoplastic antibiotics isolated from Streptomyces verticillus. Bleomycin sulfate forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bleomycin Sulfate","conceptCode":"C312","definition":"A mixture of the sulfate salts of basic glycopeptide antineoplastic antibiotics isolated from Streptomyces verticillus. Bleomycin sulfate forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682E2DE8-41F6-2546-E053-F662850A0E58","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E2DE8-420F-2546-E053-F662850A0E58","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"GW572016 Lapatinib Tykerb","valueDescription":"Lapatinib Lapatinib Ditosylate","ValueMeaning":{"publicId":"6160044","version":"1","preferredName":"Lapatinib Lapatinib Ditosylate","longName":"6160044","preferredDefinition":"A synthetic, orally-active quinazoline with potential antineoplastic properties. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.: The ditosylate salt of lapatinib, a synthetic, orally-active quinazoline with potential antineoplastic activity. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lapatinib","conceptCode":"C26653","definition":"A synthetic, orally-active quinazoline with potential antineoplastic properties. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Lapatinib Ditosylate","conceptCode":"C66878","definition":"The ditosylate salt of lapatinib, a synthetic, orally-active quinazoline with potential antineoplastic activity. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68E3D2BE-CD68-3F5E-E053-F662850A05E0","latestVersionIndicator":"Yes","beginDate":"2018-04-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68E3D2BE-CD81-3F5E-E053-F662850A05E0","beginDate":"2018-04-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","deletedIndicator":"No"},{"value":"MUC1 vaccine ImMucin","valueDescription":"MUC1 SP Vaccine","ValueMeaning":{"publicId":"6160604","version":"1","preferredName":"MUC1 SP Vaccine","longName":"6160604","preferredDefinition":"A therapeutic cancer vaccine comprised of a synthetic, 21-mer long peptide (LP) derived from the entire signal peptide (SP) domain of the tumor-associated antigen (TAA) mucin 1 (MUC1), with potential immunomodulating and antineoplastic activities. Upon intradermal administration, MUC1 SP vaccine may stimulate the host immune system to mount robust cytotoxic T-lymphocyte (CTL) and B-cell responses against MUC1-expressing tumor cells, resulting in tumor cell apoptosis and decreased tumor growth. MUC1 is overexpressed on many tumor cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MUC1 SP Vaccine","conceptCode":"C148171","definition":"A therapeutic cancer vaccine comprised of a synthetic, 21-mer long peptide (LP) derived from the entire signal peptide (SP) domain of the tumor-associated antigen (TAA) mucin 1 (MUC1), with potential immunomodulating and antineoplastic activities. Upon intradermal administration, MUC1 SP vaccine may stimulate the host immune system to mount robust cytotoxic T-lymphocyte (CTL) and B-cell responses against MUC1-expressing tumor cells, resulting in tumor cell apoptosis and decreased tumor growth. MUC1 is overexpressed on many tumor cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68E56521-ADFA-6782-E053-F662850A8F17","latestVersionIndicator":"Yes","beginDate":"2018-04-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-03","modifiedBy":"ONEDATA","dateModified":"2018-04-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68E56521-AE13-6782-E053-F662850A8F17","beginDate":"2018-04-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-03","modifiedBy":"ONEDATA","dateModified":"2018-04-03","deletedIndicator":"No"},{"value":"Everolimus Afinitor RAD001C","valueDescription":"Everolimus","ValueMeaning":{"publicId":"3379525","version":"1","preferredName":"Everolimus","longName":"3379525","preferredDefinition":"A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Everolimus","conceptCode":"C48387","definition":"A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-3294-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"COOPERM","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A3D14A-005D-7171-E053-F662850ABD85","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Etoposide VP-16 Vepesid Toposar Etopophos","valueDescription":"Etoposide","ValueMeaning":{"publicId":"2739535","version":"1","preferredName":"Etoposide","longName":"2739535","preferredDefinition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etoposide","conceptCode":"C491","definition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A728356-BAFB-71E4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"KUMMEROA","dateModified":"2022-09-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A3D14A-0071-7171-E053-F662850ABD85","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"ET-743 Ecteinascidin-743 Trabectedin Yondelis","valueDescription":"Trabectedin","ValueMeaning":{"publicId":"3380231","version":"1","preferredName":"Trabectedin","longName":"3380231","preferredDefinition":"A tetrahydroisoquinoline alkaloid isolated from the marine tunicate Ecteinascidia turbinata with potential antineoplastic activity. Binding to the minor groove of DNA, trabectedin interferes with the transcription-coupled nucleotide excision repair machinery to induce lethal DNA strand breaks and blocks the cell cycle in the G2 phase.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trabectedin","conceptCode":"C1691","definition":"A tetrahydroisoquinoline alkaloid isolated from the marine tunicate Ecteinascidia turbinata with potential antineoplastic activity. Binding to the minor groove of DNA, trabectedin interferes with the transcription-coupled nucleotide excision repair machinery to induce lethal DNA strand breaks and blocks the cell cycle in the G2 phase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97B8401-15DE-113F-E040-BB89AD431AAC","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"COLBERTM","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":"1/2/24 Added Yondelis as alt name for PCDC. mr","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A3D14A-0085-7171-E053-F662850ABD85","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Dutasteride, Avodart","valueDescription":"Dutasteride","ValueMeaning":{"publicId":"2576806","version":"1","preferredName":"Dutasteride","longName":"2576806","preferredDefinition":"A synthetic 4-azasteroid compound. Dutasteride competitively and specificly inhibits both 5-alpha-reductase 1 and 2 isoenzymes that convert testosterone to dihydrotestosterone. The type 2 isoenzyme is primarily active in the reproductive tissues, while the type 1 isoenzyme is also responsible for conversion of testosterone in the skin and liver. Inhibition of 5-alpha reductase leads to a reduction of dihydrotestosterone formation and subsequently prevents the enlargement of the prostate gland. Dutasteride is used in the treatment of benign prostatic hyperplasia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dutasteride","conceptCode":"C47503","definition":"A synthetic 4-azasteroid compound. Dutasteride competitively and specifically binds to isoenzymes 1 and 2 of 5 alpha-reductase, forming stable enzyme complexes and inhibiting the conversion of testosterone to 5 alpha-dihydrotestosterone (DHT); the reduction in DHT activity may mitigate or prevent enlargement of the prostate gland. The type 2 5 alpha-reductase isoenzyme is primarily active in the reproductive tissues, while the type 1 isoenzyme is also active in skin and the liver.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F913-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683BD763-FC51-06B2-E053-F662850AFAC2","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"DUP937 CI-937 Teloxantrone hydrochloride","valueDescription":"Teloxantrone Hydrochloride","ValueMeaning":{"publicId":"6148665","version":"1","preferredName":"Teloxantrone Hydrochloride","longName":"6148665","preferredDefinition":"The hydrochloride salt of an anthrapyrazole antineoplastic antibiotic. Teloxantrone intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair, as well as RNA and protein synthesis","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Teloxantrone Hydrochloride","conceptCode":"C74544","definition":"The hydrochloride salt of an anthrapyrazole antineoplastic antibiotic. Teloxantrone intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair, as well as RNA and protein synthesis","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"683BD763-FC5E-06B2-E053-F662850AFAC2","latestVersionIndicator":"Yes","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683BD763-FC77-06B2-E053-F662850AFAC2","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Doxil Caelyx Liposomal doxorubicin","valueDescription":"Doxorubicin Hydrochloride Liposome","ValueMeaning":{"publicId":"3379143","version":"1","preferredName":"Doxorubicin Hydrochloride Liposome","longName":"3379143","preferredDefinition":"A liposome-encapsulated form of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin.  Liposomal delivery of doxorubicin HCL improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects.  Doxorubicin intercalates into DNA and interacts with topoisomerase II, consequently inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pegylated Liposomal Doxorubicin Hydrochloride","conceptCode":"C1555","definition":"A liposome-encapsulated preparation of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin. Doxorubicin intercalates between DNA base pairs, thereby hinders the movement of replication machinery along DNA strands, as well as blocks the activity of topoisomerase II during replication. As a result, this agent causes DNA adducts formation, renders single- and double-stranded DNA breakages that induce DNA repair and or apoptotic processes. Doxorubicin also generates reactive oxygen species that leads to cytotoxicity secondary to lipid peroxidation of cell membrane lipids. Liposomal delivery of doxorubicin HCl improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects. A liposomal formulation of doxorubicin also modulates toxicity, specifically the cardiac effects commonly seen with anthracycline antitumor drugs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B917C4ED-EABF-F265-E040-BB89AD435210","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"GDEEN","dateModified":"2023-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683BD763-FC8B-06B2-E053-F662850AFAC2","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Dovitinib TKI258","valueDescription":"Dovitinib Lactate","ValueMeaning":{"publicId":"3813177","version":"1","preferredName":"Dovitinib Lactate","longName":"3813177","preferredDefinition":"The orally bioavailable lactate salt of a benzimidazole-quinolinone compound with potential antineoplastic activity. Dovitinib strongly binds to fibroblast growth factor receptor 3 (FGFR3) and inhibits its phosphorylation, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell death. In addition, this agent may inhibit other members of the RTK superfamily, including the vascular endothelial growth factor receptor; fibroblast growth factor receptor 1; platelet-derived growth factor receptor type 3; FMS-like tyrosine kinase 3; stem cell factor receptor (c-KIT); and colony-stimulating factor receptor 1; this may result in an additional reduction in cellular proliferation and angiogenesis, and the induction of tumor cell apoptosis. The activation of FGFR3 is associated with cell proliferation and survival in certain cancer cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dovitinib Lactate","conceptCode":"C62435","definition":"The orally bioavailable lactate salt of a benzimidazole-quinolinone compound with potential antineoplastic activity. Dovitinib strongly binds to fibroblast growth factor receptor 3 (FGFR3) and inhibits its phosphorylation, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell death. In addition, this agent may inhibit other members of the RTK superfamily, including the vascular endothelial growth factor receptor; fibroblast growth factor receptor 1; platelet-derived growth factor receptor type 3; FMS-like tyrosine kinase 3; stem cell factor receptor (c-KIT); and colony-stimulating factor receptor 1; this may result in an additional reduction in cellular proliferation and angiogenesis, and the induction of tumor cell apoptosis. The activation of FGFR3 is associated with cell proliferation and survival in certain cancer cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E1DC2A43-2B28-EAC1-E040-BB89AD43563F","latestVersionIndicator":"Yes","beginDate":"2013-07-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-07-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683BD763-FC9F-06B2-E053-F662850AFAC2","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Dinutuximab Unituxin","valueDescription":"Monoclonal Antibody Ch14.18","ValueMeaning":{"publicId":"3597790","version":"1","preferredName":"Monoclonal Antibody Ch14.18","longName":"3597790","preferredDefinition":"A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Monoclonal antibody Ch14.18 binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells.  GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dinutuximab","conceptCode":"C1570","definition":"A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Dinutuximab binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells.  GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CAB1DA52-E763-FF72-E040-BB89AD436B31","latestVersionIndicator":"Yes","beginDate":"2012-09-27","endDate":null,"createdBy":"WONGW","dateCreated":"2012-09-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683BD763-FCB3-06B2-E053-F662850AFAC2","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Diethylstilbestrol Honvol Stilbestrol","valueDescription":"Fosfestrol","ValueMeaning":{"publicId":"6148667","version":"1","preferredName":"Fosfestrol","longName":"6148667","preferredDefinition":"The diphosphate ester of a synthetic, nonsteroidal form of estrogen. A well-known teratogen and carcinogen, diethylstilbestrol inhibits the hypothalamic-pituitary-gonadal axis, thereby blocking the testicular synthesis of testosterone, lowering plasma testosterone, and inducing a chemical castration.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fosfestrol","conceptCode":"C1105","definition":"The diphosphate ester of a synthetic, nonsteroidal form of estrogen. A well-known teratogen and carcinogen, diethylstilbestrol inhibits the hypothalamic-pituitary-gonadal axis, thereby blocking the testicular synthesis of testosterone, lowering plasma testosterone, and inducing a chemical castration.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"683BD763-FCC0-06B2-E053-F662850AFAC2","latestVersionIndicator":"Yes","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683BD763-FCD9-06B2-E053-F662850AFAC2","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Didrocal Didronel Etidronate disodium","valueDescription":"Etidronate Disodium","ValueMeaning":{"publicId":"2597183","version":"1","preferredName":"Etidronate Disodium","longName":"2597183","preferredDefinition":"A synthetic therapeutic diphosphonate analogue of endogenous pyrophosphate. As a member of the family of drugs known as bisphosphonates, etidronate disodium differs from endogenous pyrophosphate in its resistance to enzymatic hydrolysis.  This agent adsorbs to hydroxyapatite cells and reduces the number of osteoclasts, thereby inhibiting abnormal bone resorption.  Etidronate may also directly stimulate bone formation by osteoblasts. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etidronate Disodium","conceptCode":"C831","definition":"A synthetic therapeutic diphosphonate analogue of endogenous pyrophosphate. As a member of the family of drugs known as bisphosphonates, etidronate disodium differs from endogenous pyrophosphate in its resistance to enzymatic hydrolysis.  This agent adsorbs to hydroxyapatite cells and reduces the number of osteoclasts, thereby inhibiting abnormal bone resorption.  Etidronate may also directly stimulate bone formation by osteoblasts. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2972C1E6-9866-54DE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683BD763-FCED-06B2-E053-F662850AFAC2","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Didemnin B","valueDescription":"Didemnin B","ValueMeaning":{"publicId":"6148669","version":"1","preferredName":"Didemnin B","longName":"6148669","preferredDefinition":"A cyclic depsipeptide extracted from the Caribbean tunicate Trididemnum cyanophorum.  Didemnin B activates caspase, thereby inducing apoptosis, and prevents eukaryotic elongation factor 2 (eEF-2)-dependent translocation, thereby inhibiting protein synthesis.  This agent also has immunosuppressive and antiviral properties. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Didemnin B","conceptCode":"C1364","definition":"A cyclic depsipeptide extracted from the Caribbean tunicate Trididemnum cyanophorum.  Didemnin B activates caspase, thereby inducing apoptosis, and prevents eukaryotic elongation factor 2 (eEF-2)-dependent translocation, thereby inhibiting protein synthesis.  This agent also has immunosuppressive and antiviral properties. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"683BD763-FCFA-06B2-E053-F662850AFAC2","latestVersionIndicator":"Yes","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683BD763-FD13-06B2-E053-F662850AFAC2","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Dexamethasone Decadron","valueDescription":"Dexamethasone","ValueMeaning":{"publicId":"3028376","version":"1","preferredName":"Dexamethasone","longName":"3028376","preferredDefinition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04) [Source: NCI]","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dexamethasone","conceptCode":"C422","definition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8223B6A1-980B-C0E8-E040-BB89AD43538F","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-03-19","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683BD763-FD27-06B2-E053-F662850AFAC2","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"Deoxycoformycin Pentostatin Nipent","valueDescription":"Pentostatin","ValueMeaning":{"publicId":"5127413","version":"1","preferredName":"Pentostatin","longName":"5127413","preferredDefinition":"The active ingredient in a drug that is used to treat hairy cell leukemia and is being studied in the treatment of other types of cancer. Pentostatin blocks a protein needed for cell growth and may kill cancer cells. It is made by a bacterium. It is a type of adenosine deaminase inhibitor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pentostatin","conceptCode":"C732","definition":"A purine nucleotide analogue antibiotic isolated from the bacterium Streptomyces antibioticus. Also known as 2'-deoxycoformycin, pentostatin binds to and inhibits adenine deaminase (ADA), an enzyme essential to purine metabolism; ADA activity is greatest in cells of the lymphoid system with T-cells having higher activity than B-cells and T-cell malignancies higher ADA activity than B-cell malignancies. Pentostatin inhibition of ADA appears to result in elevated intracellular levels of dATP which may block DNA synthesis through the inhibition of ribonucleotide reductase. This agent may also inhibit RNA synthesis and may selectively deplete CD26+ lymphocytes. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FAA7-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"683BD763-FD3B-06B2-E053-F662850AFAC2","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","deletedIndicator":"No"},{"value":"SR49059","valueDescription":"Relcovaptan","ValueMeaning":{"publicId":"6159933","version":"1","preferredName":"Relcovaptan","longName":"6159933","preferredDefinition":"A substance being studied in the treatment of cancer. It inhibits a hormone growth factor that causes some cancer cells to divide. It is a type of vasopressin receptor antagonist.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Relcovaptan","conceptCode":"C1497","definition":"A substance being studied in the treatment of cancer. It inhibits a hormone growth factor that causes some cancer cells to divide. It is a type of vasopressin receptor antagonist.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68AE1FEE-5FEB-3A56-E053-F662850AAD03","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AE1FEE-6004-3A56-E053-F662850AAD03","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Spirogermanium","valueDescription":"Spirogermanium","ValueMeaning":{"publicId":"6159935","version":"1","preferredName":"Spirogermanium","longName":"6159935","preferredDefinition":"A synthetic organometallic compound containing the element germanium with possible antineoplastic activity. Spirogermanium exhibits significant toxicity, particularly neurotoxicity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Spirogermanium","conceptCode":"C1232","definition":"A synthetic organometallic compound containing the element germanium with possible antineoplastic activity. Spirogermanium exhibits significant toxicity, particularly neurotoxicity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68AE1FEE-6011-3A56-E053-F662850AAD03","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AE1FEE-602A-3A56-E053-F662850AAD03","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Solumedrol Methylprednisolone sodium succinate","valueDescription":"Methylprednisolone Sodium Succinate","ValueMeaning":{"publicId":"6159937","version":"1","preferredName":"Methylprednisolone Sodium Succinate","longName":"6159937","preferredDefinition":"The sodium succinate salt of a synthetic glucocorticoid receptor agonist with immunosuppressive and anti-inflammatory effects. Methylprednisolone sodium succinate is converted into active prednisolone in the body, which activates glucocorticoid receptor mediated gene expression. This includes inducing synthesis of anti-inflammatory protein IkappaB-alpha and inhibiting synthesis of nuclear factor kappaB (NF-kappaB). As a result, proinflammatory cytokine production such as IL-1, IL-2 and IL-6 is down-regulated and cytotoxic T-lymphocyte activation is inhibited. Therefore, an overall reduction in chronic inflammation and autoimmune reactions may be achieved.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methylprednisolone Sodium Succinate","conceptCode":"C48004","definition":"The sodium succinate salt of a synthetic glucocorticoid receptor agonist with immunosuppressive and anti-inflammatory effects. Methylprednisolone sodium succinate is converted into active prednisolone in the body, which activates glucocorticoid receptor mediated gene expression. This includes inducing synthesis of anti-inflammatory protein IkappaB-alpha and inhibiting synthesis of nuclear factor kappaB (NF-kappaB). As a result, proinflammatory cytokine production such as IL-1, IL-2 and IL-6 is down-regulated and cytotoxic T-lymphocyte activation is inhibited. Therefore, an overall reduction in chronic inflammation and autoimmune reactions may be achieved.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68AE1FEE-6037-3A56-E053-F662850AAD03","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AE1FEE-6050-3A56-E053-F662850AAD03","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Solucortef Hydrocortisone sodium succinate","valueDescription":"Hydrocortisone Sodium Succinate","ValueMeaning":{"publicId":"6159939","version":"1","preferredName":"Hydrocortisone Sodium Succinate","longName":"6159939","preferredDefinition":"The sodium salt of hydrocortisone succinate with glucocorticoid property. Hydrocortisone sodium succinate is chemically similar to the endogenous hormone that stimulates anti-inflammatory and immunosuppressive activities, in addition to exhibiting minor mineralocorticoid effects. This agent binds to intracellular glucocorticoid receptors and is translocated into the nucleus, where it initiates the transcription of glucocorticoid-responsive genes, such as various cytokines and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both potent mediators of inflammation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydrocortisone Sodium Succinate","conceptCode":"C1819","definition":"The sodium salt of hydrocortisone succinate with glucocorticoid property. Hydrocortisone sodium succinate is chemically similar to the endogenous hormone that stimulates anti-inflammatory and immunosuppressive activities, in addition to exhibiting minor mineralocorticoid effects. This agent binds to intracellular glucocorticoid receptors and is translocated into the nucleus, where it initiates the transcription of glucocorticoid-responsive genes, such as various cytokines and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both potent mediators of inflammation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68AE1FEE-605D-3A56-E053-F662850AAD03","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AE1FEE-6076-3A56-E053-F662850AAD03","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"GSK2126458 Omipalisib","valueDescription":"Omipalisib","ValueMeaning":{"publicId":"6159819","version":"1","preferredName":"Omipalisib","longName":"6159819","preferredDefinition":"A small-molecule pyridylsulfonamide inhibitor of phosphatidylinositol 3-kinase (PI3K) with potential antineoplastic activity. Omipalisib binds to and inhibits PI3K in the PI3K/mTOR signaling pathway, which may trigger the translocation of cytosolic Bax to the mitochondrial outer membrane, increasing mitochondrial membrane permeability and inducing apoptotic cell death. Bax is a member of the proapoptotic Bcl2 family of proteins. PI3K, often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Omipalisib","conceptCode":"C88270","definition":"A small-molecule pyridylsulfonamide inhibitor of phosphatidylinositol 3-kinase (PI3K) with potential antineoplastic activity. Omipalisib binds to and inhibits PI3K in the PI3K/mTOR signaling pathway, which may trigger the translocation of cytosolic Bax to the mitochondrial outer membrane, increasing mitochondrial membrane permeability and inducing apoptotic cell death. Bax is a member of the proapoptotic Bcl2 family of proteins. PI3K, often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A4DC85-E2A6-51D4-E053-F662850A3401","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A4DC85-E2BF-51D4-E053-F662850A3401","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"GS7836 4-THIO-ARAC OSI-7836","valueDescription":"Thiarabine","ValueMeaning":{"publicId":"6159821","version":"1","preferredName":"Thiarabine","longName":"6159821","preferredDefinition":"A analog of antimetabolite cytarabine (ara-C), with potential antineoplastic activity. Upon administration, thiarabine (T-araC) is phosphorylated to the triphosphate form T-araCTP and competes with cytidine for incorporation into DNA. This results in an inhibition of DNA replication and RNA synthesis, chain termination and may eventually decrease tumor cell proliferation. Compared to ara-C, T-araC appears to have a longer half-life and has a higher efficacy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thiarabine","conceptCode":"C92589","definition":"A analog of antimetabolite cytarabine (ara-C), with potential antineoplastic activity. Upon administration, thiarabine (T-araC) is phosphorylated to the triphosphate form T-araCTP and competes with cytidine for incorporation into DNA. This results in an inhibition of DNA replication and RNA synthesis, chain termination and may eventually decrease tumor cell proliferation. Compared to ara-C, T-araC appears to have a longer half-life and has a higher efficacy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A4DC85-E2CC-51D4-E053-F662850A3401","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A4DC85-E2E5-51D4-E053-F662850A3401","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"GS-101 Aganirsen","valueDescription":"Aganirsen","ValueMeaning":{"publicId":"6159822","version":"1","preferredName":"Aganirsen","longName":"6159822","preferredDefinition":"A 25-mer antisense oligonucleotide (ASO) that targets the mRNA transcript for insulin receptor substrate (IRS-1), a protein required for the formation and growth of new blood vessels, that can be used to reduce corneal angiogenesis and neovascularization. Upon ocular administration, aganirsen binds to IRS-1 mRNA and blocks the synthesis of IRS-1. By blocking the expression of IRS-1 in pro-angiogenic conditions, such as those seen in corneal grafts and other inflammatory-based ocular diseases, aganirsen blocks the corneal neovascularization pathway, inhibits vascular endothelial growth factor (VEGF) production, which is a key component of neovascularization, and prevents the production of various pro-inflammatory cytokines, which together decrease the risk of corneal neovascularization. Additionally, upon corneal transplantation, neovascularization induces an immune response that can lead to immunological corneal graft rejection; therefore, by inhibiting neovascularization this agent can decrease the risk of corneal graft rejection. IRS-1, overexpressed in endothelial cells during corneal neovascularization, plays a key role in the regulation of angiogenesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aganirsen","conceptCode":"C148131","definition":"A 25-mer antisense oligonucleotide (ASO) that targets the mRNA transcript for insulin receptor substrate (IRS-1), a protein required for the formation and growth of new blood vessels, that can be used to reduce corneal angiogenesis and neovascularization. Upon ocular administration, aganirsen binds to IRS-1 mRNA and blocks the synthesis of IRS-1. By blocking the expression of IRS-1 in pro-angiogenic conditions, such as those seen in corneal grafts and other inflammatory-based ocular diseases, aganirsen blocks the corneal neovascularization pathway, inhibits vascular endothelial growth factor (VEGF) production, which is a key component of neovascularization, and prevents the production of various pro-inflammatory cytokines, which together decrease the risk of corneal neovascularization. Additionally, upon corneal transplantation, neovascularization induces an immune response that can lead to immunological corneal graft rejection; therefore, by inhibiting neovascularization this agent can decrease the risk of corneal graft rejection. IRS-1, overexpressed in endothelial cells during corneal neovascularization, plays a key role in the regulation of angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A4DC85-E2F1-51D4-E053-F662850A3401","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A4DC85-E30A-51D4-E053-F662850A3401","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Granulocyte-macrophage CSF Leukine GM-CSF Prokine Sargramostim","valueDescription":"Sargramostim","ValueMeaning":{"publicId":"6159823","version":"1","preferredName":"Sargramostim","longName":"6159823","preferredDefinition":"A recombinant therapeutic agent chemically identical to endogenous human GM-CSF except a leucine substitution in position 23.  Binding to specific cell surface receptors, sargramostim modulates the proliferation and differentiation of a variety of hematopoietic progenitor cells with some specificity towards stimulation of leukocyte production and may reverse treatment-induced neutropenias. This agent also promotes antigen presentation, up-regulates antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function; it may also augment host antitumoral immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sargramostim","conceptCode":"C1492","definition":"A recombinant therapeutic agent chemically identical to endogenous human GM-CSF except a leucine substitution in position 23.  Binding to specific cell surface receptors, sargramostim modulates the proliferation and differentiation of a variety of hematopoietic progenitor cells with some specificity towards stimulation of leukocyte production and may reverse treatment-induced neutropenias. This agent also promotes antigen presentation, up-regulates antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function; it may also augment host antitumoral immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A4DC85-E316-51D4-E053-F662850A3401","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A4DC85-E32E-51D4-E053-F662850A3401","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Goserelin acetate Zoladex","valueDescription":"Goserelin Acetate","ValueMeaning":{"publicId":"3380783","version":"1","preferredName":"Goserelin Acetate","longName":"3380783","preferredDefinition":"The acetate salt of a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH).  Continuous, prolonged administration of goserelin in males results in inhibition of pituitary gonadotropin secretion, leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Goserelin Acetate","conceptCode":"C1417","definition":"The acetate salt of a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH).  Continuous, prolonged administration of goserelin in males results in inhibition of pituitary gonadotropin secretion, leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B980D66E-5B54-FB86-E040-BB89AD43770B","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A4DC85-E343-51D4-E053-F662850A3401","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"GM2-KLH/QS-21","valueDescription":"GM2-KLH Vaccine/QS21","ValueMeaning":{"publicId":"6159825","version":"1","preferredName":"GM2-KLH Vaccine/QS21","longName":"6159825","preferredDefinition":"A cancer vaccine based on the immunogenic ganglioside GM2, The GM2-KLH Vaccine/QS21 vaccine consists of GM2 conjugated with KLH keyhole limpet hemocyanin (KLH), a potent immunostimulant, and is admixed with the adjuvant QS21, a saponin fraction extracted from the bark of the South American tree Quillaja saponaria Molina. GM2 is a cell surface carbohydrate antigen expressed by most melanoma cells and various other tumor cell types. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"GM2-KLH Vaccine/QS21","conceptCode":"C11571","definition":"A cancer vaccine based on the immunogenic ganglioside GM2, The GM2-KLH Vaccine/QS21 vaccine consists of GM2 conjugated with KLH keyhole limpet hemocyanin (KLH), a potent immunostimulant, and is admixed with the adjuvant QS21, a saponin fraction extracted from the bark of the South American tree Quillaja saponaria Molina. GM2 is a cell surface carbohydrate antigen expressed by most melanoma cells and various other tumor cell types. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A4DC85-E350-51D4-E053-F662850A3401","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A4DC85-E369-51D4-E053-F662850A3401","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Glesatinib, MGCD265","valueDescription":"Multitargeted Tyrosine Kinase Inhibitor MGCD265","ValueMeaning":{"publicId":"3434560","version":"1","preferredName":"Multitargeted Tyrosine Kinase Inhibitor MGCD265","longName":"3434560","preferredDefinition":"An orally bioavailable, small-molecule, multitargeted tyrosine kinase inhibitor with potential antineoplastic activity. Multitargeted tyrosine kinase inhibitor MGCD265 binds to and inhibits the phosphorylation of several receptor tyrosine kinases (RTKs), including the c-Met receptor (hepatocyte growth factor receptor); the Tek/Tie-2 receptor; vascular endothelial growth factor receptor (VEGFR) types 1, 2, and 3; and the macrophage-stimulating 1 receptor (MST1R or RON). Inhibition of these RTKs and their downstream signaling pathways may result in the inhibition of tumor angiogenesis and tumor cell proliferation in tumors overexpressing these RTKs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glesatinib","conceptCode":"C77876","definition":"An orally bioavailable, small-molecule, multitargeted tyrosine kinase inhibitor with potential antineoplastic activity. Glesatinib binds to and inhibits the phosphorylation of several receptor tyrosine kinases (RTKs), including the c-Met receptor (hepatocyte growth factor receptor); the Tek/Tie-2 receptor; vascular endothelial growth factor receptor (VEGFR) types 1, 2, and 3; and the macrophage-stimulating 1 receptor (MST1R or RON). Inhibition of these RTKs and their downstream signaling pathways may result in the inhibition of tumor angiogenesis and tumor cell proliferation in tumors overexpressing these RTKs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD3F6081-657D-1C16-E040-BB89AD431E82","latestVersionIndicator":"Yes","beginDate":"2012-04-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A4DC85-E37D-51D4-E053-F662850A3401","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"GDC-0941 Pictilisib","valueDescription":"PI3K Inhibitor GDC-0941 Bismesylate","ValueMeaning":{"publicId":"3653960","version":"1","preferredName":"PI3K Inhibitor GDC-0941 Bismesylate","longName":"3653960","preferredDefinition":"The orally bioavailable bismesylate salt of a potent small-molecule thieno[3,2-d]pyrimidine inhibitor of the class I phosphatidylinositol 3 kinase (PI3K) isoforms p100alpha and p100delta with potential antineoplastic activity. PI3K inhibitor GDC-0941 selectively binds to PI3K isoforms in an ATP-competitive manner, inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K/Akt signaling pathway; inhibition of tumor cell growth, motility and survival in susceptible tumor cell populations may result. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis; dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pictilisib Bismesylate","conceptCode":"C82380","definition":"The orally bioavailable bismesylate salt of pictilisib, a small molecule inhibitor of class I phosphatidylinositol 3 kinase (PI3K), with potential antineoplastic activity. Upon administration, pictilisib selectively binds to PI3K in an ATP-competitive manner, inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K/Akt signaling pathway. This may result in inhibition of tumor cell growth, motility and survival in susceptible tumor cell populations. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis; dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D3E1EFE4-4611-52B6-E040-BB89AD431E3D","latestVersionIndicator":"Yes","beginDate":"2013-01-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-01-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A4DC85-E391-51D4-E053-F662850A3401","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"G-CSF Granulocyte colony stimulating factor Neupogen","valueDescription":"Filgrastim","ValueMeaning":{"publicId":"3379062","version":"1","preferredName":"Filgrastim","longName":"3379062","preferredDefinition":"A colony-stimulating factor that stimulates the production of neutrophils (a type of white blood cell). It is a cytokine that belongs to the family of drugs called hematopoietic (blood-forming) agents. Also called granulocyte colony-stimulating factor (G-CSF).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Filgrastim","conceptCode":"C1474","definition":"A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914C2F8-AD83-3067-E040-BB89AD433056","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A4DC85-E3A5-51D4-E053-F662850A3401","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Galeterone TOK001","valueDescription":"Galeterone","ValueMeaning":{"publicId":"5811373","version":"1","preferredName":"Galeterone","longName":"5811373","preferredDefinition":"An orally bioavailable small-molecule androgen receptor modulator and CYP17 lyase inhibitor with potential antiandrogen activity. Galeterone exhibits three distinct mechanisms of action: 1) as an androgen receptor antagonist, 2) as a CYP17 lyase inhibitor and 3) by decreasing overall androgen receptor levels in prostate cancer tumors, all of which may result in a decrease in androgen-dependent growth signaling. Localized to the endoplasmic reticulum (ER), the cytochrome P450 enzyme CYP17 (P450C17 or CYP17A1) exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Galeterone","conceptCode":"C84866","definition":"An orally bioavailable small-molecule androgen receptor modulator and CYP17 lyase inhibitor with potential antiandrogen activity. Galeterone exhibits three distinct mechanisms of action: 1) as an androgen receptor antagonist, 2) as a CYP17 lyase inhibitor and 3) by decreasing overall androgen receptor levels in prostate cancer tumors, all of which may result in a decrease in androgen-dependent growth signaling. Localized to the endoplasmic reticulum (ER), the cytochrome P450 enzyme CYP17 (P450C17 or CYP17A1) exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F2E845A-26AF-6A9B-E053-F662850ACCDA","latestVersionIndicator":"Yes","beginDate":"2017-05-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-05-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A4DC85-E3B9-51D4-E053-F662850A3401","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Eulexin Flutamide","valueDescription":"Flutamide","ValueMeaning":{"publicId":"3379052","version":"1","preferredName":"Flutamide","longName":"3379052","preferredDefinition":"An anticancer drug that belongs to the family of drugs called antiandrogens.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Flutamide","conceptCode":"C509","definition":"A toluidine derivative and a nonsteroidal antiandrogen that is structurally related to bicalutamide and nilutamide. Flutamide and its more potent active metabolite 2-hydroxyflutamide competitively block dihydrotestosterone binding at androgen receptors, forming inactive complexes which cannot translocate into the cell nucleus. Formation of inactive receptors inhibits androgen-dependent DNA and protein synthesis, resulting in tumor cell growth arrest or transient tumor regression. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914931D-212B-28A3-E040-BB89AD437288","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68E1E0E5-A993-33BB-E053-F662850A5F14","beginDate":"2018-03-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","deletedIndicator":"No"},{"value":"PX-866","valueDescription":"Sonolisib","ValueMeaning":{"publicId":"6159907","version":"1","preferredName":"Sonolisib","longName":"6159907","preferredDefinition":"A small-molecule wortmannin analogue inhibitor of the alpha, gamma, and delta isoforms of phosphoinositide 3-kinase (PI3K) with potential antineoplastic activity. Sonolisib inhibits the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K/Akt signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sonolisib","conceptCode":"C78848","definition":"A small-molecule wortmannin analogue inhibitor of the alpha, gamma, and delta isoforms of phosphoinositide 3-kinase (PI3K) with potential antineoplastic activity. Sonolisib inhibits the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K/Akt signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A6D7EC-5B59-2303-E053-F662850A11B7","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68E1E0E5-A9A7-33BB-E053-F662850A5F14","beginDate":"2018-03-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","deletedIndicator":"No"},{"value":"Nilotinib Tasigna","valueDescription":"Nilotinib","ValueMeaning":{"publicId":"5805905","version":"1","preferredName":"Nilotinib","longName":"5805905","preferredDefinition":"An orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl protein of the Bcr-Abl fusion protein, resulting in the inhibition of the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R) and c-kit, a receptor tyrosine kinase mutated and constitutively activated in most gastrointestinal stromal tumors (GISTs). With a binding mode that is energetically more favorable than that of imatinib, nilotinib has been shown to have an approximately 20-fold increased potency in kinase and proliferation assays compared to imatinib.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nilotinib","conceptCode":"C48375","definition":"An orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl protein of the Bcr-Abl fusion protein, resulting in the inhibition of the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R) and c-kit, a receptor tyrosine kinase mutated and constitutively activated in most gastrointestinal stromal tumors (GISTs). With a binding mode that is energetically more favorable than that of imatinib, nilotinib has been shown to have an approximately 20-fold increased potency in kinase and proliferation assays compared to imatinib.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4EA044AC-B549-3351-E053-F662850A8B45","latestVersionIndicator":"Yes","beginDate":"2017-05-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68ACAECC-209B-3CAB-E053-F662850AD2FD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Neulasta Pegfilgrastim","valueDescription":"Pegfilgrastim","ValueMeaning":{"publicId":"2775105","version":"1","preferredName":"Pegfilgrastim","longName":"2775105","preferredDefinition":"A long-acting pegylated form of a recombinant therapeutic agent which is chemically identical to or similar to an endogenous human granulocyte colony-stimulating factor (G-CSF). Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions. Conjugation of the cytokine with a branched polyethylene glycol molecule (pegylation) significantly increases its therapeutic half-life. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pegfilgrastim","conceptCode":"C1854","definition":"A long-acting pegylated form of a recombinant therapeutic agent which is chemically identical to or similar to an endogenous human granulocyte colony-stimulating factor (G-CSF). Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions. Conjugation of the cytokine with a branched polyethylene glycol molecule (pegylation) significantly increases its therapeutic half-life. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54D3AA38-DF52-52EA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-08-19","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68ACAECC-20AF-3CAB-E053-F662850AD2FD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Neratinib, HKI-272","valueDescription":"Neratinib","ValueMeaning":{"publicId":"3720773","version":"1","preferredName":"Neratinib","longName":"3720773","preferredDefinition":"An orally available, 6,7-disubstituted-4-anilinoquinoline-3-carbonitrile irreversible inhibitor of the HER-2 receptor tyrosine kinase with potential antineoplastic activity. Neratinib binds to the HER-2 receptor irreversibly, thereby reducing autophosphorylation in cells, apparently by targeting a cysteine residue in the ATP-binding pocket of the receptor. Treatment of cells with this agent results in inhibition of downstream signal transduction events and cell cycle regulatory pathways; arrest at the G1-S (Gap 1/DNA synthesis)-phase transition of the cell division cycle; and ultimately decreased cellular proliferation. Neratinib also inhibits the epidermal growth factor receptor (EGFR) kinase and the proliferation of EGFR-dependent cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neratinib","conceptCode":"C49094","definition":"An orally available, 6,7-disubstituted-4-anilinoquinoline-3-carbonitrile irreversible inhibitor of the HER-2 receptor tyrosine kinase with potential antineoplastic activity. Neratinib binds to the HER-2 receptor irreversibly, thereby reducing autophosphorylation in cells, apparently by targeting a cysteine residue in the ATP-binding pocket of the receptor. Treatment of cells with this agent results in inhibition of downstream signal transduction events and cell cycle regulatory pathways; arrest at the G1-S (Gap 1/DNA synthesis)-phase transition of the cell division cycle; and ultimately decreased cellular proliferation. Neratinib also inhibits the epidermal growth factor receptor (EGFR) kinase and the proliferation of EGFR-dependent cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DA06151A-148F-0504-E040-BB89AD437F71","latestVersionIndicator":"Yes","beginDate":"2013-04-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-04-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68ACAECC-20C3-3CAB-E053-F662850AD2FD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Necitumumab Portrazza IMC-11F8","valueDescription":"Necitumumab","ValueMeaning":{"publicId":"6084996","version":"1","preferredName":"Necitumumab","longName":"6084996","preferredDefinition":"A fully human IgG1 monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Necitumumab binds to and blocks the ligand binding site of EGFR, thereby preventing the activation and subsequent dimerization of the receptor. This may lead to an inhibition of EGFR-dependent downstream pathways and so inhibition of EGFR-dependent tumor cell proliferation and metastasis.  EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surfaces of various tumor cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Necitumumab","conceptCode":"C88281","definition":"A fully human IgG1 monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Necitumumab binds to and blocks the ligand binding site of EGFR, thereby preventing the activation and subsequent dimerization of the receptor. This may lead to an inhibition of EGFR-dependent downstream pathways and so inhibition of EGFR-dependent tumor cell proliferation and metastasis.  EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surfaces of various tumor cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"66217E39-C8D2-01DB-E053-F662850AFD24","latestVersionIndicator":"Yes","beginDate":"2018-02-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-02-26","modifiedBy":"COOPERM","dateModified":"2018-03-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68ACAECC-20D7-3CAB-E053-F662850AD2FD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Nab-paclitaxel Abraxane","valueDescription":"Paclitaxel Albumin-Stabilized Nanoparticle Formulation","ValueMeaning":{"publicId":"5567089","version":"1","preferredName":"Paclitaxel Albumin-Stabilized Nanoparticle Formulation","longName":"5567089","preferredDefinition":"A Cremophor EL-free, albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. This formulation solubilizes paclitaxel without the use of the solvent Cremophor, thereby permitting the administration of larger doses of paclitaxel while avoiding the toxic effects associated with Cremophor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nab-paclitaxel","conceptCode":"C2688","definition":"A Cremophor EL-free, albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. This formulation solubilizes paclitaxel without the use of the solvent Cremophor, thereby permitting the administration of larger doses of paclitaxel while avoiding the toxic effects associated with Cremophor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"40CFD039-BC75-556D-E053-F662850AED1E","latestVersionIndicator":"Yes","beginDate":"2016-11-08","endDate":null,"createdBy":"PATELV","dateCreated":"2016-11-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68ACAECC-20EB-3CAB-E053-F662850AD2FD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Mylotarg Gemtuzumab ozogamicin","valueDescription":"Gemtuzumab Ozogamicin","ValueMeaning":{"publicId":"2741177","version":"1","preferredName":"Gemtuzumab Ozogamicin","longName":"2741177","preferredDefinition":"A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin.  In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gemtuzumab Ozogamicin","conceptCode":"C1806","definition":"A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin.  In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AE9C122-FED1-5AF3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-15","modifiedBy":"MAESKEB","dateModified":"2021-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68ACAECC-20FF-3CAB-E053-F662850AD2FD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"MRX34 miR-Rx34","valueDescription":"Liposome-encapsulated miR-34 Mimic MRX34","ValueMeaning":{"publicId":"6159879","version":"1","preferredName":"Liposome-encapsulated miR-34 Mimic MRX34","longName":"6159879","preferredDefinition":"A liposomal formulation containing a nucleotide that mimics the human tumor suppressor microRNA (miRNA) miR-34, with potential antineoplastic activity. Upon administration, liposome-encapsulated MRX34 mimics miR-34 by inhibiting the expression of a variety of oncogenes including MYC, MET, BCL2, and beta-catenin. This induces cell cycle arrest, senescence and apoptosis in susceptible tumor cells. miR-34 is downregulated in most solid and hematologic malignancies and regulates the expression of a variety of genes. This miRNA plays an important role in the inhibition of cancer cell stemness, metastasis and cancer cell survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liposome-encapsulated miR-34 Mimic MRX34","conceptCode":"C105802","definition":"A liposomal formulation containing a nucleotide that mimics the human tumor suppressor microRNA (miRNA) miR-34, with potential antineoplastic activity. Upon administration, liposome-encapsulated MRX34 mimics miR-34 by inhibiting the expression of a variety of oncogenes including MYC, MET, BCL2, and beta-catenin. This induces cell cycle arrest, senescence and apoptosis in susceptible tumor cells. miR-34 is downregulated in most solid and hematologic malignancies and regulates the expression of a variety of genes. This miRNA plays an important role in the inhibition of cancer cell stemness, metastasis and cancer cell survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68ACAECC-210C-3CAB-E053-F662850AD2FD","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68ACAECC-2125-3CAB-E053-F662850AD2FD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"MK-2206","valueDescription":"Akt Inhibitor MK2206","ValueMeaning":{"publicId":"3374409","version":"1","preferredName":"Akt Inhibitor MK2206","longName":"3374409","preferredDefinition":"An orally bioavailable allosteric inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor MK2206 binds to and inhibits the activity of Akt in a non-ATP competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Akt Inhibitor MK2206","conceptCode":"C90581","definition":"An orally bioavailable allosteric inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor MK2206 binds to and inhibits the activity of Akt in a non-ATP competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B87BD737-997B-575D-E040-BB89AD434B6E","latestVersionIndicator":"Yes","beginDate":"2012-02-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68ACAECC-2139-3CAB-E053-F662850AD2FD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Mitoxantrone Novantrone","valueDescription":"Mitoxantrone Hydrochloride","ValueMeaning":{"publicId":"2576635","version":"1","preferredName":"Mitoxantrone Hydrochloride","longName":"2576635","preferredDefinition":"An anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication.  This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair.  Mitoxantrone is less cardiotoxic compared to doxorubicin. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mitoxantrone Hydrochloride","conceptCode":"C665","definition":"The hydrochloride salt of an anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication.  This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair.  Mitoxantrone is less cardiotoxic compared to doxorubicin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F868-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68ACAECC-214D-3CAB-E053-F662850AD2FD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Mitomycin-C Mutamycin","valueDescription":"Mitomycin","ValueMeaning":{"publicId":"4147714","version":"1","preferredName":"Mitomycin","longName":"4147714","preferredDefinition":"A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species.  Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis.  Preferentially toxic to hypoxic cells, mitomycin C also inhibits RNA and protein synthesis at high concentrations. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mitomycin","conceptCode":"C1820","definition":"A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species.  Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis.  Preferentially toxic to hypoxic cells, mitomycin C also inhibits RNA and protein synthesis at high concentrations. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F224FB27-D5DD-DD58-E040-BB89AD437691","latestVersionIndicator":"Yes","beginDate":"2014-02-11","endDate":null,"createdBy":"BASSG","dateCreated":"2014-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68ACAECC-2161-3CAB-E053-F662850AD2FD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Mithramycin Plicamycin Mithracin","valueDescription":"Plicamycin","ValueMeaning":{"publicId":"3379486","version":"1","preferredName":"Plicamycin","longName":"3379486","preferredDefinition":"An antibiotic isolated from the bacterium Streptomyces plicatus with antineoplastic activity. Plicamycin, also known as mithramycin, binds to the minor groove of DNA at GC-rich sites, resulting in inhibition of RNA synthesis; this agent also inhibits mRNA expression, resulting in a reduction in protein synthesis. In addition, plicamycin may inhibit bone resorption by down regulating transcription of c-src, an oncogene involved in bone metabolism and resorption. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plicamycin","conceptCode":"C658","definition":"An antibiotic isolated from the bacterium Streptomyces plicatus with antineoplastic activity. Plicamycin, also known as mithramycin, binds to the minor groove of DNA at GC-rich sites, resulting in inhibition of RNA synthesis; this agent also inhibits mRNA expression, resulting in a reduction in protein synthesis. In addition, plicamycin may inhibit bone resorption by down regulating transcription of c-src, an oncogene involved in bone metabolism and resorption. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-25DA-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68ACAECC-2175-3CAB-E053-F662850AD2FD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Mifepristone RU486 Mifeprex","valueDescription":"Mifepristone","ValueMeaning":{"publicId":"6159881","version":"1","preferredName":"Mifepristone","longName":"6159881","preferredDefinition":"A derivative of the synthetic progestin norethindrone with antiprogesterone activity. Mifepristone competitively binds to the progesterone receptor, resulting in inhibition of the effects of endogenous or exogenous progesterone. This agent also exhibits antiglucocorticoid and weak antiandrogenic activities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mifepristone","conceptCode":"C655","definition":"A derivative of the synthetic progestin norethindrone with antiprogesterone activity. Mifepristone competitively binds to the progesterone receptor, resulting in inhibition of the effects of endogenous or exogenous progesterone. This agent also exhibits antiglucocorticoid and weak antiandrogenic activities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68ACAECC-2182-3CAB-E053-F662850AD2FD","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68ACAECC-219B-3CAB-E053-F662850AD2FD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Thalidomide Thalomid","valueDescription":"Thalidomide","ValueMeaning":{"publicId":"2568117","version":"1","preferredName":"Thalidomide","longName":"2568117","preferredDefinition":"A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties.  Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons.  This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis.  In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thalidomide","conceptCode":"C870","definition":"A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties.  Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons.  This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis.  In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D722-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-26","modifiedBy":"REEVESD","dateModified":"2016-05-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D60740-FD1A-6D00-E053-F662850A2EFA","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Testolactone Teslac","valueDescription":"Testolactone","ValueMeaning":{"publicId":"6159974","version":"1","preferredName":"Testolactone","longName":"6159974","preferredDefinition":"A progesterone derivative with antineoplastic activity. Testolactone inhibits steroid aromatase, thereby preventing the formation of estrogen from adrenal androstenedione and reducing endogenous estrogen levels. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Testolactone","conceptCode":"C2301","definition":"A progesterone derivative with antineoplastic activity. Testolactone inhibits steroid aromatase, thereby preventing the formation of estrogen from adrenal androstenedione and reducing endogenous estrogen levels. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68D60740-FD27-6D00-E053-F662850A2EFA","latestVersionIndicator":"Yes","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D60740-FD40-6D00-E053-F662850A2EFA","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Temodal Temozolamide","valueDescription":"Temozolomide","ValueMeaning":{"publicId":"3380202","version":"1","preferredName":"Temozolomide","longName":"3380202","preferredDefinition":"A triazene analog of dacarbazine with antineoplastic activity.  As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of  DNA replication.  Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Temozolomide","conceptCode":"C1244","definition":"A triazene analog of dacarbazine with antineoplastic activity.  As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of DNA replication. Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A755C-D717-40C9-E040-BB89AD4320DE","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"COLBERTM","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":"1/2/24 Added Temodar as alt name for PCDC. mr","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D60740-FD68-6D00-E053-F662850A2EFA","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Sipuleucel-T Provenge","valueDescription":"APC8015 Vaccine","ValueMeaning":{"publicId":"3439565","version":"1","preferredName":"APC8015 Vaccine","longName":"3439565v1.00","preferredDefinition":"A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells.  Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sipuleucel-T","conceptCode":"C1985","definition":"A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells.  Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE0C4833-1C2E-5DC6-E040-BB89AD434EEE","latestVersionIndicator":"Yes","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-19","modifiedBy":"GDEEN","dateModified":"2023-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AE1FEE-609F-3A56-E053-F662850AAD03","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Lonidamine","valueDescription":"Lonidamine","ValueMeaning":{"publicId":"6159849","version":"1","preferredName":"Lonidamine","longName":"6159849","preferredDefinition":"An indazole carboxylic acid derivative that exhibits radiosensitizing and antiparasitic effects and interferes with the multidrug resistance mechanism.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lonidamine","conceptCode":"C1146","definition":"An indazole carboxylic acid derivative that exhibits radiosensitizing and antiparasitic effects and interferes with the multidrug resistance mechanism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A77B6F-519A-2619-E053-F662850A3197","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A77B6F-51B3-2619-E053-F662850A3197","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"L-folinic acid L-leucovorin","valueDescription":"Levoleucovorin","ValueMeaning":{"publicId":"6159851","version":"1","preferredName":"Levoleucovorin","longName":"6159851","preferredDefinition":"The active l-isomer of the racemic mixture of the 5-formyl derivative of tetrahydrofolic acid. Metabolically active, l-leucovorin, also known levoleucovorin, does not require bioactivation by dihydrofolate reductase, an enzyme inhibited by folic acid antagonists. This agent may enhance the effects of fluoropyrimidines by stabilizing their binding to the enzyme thymidylate synthase. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Levoleucovorin","conceptCode":"C1559","definition":"The active l-isomer of the racemic mixture of the 5-formyl derivative of tetrahydrofolic acid. Metabolically active, l-leucovorin, also known levoleucovorin, does not require bioactivation by dihydrofolate reductase, an enzyme inhibited by folic acid antagonists. This agent may enhance the effects of fluoropyrimidines by stabilizing their binding to the enzyme thymidylate synthase. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A77B6F-51C0-2619-E053-F662850A3197","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A77B6F-51D8-2619-E053-F662850A3197","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Levamisole Ergamisol","valueDescription":"Levamisole","ValueMeaning":{"publicId":"2578219","version":"1","preferredName":"Levamisole","longName":"2578219","preferredDefinition":"An anthelmintic drug. Co-administered with fluorouracil in the treatment of Dukes' stage C colon cancer, levamisole restores immune function through stimulating antibody formation, enhancing T-cell activity, and potentiating macrophage function. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Levamisole Hydrochloride","conceptCode":"C610","definition":"The hydrochloride salt of the synthetic imidazothiazole derivative levamisole with anthelminthic and immunomodulating activities. In immunosuppressed states, levamisole may restore immune function by: 1) stimulating antibody formation, 2) stimulating T-cell activation and proliferation, 3) potentiating monocyte and macrophage phagocytosis and chemotaxis and 4) increasing neutrophil mobility, adherence, and chemotaxis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE98-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A77B6F-51ED-2619-E053-F662850A3197","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Leuprolide acetate Lupron Eligard","valueDescription":"Leuprolide Acetate","ValueMeaning":{"publicId":"2576645","version":"1","preferredName":"Leuprolide Acetate","longName":"2576645","preferredDefinition":"A synthetic nonapeptide analogue of gonadotropin-releasing hormone. Leuprolide binds to and activates gonadotropin-releasing hormone (GnRH) receptors. Continuous, prolonged administration of leuprolide in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. This agent reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leuprolide Acetate","conceptCode":"C1319","definition":"The acetate salt of a synthetic nonapeptide analogue of gonadotropin-releasing hormone. Leuprolide binds to and activates gonadotropin-releasing hormone (GnRH) receptors. Continuous, prolonged administration of leuprolide in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. This agent reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F872-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A77B6F-5201-2619-E053-F662850A3197","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Lenvatinib mesylate Lenvima","valueDescription":"Lenvatinib Mesylate","ValueMeaning":{"publicId":"4828174","version":"1","preferredName":"Lenvatinib Mesylate","longName":"4828174","preferredDefinition":"A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. E7080 blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lenvatinib Mesylate","conceptCode":"C48636","definition":"A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. E7080 blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"16714A24-91CD-6277-E050-BB89AD433DE7","latestVersionIndicator":"Yes","beginDate":"2015-05-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-05-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A77B6F-5215-2619-E053-F662850A3197","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Lanreotide acetate Somatuline depot","valueDescription":"Lanreotide Acetate","ValueMeaning":{"publicId":"6159853","version":"1","preferredName":"Lanreotide Acetate","longName":"6159853","preferredDefinition":"The acetate salt of a synthetic cyclic octapeptide analogue of somatostatin. Lanreotide binds to somatostatin receptors (SSTR), specifically SSTR-2 and also to SSTR-5 with a lesser affinity. However, compare with octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Furthermore, lanreotide has an acute effect on decreasing circulating total and free insulin-like growth factor 1 (IGF-I).  This agent is usually given as a prolonged-release microparticle or Autogel formulation for the treatment of acromegaly and to relieve the symptoms of neuroendocrine tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lanreotide Acetate","conceptCode":"C74584","definition":"The acetate salt of a synthetic cyclic octapeptide analogue of somatostatin. Lanreotide binds to somatostatin receptors (SSTR), specifically SSTR-2 and also to SSTR-5 with a lesser affinity. However, compare with octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Furthermore, lanreotide has an acute effect on decreasing circulating total and free insulin-like growth factor 1 (IGF-I).  This agent is usually given as a prolonged-release microparticle or Autogel formulation for the treatment of acromegaly and to relieve the symptoms of neuroendocrine tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A77B6F-5222-2619-E053-F662850A3197","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A77B6F-523B-2619-E053-F662850A3197","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Ketoconazole Nizoral","valueDescription":"Ketoconazole","ValueMeaning":{"publicId":"2578210","version":"1","preferredName":"Ketoconazole","longName":"2578210","preferredDefinition":"A synthetic derivative of phenylpiperazine with broad antifungal properties and potential antineoplastic activity.  Ketoconazole inhibits sterol 14-a-dimethylase, a microsomal cytochrome P450-dependent enzyme, thereby disrupting synthesis of ergosterol, an important component of the fungal cell wall. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ketoconazole","conceptCode":"C605","definition":"A synthetic derivative of phenylpiperazine with broad antifungal properties and potential antineoplastic activity.  Ketoconazole inhibits sterol 14-a-dimethylase, a microsomal cytochrome P450-dependent enzyme, thereby disrupting synthesis of ergosterol, an important component of the fungal cell wall. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE8F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A77B6F-524F-2619-E053-F662850A3197","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"JM216 BMS182751 Satraplatin","valueDescription":"Satraplatin","ValueMeaning":{"publicId":"3379548","version":"1","preferredName":"Satraplatin","longName":"3379548","preferredDefinition":"An orally administered third generation platinum compound with potential antineoplastic activity. Satraplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in cell growth inhibition and apoptosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Satraplatin","conceptCode":"C1493","definition":"An orally administered third generation platinum compound with potential antineoplastic activity. Satraplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in cell growth inhibition and apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-34D3-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A77B6F-5263-2619-E053-F662850A3197","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Ixazomib citrate Nonlaro","valueDescription":"Ixazomib Citrate","ValueMeaning":{"publicId":"6025022","version":"1","preferredName":"Ixazomib Citrate","longName":"6025022","preferredDefinition":"The citrate salt form of ixazomib, an orally bioavailable second generation proteasome inhibitor (PI) with potential antineoplastic activity. Ixazomib inhibits the activity of the proteasome, blocking the targeted proteolysis normally performed by the proteasome, which results in an accumulation of unwanted or misfolded proteins; disruption of various cell signaling pathways may follow, resulting in the induction of apoptosis. Compared to first generation PIs, second generation PIs may have an improved pharmacokinetic profile with increased potency and less toxicity. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquinated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ixazomib Citrate","conceptCode":"C82653","definition":"The citrate salt form of ixazomib, an orally bioavailable second generation proteasome inhibitor (PI) with potential antineoplastic activity. Ixazomib inhibits the activity of the proteasome, blocking the targeted proteolysis normally performed by the proteasome, which results in an accumulation of unwanted or misfolded proteins; disruption of various cell signaling pathways may follow, resulting in the induction of apoptosis. Compared to first generation PIs, second generation PIs may have an improved pharmacokinetic profile with increased potency and less toxicity. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquinated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5D64DFD7-C3D9-166D-E053-F662850A1FF3","latestVersionIndicator":"Yes","beginDate":"2017-11-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-11-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A77B6F-5277-2619-E053-F662850A3197","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"ISIS 5132","valueDescription":"ISIS 5132","ValueMeaning":{"publicId":"6159855","version":"1","preferredName":"ISIS 5132","longName":"6159855","preferredDefinition":"A synthetic, 20-base antisense oligodeoxynucleotide that hybridizes to c-raf kinase messenger RNA.  ISIS 5132 has been shown to specifically suppress Raf-1 expression both in vitro and in vivo.  Raf-1 serine/threonine kinase functions as a critical effector of Ras-mediated signal transduction; constitutive activation of this pathway directly contributes to malignant transformation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"c-raf Antisense Oligonucleotide ISIS 5132","conceptCode":"C2721","definition":"A synthetic, 20-base antisense oligodeoxynucleotide that hybridizes to c-raf kinase messenger RNA.  ISIS 5132 has been shown to specifically suppress Raf-1 expression both in vitro and in vivo.  Raf-1 serine/threonine kinase functions as a critical effector of Ras-mediated signal transduction; constitutive activation of this pathway directly contributes to malignant transformation. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A77B6F-5284-2619-E053-F662850A3197","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A77B6F-529D-2619-E053-F662850A3197","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"ISIS 3521 Affinitac","valueDescription":"ISIS 3521","ValueMeaning":{"publicId":"6159857","version":"1","preferredName":"ISIS 3521","longName":"6159857","preferredDefinition":"A synthetic phosphorothioate oligodeoxynucleotide. As an antisense molecule, ISIS 3521 hybridizes to the 3-untranslated region of the human protein kinase C (PKC-alpha) mRNA, thereby inhibiting PKC-alpha expression and growth of PKC-alpha-dependent tumor cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aprinocarsen","conceptCode":"C1788","definition":"A synthetic phosphorothioate oligodeoxynucleotide. As an antisense molecule, aprinocarsen hybridizes to the 3-untranslated region of the human protein kinase C (PKC-alpha) mRNA, thereby inhibiting PKC-alpha expression and growth of PKC-alpha-dependent tumor cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A77B6F-52AA-2619-E053-F662850A3197","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A77B6F-52C3-2619-E053-F662850A3197","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Ipilimumab, Yervoy, MDX-010","valueDescription":"Ipilimumab","ValueMeaning":{"publicId":"3185135","version":"1","preferredName":"Ipilimumab","longName":"3185135","preferredDefinition":"A monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen-4 (CTLA4), an antigen that is expressed on activated T-cells and exhibits affinity for B7 co-stimulatory molecules. By binding CTLA4, ipilimumab enhances T-cell activation and blocks B7-1 and B7-2 T-cell co-stimulatory pathways.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ipilimumab","conceptCode":"C2654","definition":"A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A4E41E5-A2F1-57BF-E040-BB89AD4327A8","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A77B6F-52D7-2619-E053-F662850A3197","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"IPH2201, Monalizumab","valueDescription":"Monalizumab","ValueMeaning":{"publicId":"6159859","version":"1","preferredName":"Monalizumab","longName":"6159859","preferredDefinition":"A humanized immunoglobulin G4 (IgG4) monoclonal antibody against the human natural killer (NK) and T-lymphocyte cell checkpoint inhibitor killer cell lectin-like receptor subfamily C member 1 (NKG2A), with potential antineoplastic activity. Upon administration, monalizumab binds to NKG2A and prevents the binding of NKG2A to its ligand human leukocyte antigen-E (HLA-E), which is overexpressed on tumor cells. This blocks the HLA-E-mediated inhibition of NKG2A-positive infiltrating NK and cytotoxic T-lymphocytes (CTLs) and induces a NK and CTL-mediated immune response against the cancer cells leading to their destruction. Human NKG2A, an inhibitory cell surface receptor covalently bound to CD94, is expressed by NK cells and CTLs. Stimulation of the CD94/NKG2A complex inhibits the cytotoxic activity of these cells. HLA-E, a nonclassical HLA class Ib molecule, is often overexpressed on tumor cells and is associated with poor prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monalizumab","conceptCode":"C120208","definition":"A humanized immunoglobulin G4 (IgG4) monoclonal antibody against the human natural killer (NK) and T-lymphocyte cell checkpoint inhibitor killer cell lectin-like receptor subfamily C member 1 (NKG2A), with potential antineoplastic activity. Upon administration, monalizumab binds to NKG2A and prevents the binding of NKG2A to its ligand human leukocyte antigen-E (HLA-E), which is overexpressed on tumor cells. This blocks the HLA-E-mediated inhibition of NKG2A-positive infiltrating NK and cytotoxic T-lymphocytes (CTLs) and induces a NK and CTL-mediated immune response against the cancer cells leading to their destruction. Human NKG2A, an inhibitory cell surface receptor covalently bound to CD94, is expressed by NK cells and CTLs. Stimulation of the CD94/NKG2A complex inhibits the cytotoxic activity of these cells. HLA-E, a nonclassical HLA class Ib molecule, is often overexpressed on tumor cells and is associated with poor prognosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A77B6F-52E4-2619-E053-F662850A3197","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A77B6F-52FD-2619-E053-F662850A3197","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Interleukin-6 IL6","valueDescription":"Interleukin-6","ValueMeaning":{"publicId":"2578190","version":"1","preferredName":"Interleukin-6","longName":"2578190","preferredDefinition":"Interleukin-6 (IL-6), a glycoprotein produced by activated T-cells and a variety of other cells, induces the production of IgM by B-cells and can be used to replace feeder cells for the growth and maintenance of B-cell hybridomas in vitro.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interleukin-6","conceptCode":"C20451","definition":"Interleukin-6 (212 aa, ~24 kDa) is encoded by the human IL6 gene. This protein is involved in signaling affecting a wide variety of cell types including monocytes, lymphocytes, hepatocytes and nerve cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE7B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A77B6F-5311-2619-E053-F662850A3197","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Vincristine sulphate Oncovin Vincasar Leurocristine","valueDescription":"Vincristine Sulfate","ValueMeaning":{"publicId":"6159977","version":"1","preferredName":"Vincristine Sulfate","longName":"6159977","preferredDefinition":"The sulfate salt of a natural alkaloid isolated from the plant Catharanthus roseus (Vinca rosea L.) with antimitotic and antineoplastic activities. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca(2+)-activated ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vincristine Sulfate","conceptCode":"C1739","definition":"The sulfate salt of a natural alkaloid isolated from the plant Catharanthus roseus (Vinca rosea L.) with antimitotic and antineoplastic activities. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca(2+)-activated ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68D64A63-4CB5-54A6-E053-F662850A6CA8","latestVersionIndicator":"Yes","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D64A63-4CCE-54A6-E053-F662850A6CA8","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Vinblastine sulfate Velban Velbe Velsar VLB","valueDescription":"Vinblastine Sulfate","ValueMeaning":{"publicId":"6159978","version":"1","preferredName":"Vinblastine Sulfate","longName":"6159978","preferredDefinition":"The sulfate salt of vinblastine, a natural alkaloid isolated from the plant Catharanthus roseus (Madagascar periwinkle) with antineoplastic properties.  Vinblastine disrupts microtubule formation and function during mitosis and interferes with glutamic acid metabolism. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vinblastine Sulfate","conceptCode":"C931","definition":"The sulfate salt of vinblastine, a natural alkaloid isolated from the plant Catharanthus roseus (Madagascar periwinkle) with antineoplastic properties.  Vinblastine disrupts microtubule formation and function during mitosis and interferes with glutamic acid metabolism. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68D64A63-4CD8-54A6-E053-F662850A6CA8","latestVersionIndicator":"Yes","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D64A63-4CF1-54A6-E053-F662850A6CA8","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Vindesine sulphate VDS Eldisine","valueDescription":"Vindesine Sulfate","ValueMeaning":{"publicId":"6159976","version":"1","preferredName":"Vindesine Sulfate","longName":"6159976","preferredDefinition":"The sulfate salt form of Vindesine.  Vindesine binds to and stabilizes tubulin, thereby interrupting tubulin polymerization and preventing the formation of the mitotic spindle and cell division; treated cells are unable to undergo mitosis and are arrested in metaphase. This agent also disrupts macromolecular synthesis. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vindesine Sulfate","conceptCode":"C935","definition":"The sulfate salt form of Vindesine.  Vindesine binds to and stabilizes tubulin, thereby interrupting tubulin polymerization and preventing the formation of the mitotic spindle and cell division; treated cells are unable to undergo mitosis and are arrested in metaphase. This agent also disrupts macromolecular synthesis. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68D64A63-4C90-54A6-E053-F662850A6CA8","latestVersionIndicator":"Yes","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D64A63-4CA9-54A6-E053-F662850A6CA8","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Venetoclax Venclexta","valueDescription":"Venetoclax","ValueMeaning":{"publicId":"5944045","version":"1","preferredName":"Venetoclax","longName":"5944045","preferredDefinition":"An orally bioavailable, selective small molecule inhibitor of the anti-apoptotic protein Bcl-2, with potential antineoplastic activity. Venetoclax mimics BH3-only proteins, the native ligands of Bcl-2 and apoptosis activators, by binding to the hydrophobic groove of Bcl-2 proteins thereby repressing Bcl-2 activity and restoring apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in some cancers and plays an important role in the regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival. Compared to the Bcl-2 inhibitor navitoclax, this agent does not inhibit bcl-XL and does not cause bcl-XL-mediated thrombocytopenia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Venetoclax","conceptCode":"C103147","definition":"An orally bioavailable, selective small molecule inhibitor of the anti-apoptotic protein Bcl-2, with potential antineoplastic activity. Venetoclax mimics BH3-only proteins, the native ligands of Bcl-2 and apoptosis activators, by binding to the hydrophobic groove of Bcl-2 proteins thereby repressing Bcl-2 activity and restoring apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in some cancers and plays an important role in the regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival. Compared to the Bcl-2 inhibitor navitoclax, this agent does not inhibit bcl-XL and does not cause bcl-XL-mediated thrombocytopenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"57E65346-8D8B-6C22-E053-F662850A5722","latestVersionIndicator":"Yes","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D64A63-4D05-54A6-E053-F662850A6CA8","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Vemurafenib Zelboraf","valueDescription":"Vemurafenib","ValueMeaning":{"publicId":"3422122","version":"1","preferredName":"Vemurafenib","longName":"3422122","preferredDefinition":"An orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. Approximately 90% of BRAF gene mutations involve a valine-to-glutamic acid mutation at residue 600 (V600E); the oncogene protein product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) gene mutation has been found to occur in approximately 60% of melanomas, and in about 8% of all solid tumors, including melanoma, colorectal, thyroid and other cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vemurafenib","conceptCode":"C64768","definition":"An orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. Approximately 90% of BRAF gene mutations involve a valine-to-glutamic acid mutation at residue 600 (V600E); the oncogene protein product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) gene mutation has been found to occur in approximately 60% of melanomas, and in about 8% of all solid tumors, including melanoma, colorectal, thyroid and other cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC3ACCEE-3440-DAF6-E040-BB89AD433B37","latestVersionIndicator":"Yes","beginDate":"2012-03-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-03-27","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D64A63-4D19-54A6-E053-F662850A6CA8","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Veliparib ABT-88","valueDescription":"Veliparib","ValueMeaning":{"publicId":"3378148","version":"1","preferredName":"Veliparib","longName":"3378148","preferredDefinition":"A poly(ADP-ribose) polymerase (PARP) -1 and -2 inhibitor with chemosensitizing and antitumor activities. With no antiproliferative effects as a single agent at therapeutic concentrations, ABT-888 inhibits PARPs, thereby inhibiting DNA repair and potentiating the cytotoxicity of DNA-damaging agents. PARP nuclear enzymes are activated by DNA single or double strand breaks, resulting in the poly(ADP-ribosyl)ation of other nuclear DNA binding proteins involved in DNA repair; poly(ADP-ribosyl)ation contributes to efficient DNA repair and to survival of proliferating cells exposed to mild genotoxic stresses as induced by as oxidants, alkylating agents or ionizing radiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Veliparib","conceptCode":"C60768","definition":"A poly(ADP-ribose) polymerase (PARP) -1 and -2 inhibitor with chemosensitizing and antitumor activities. With no antiproliferative effects as a single agent at therapeutic concentrations, ABT-888 inhibits PARPs, thereby inhibiting DNA repair and potentiating the cytotoxicity of DNA-damaging agents. PARP nuclear enzymes are activated by DNA single or double strand breaks, resulting in the poly(ADP-ribosyl)ation of other nuclear DNA binding proteins involved in DNA repair; poly(ADP-ribosyl)ation contributes to efficient DNA repair and to survival of proliferating cells exposed to mild genotoxic stresses as induced by as oxidants, alkylating agents or ionizing radiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90390BA-6C1F-6B71-E040-BB89AD432BAA","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D64A63-4D2D-54A6-E053-F662850A6CA8","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"VB4-845 Proxinium Anti-epcam-pseudomonas-exotoxin fusion protein","valueDescription":"Oportuzumab Monatox","ValueMeaning":{"publicId":"6159980","version":"1","preferredName":"Oportuzumab Monatox","longName":"6159980","preferredDefinition":"A fusion protein immunotoxin consisting of a humanized, single-chain monoclonal antibody fragment specific for the epithelial cell adhesion molecule (EpCAM) conjugated with a truncated form of Pseudomonas exotoxin A with potential antineoplastic activity. Oportuzumab monatox binds to Ep-CAM-positive tumor cells, thereby delivering the Pseudomonas exotoxin A moiety specifically; the Pseudomonas exotoxin A moiety then inactivates elongation factor 2 (EF-2) through ADP ribosylation, resulting in inhibition of protein synthesis in target cells. EpCAM, a cell surface protein, is expressed by a variety of tumor cells and is frequently found in head and neck cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oportuzumab Monatox","conceptCode":"C61307","definition":"A fusion protein immunotoxin consisting of a humanized, single-chain monoclonal antibody fragment specific for the epithelial cell adhesion molecule (EpCAM) conjugated with a truncated form of Pseudomonas exotoxin A with potential antineoplastic activity. Oportuzumab monatox binds to Ep-CAM-positive tumor cells, thereby delivering the Pseudomonas exotoxin A moiety specifically; the Pseudomonas exotoxin A moiety then inactivates elongation factor 2 (EF-2) through ADP ribosylation, resulting in inhibition of protein synthesis in target cells. EpCAM, a cell surface protein, is expressed by a variety of tumor cells and is frequently found in head and neck cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68D64A63-4D3A-54A6-E053-F662850A6CA8","latestVersionIndicator":"Yes","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D64A63-4D53-54A6-E053-F662850A6CA8","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Vatalanib PTK787/ZK 222854","valueDescription":"Vatalanib","ValueMeaning":{"publicId":"3379414","version":"1","preferredName":"Vatalanib","longName":"3379414","preferredDefinition":"An orally bioavailable anilinophthalazine with potential antineoplastic activity.  Vatalanib binds to and inhibits the protein kinase domain of vascular endothelial growth factor receptors 1 and 2; both receptor tyrosine kinases are involved in angiogenesis.  This agent also binds to and inhibits related receptor tyrosine kinases, including platelet-derived growth factor (PDGF) receptor, c-Kit, and c-Fms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vatalanib","conceptCode":"C1868","definition":"An orally bioavailable anilinophthalazine with potential antineoplastic activity.  Vatalanib binds to and inhibits the protein kinase domain of vascular endothelial growth factor receptors 1 and 2; both receptor tyrosine kinases are involved in angiogenesis.  This agent also binds to and inhibits related receptor tyrosine kinases, including platelet-derived growth factor (PDGF) receptor, c-Kit, and c-Fms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-1F45-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D64A63-4D67-54A6-E053-F662850A6CA8","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Uracil mustard Uramustine","valueDescription":"Uracil Mustard","ValueMeaning":{"publicId":"6159982","version":"1","preferredName":"Uracil Mustard","longName":"6159982","preferredDefinition":"An alkylating derivative of the pyrimidine nucleobase uracil that is bound to nitrogen mustard, with antineoplastic activity. Uramustine alkylates and damages DNA by binding to the guanine and cytosine moieties of DNA. This leads to cross-linking of DNA, which inhibits DNA synthesis and promotes cell death in rapidly metabolizing cells, such as cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Uracil Mustard","conceptCode":"C918","definition":"An alkylating derivative of the pyrimidine nucleobase uracil that is bound to nitrogen mustard, with antineoplastic activity. Uramustine alkylates and damages DNA by binding to the guanine and cytosine moieties of DNA. This leads to cross-linking of DNA, which inhibits DNA synthesis and promotes cell death in rapidly metabolizing cells, such as cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68D64A63-4D74-54A6-E053-F662850A6CA8","latestVersionIndicator":"Yes","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D64A63-4D8D-54A6-E053-F662850A6CA8","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Tumor growth factor B TGF-B","valueDescription":"Transforming Growth Factor-Beta","ValueMeaning":{"publicId":"3219010","version":"1","preferredName":"Transforming Growth Factor-Beta","longName":"3219010","preferredDefinition":"A family of structurally-related cytokines that bind to their cognate serine/threonine kinase receptors as homodimers or heterodimers linked by a single disulfide bond. These proteins play a role in embryonic development, hematopoiesis, tissue repair and extracellular matrix remodeling.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Transforming Growth Factor-Beta Superfamily","conceptCode":"C20455","definition":"A family of structurally-related cytokines that bind to their cognate serine/threonine kinase receptors as homodimers or heterodimers linked by a single disulfide bond. These proteins play a role in embryonic development, hematopoiesis, tissue repair and extracellular matrix remodeling.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9FCC4C71-025F-22D8-E040-BB89AD433633","latestVersionIndicator":"Yes","beginDate":"2011-03-31","endDate":null,"createdBy":"MAESKEB","dateCreated":"2011-03-31","modifiedBy":"ONEDATA_WA","dateModified":"2023-12-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D64A63-4DA1-54A6-E053-F662850A6CA8","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Trimetrexate glucuronateTMTX Neutrexin","valueDescription":"Trimetrexate Glucuronate","ValueMeaning":{"publicId":"3380224","version":"1","preferredName":"Trimetrexate Glucuronate","longName":"3380224","preferredDefinition":"A lipid soluble methotrexate derivative with potential antineoplastic activity.  Trimetrexate glucuronate inhibits the enzyme dihydrofolate reductase, thereby preventing the synthesis of purine nucleotides and thymidylate, with subsequent inhibition of DNA and RNA synthesis.  Trimetrexate glucuronate also exhibits antiviral activity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trimetrexate Glucuronate","conceptCode":"C1265","definition":"A lipid soluble methotrexate derivative with potential antineoplastic activity.  Trimetrexate glucuronate inhibits the enzyme dihydrofolate reductase, thereby preventing the synthesis of purine nucleotides and thymidylate, with subsequent inhibition of DNA and RNA synthesis.  Trimetrexate glucuronate also exhibits antiviral activity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97B8401-153D-113F-E040-BB89AD431AAC","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D64A63-4DB6-54A6-E053-F662850A6CA8","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Triapine 3-AP 3-Aminopyridine-2-carboxaldehyde thiosemicarbazone","valueDescription":"Triapine","ValueMeaning":{"publicId":"6159983","version":"1","preferredName":"Triapine","longName":"6159983","preferredDefinition":"A synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity. Triapine inhibits the enzyme ribonucleotide reductase, resulting in the inhibition of the conversion of ribonucleoside diphosphates to deoxyribonucleotides necessary for DNA synthesis. This agent has been shown to inhibit tumor growth in vitro. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Triapine","conceptCode":"C2242","definition":"A synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity. Triapine inhibits the enzyme ribonucleotide reductase, resulting in the inhibition of the conversion of ribonucleoside diphosphates to deoxyribonucleotides necessary for DNA synthesis. This agent has been shown to inhibit tumor growth in vitro. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68D64A63-4DC2-54A6-E053-F662850A6CA8","latestVersionIndicator":"Yes","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D64A63-4DDB-54A6-E053-F662850A6CA8","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Tremelimumab CP675206","valueDescription":"Tremelimumab","ValueMeaning":{"publicId":"3185137","version":"1","preferredName":"Tremelimumab","longName":"3185137","preferredDefinition":"A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tremelimumab","conceptCode":"C49085","definition":"A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A4E41E5-A317-57BF-E040-BB89AD4327A8","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D64A63-4DEF-54A6-E053-F662850A6CA8","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Trastuzumab Herceptin","valueDescription":"Trastuzumab","ValueMeaning":{"publicId":"2576422","version":"1","preferredName":"Trastuzumab","longName":"2576422","preferredDefinition":"A humanized recombinant monoclonal antibody directed against the HER2- receptor protein.  Trastuzumab binds to the extracellular domain of the growth factor protein HER2, thereby inhibiting proliferation of HER2 overexpressing tumor cells.  Binding with HER2 protein also initiates an antibody-dependent cell cytotoxicity.(NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trastuzumab","conceptCode":"C1647","definition":"A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F793-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-10-04","modifiedBy":"REEVESD","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D64A63-4E03-54A6-E053-F662850A6CA8","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Trametinib Mekinist GSK1120212","valueDescription":"Trametinib","ValueMeaning":{"publicId":"3523220","version":"1","preferredName":"Trametinib","longName":"3523220","preferredDefinition":"An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MEK MAPK/ERK kinase) with potential antineoplastic activity. Trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity threonine/tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trametinib","conceptCode":"C77908","definition":"An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and 2, with potential antineoplastic activity. Upon oral administration, trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity serine/threonine and tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4A309D0-4590-6212-E040-BB89AD4364ED","latestVersionIndicator":"Yes","beginDate":"2012-07-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-12","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D64A63-4E17-54A6-E053-F662850A6CA8","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Toremifene Fareston","valueDescription":"Toremifene","ValueMeaning":{"publicId":"2563593","version":"1","preferredName":"Toremifene","longName":"2563593","preferredDefinition":"An anticancer drug that belongs to the family of drugs called antiestrogens. Toremifene blocks the effect of the hormone estrogen in the body. It may help control some cancers from growing, and it may delay or reduce the risk of cancer recurrence.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Toremifene","conceptCode":"C1256","definition":"A nonsteroidal triphenylethylene antiestrogen.  Chemically related to tamoxifen, toremifene is a selective estrogen receptor modulator (SERM).  This agent binds competitively to estrogen receptors, thereby interfering with estrogen activity.  Toremifene also has intrinsic estrogenic properties, which are manifested according to tissue type or species. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C576-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-12-04","endDate":null,"createdBy":"CVALMONT","dateCreated":"2002-12-04","modifiedBy":"COOPERM","dateModified":"2016-08-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D64A63-4E3F-54A6-E053-F662850A6CA8","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Tomudex Raltitrexed disodium","valueDescription":"Raltitrexed","ValueMeaning":{"publicId":"3378925","version":"1","preferredName":"Raltitrexed","longName":"3378925","preferredDefinition":"A quinazoline folate analogue with antineoplastic activity.  After transport into cells via the reduced folate carrier, raltitrexed undergoes intracellular polyglutamation and blocks the folate-binding site of thymidylate synthase, thereby inhibiting tetrahydrofolate activity and DNA replication and repair and resulting in cytotoxicity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Raltitrexed","conceptCode":"C1804","definition":"A quinazoline folate analogue with antineoplastic activity.  After transport into cells via the reduced folate carrier, raltitrexed undergoes intracellular polyglutamation and blocks the folate-binding site of thymidylate synthase, thereby inhibiting tetrahydrofolate activity and DNA replication and repair and resulting in cytotoxicity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B907AE08-2C18-59CE-E040-BB89AD436C6D","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D64A63-4E67-54A6-E053-F662850A6CA8","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Tisagenlecleucal Kymriah","valueDescription":"CD19CAR-CD3zeta-4-1BB-expressing Autologous T-lymphocytes","ValueMeaning":{"publicId":"5621736","version":"1","preferredName":"CD19CAR-CD3zeta-4-1BB-expressing Autologous T-lymphocytes","longName":"5621736","preferredDefinition":"Autologous T-lymphocytes transduced with a modified lentiviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) and the zeta chain of the TCR/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. Upon transfusion, CD19CAR-CD3zeta-4-1BB-expressing autologous T-lymphocytes direct the T-lymphocytes to CD19-expressing tumor cells, thereby inducing a selective toxicity in CD19-expressing tumor cells. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19 and the inclusion of this signaling domain may increase the antitumor activity compared to the inclusion of the CD3-zeta chain alone. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. CD3-zeta (or CD247) is a transmembrane signaling adaptor polypeptide that regulates the assembly of complete TCR complexes and their expression on the cell surface.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tisagenlecleucel","conceptCode":"C102758","definition":"Autologous T-lymphocytes transduced with a modified lentiviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) and the zeta chain of the TCR/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. Upon transfusion, tisagenlecleucel directs the T-lymphocytes to CD19-expressing tumor cells, thereby inducing a selective toxicity in CD19-expressing tumor cells. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19 and the inclusion of this signaling domain may increase the antitumor activity compared to the inclusion of the CD3-zeta chain alone. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. CD3-zeta (or CD247) is a transmembrane signaling adaptor polypeptide that regulates the assembly of complete TCR complexes and their expression on the cell surface.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AECAE5-BD2A-28A7-E053-F662850AD609","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D64A63-4E7B-54A6-E053-F662850A6CA8","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Tirapazamine Tirazone","valueDescription":"Tirapazamine","ValueMeaning":{"publicId":"6159985","version":"1","preferredName":"Tirapazamine","longName":"6159985","preferredDefinition":"A benzotriazine di-N-oxide with potential antineoplastic activity.  Tirapazamine is selectively activated by multiple reductases to form free radicals in hypoxic cells, thereby inducing single-and double-strand breaks in DNA, base damage, and cell death.  This agent also sensitizes hypoxic cells to ionizing radiation and inhibits the repair of radiation-induced DNA strand breaks via inhibition of topoisomerase II. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tirapazamine","conceptCode":"C1464","definition":"A benzotriazine di-N-oxide with potential antineoplastic activity.  Tirapazamine is selectively activated by multiple reductases to form free radicals in hypoxic cells, thereby inducing single-and double-strand breaks in DNA, base damage, and cell death.  This agent also sensitizes hypoxic cells to ionizing radiation and inhibits the repair of radiation-induced DNA strand breaks via inhibition of topoisomerase II. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68D64A63-4E88-54A6-E053-F662850A6CA8","latestVersionIndicator":"Yes","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D64A63-4EA1-54A6-E053-F662850A6CA8","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Tiazofurin Tiazole","valueDescription":"Tiazofurin","ValueMeaning":{"publicId":"6159987","version":"1","preferredName":"Tiazofurin","longName":"6159987","preferredDefinition":"A synthetic nucleoside analogue with antineoplastic activity. Tiazofurin (TR) is anabolized intracellularly to an analogue of NAD, tiazole-4-carboxamide adenine dinucleotide (TAD), a potent inhibitor of IMP dehydrogenase (IMPDH); IMPDH is the rate-limiting enzyme for de novo purine synthesis. Inhibition of IMPDH results in reduced levels of guanylates, resulting in the inhibition tumor cell growth in vitro and in vivo. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tiazofurin","conceptCode":"C1254","definition":"A synthetic nucleoside analogue with antineoplastic activity. Tiazofurin (TR) is anabolized intracellularly to an analogue of NAD, tiazole-4-carboxamide adenine dinucleotide (TAD), a potent inhibitor of IMP dehydrogenase (IMPDH); IMPDH is the rate-limiting enzyme for de novo purine synthesis. Inhibition of IMPDH results in reduced levels of guanylates, resulting in the inhibition tumor cell growth in vitro and in vivo. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68D64A63-4EAE-54A6-E053-F662850A6CA8","latestVersionIndicator":"Yes","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D64A63-4EC7-54A6-E053-F662850A6CA8","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","deletedIndicator":"No"},{"value":"Adriamycin Doxorubicin HCL","valueDescription":"Doxorubicin Hydrochloride","ValueMeaning":{"publicId":"5544727","version":"1","preferredName":"Doxorubicin Hydrochloride","longName":"5544727","preferredDefinition":"The hydrochloride salt of doxorubicin, an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxorubicin Hydrochloride","conceptCode":"C1326","definition":"The hydrochloride salt of doxorubicin, an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3FCC725E-1760-054A-E053-F662850A831B","latestVersionIndicator":"Yes","beginDate":"2016-10-26","endDate":null,"createdBy":"ZHANGW","dateCreated":"2016-10-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682DF2C6-773F-47D7-E053-F662850A61D2","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"AEG35156 GEM640","valueDescription":"AEG35156","ValueMeaning":{"publicId":"6148601","version":"1","preferredName":"AEG35156","longName":"6148601","preferredDefinition":"A second-generation synthetic antisense oligonucleotide with potential antineoplastic activity. AEG35156 selectively blocks the cellular expression of X-linked inhibitor of apoptosis protein (XIAP), a pivotal inhibitor of apoptosis that is overexpressed in many tumors. This agent reduces total levels of XIAP in tumor cells, working synergistically with cytotoxic drugs to overcome tumor cell resistance to apoptosis. XIAP interferes with both the intrinsic and extrinsic program-death signaling pathways, which may render tumor cells resistant to apoptosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"XIAP Antisense Oligonucleotide AEG35156","conceptCode":"C49180","definition":"A second-generation synthetic antisense oligonucleotide with potential antineoplastic activity. AEG35156 selectively blocks the cellular expression of X-linked inhibitor of apoptosis protein (XIAP), a pivotal inhibitor of apoptosis that is overexpressed in many tumors. This agent reduces total levels of XIAP in tumor cells, working synergistically with cytotoxic drugs to overcome tumor cell resistance to apoptosis. XIAP interferes with both the intrinsic and extrinsic program-death signaling pathways, which may render tumor cells resistant to apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682DF2C6-7712-47D7-E053-F662850A61D2","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682DF2C6-772B-47D7-E053-F662850A61D2","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Acodazole ","valueDescription":"Acodazole","ValueMeaning":{"publicId":"6148603","version":"1","preferredName":"Acodazole","longName":"6148603","preferredDefinition":"A synthetic imidazoquinoline with antineoplastic activity. Acodazole intercalates into DNA, resulting in disruption of DNA replication.  Use of this agent has been associated with significant cardiotoxicity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acodazole","conceptCode":"C988","definition":"A synthetic imidazoquinoline with antineoplastic activity. Acodazole intercalates into DNA, resulting in disruption of DNA replication.  Use of this agent has been associated with significant cardiotoxicity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682DF2C6-774C-47D7-E053-F662850A61D2","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682DF2C6-7765-47D7-E053-F662850A61D2","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Acivicin AT-125","valueDescription":"Acivicin","ValueMeaning":{"publicId":"3377410","version":"1","preferredName":"Acivicin","longName":"3377410","preferredDefinition":"A modified amino acid and structural analog of glutamine.  Acivicin inhibits glutamine amidotransferases in the purine and pyrimidine biosynthetic pathways, thereby inhibiting tumor growth in cell lines dependent on glutamine metabolism. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acivicin","conceptCode":"C986","definition":"A modified amino acid and structural analog of glutamine.  Acivicin inhibits glutamine amidotransferases in the purine and pyrimidine biosynthetic pathways, thereby inhibiting tumor growth in cell lines dependent on glutamine metabolism. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DF6309-9F28-1E33-E040-BB89AD43040B","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682DF2C6-7779-47D7-E053-F662850A61D2","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Acalabrutinib Calquence","valueDescription":"Acalabrutinib","ValueMeaning":{"publicId":"6028593","version":"1","preferredName":"Acalabrutinib","longName":"6028593","preferredDefinition":"An orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, acalabrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acalabrutinib","conceptCode":"C113442","definition":"An orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, acalabrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E1C8E98-260C-503F-E053-F662850A8F36","latestVersionIndicator":"Yes","beginDate":"2017-11-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-11-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682DF2C6-778D-47D7-E053-F662850A61D2","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Abiraterone Acetate, Zytiga, CB7630","valueDescription":"Abiraterone Acetate","ValueMeaning":{"publicId":"5425971","version":"1","preferredName":"Abiraterone Acetate","longName":"5425971","preferredDefinition":"An orally active acetate salt of the steroidal compound abiraterone with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abiraterone Acetate","conceptCode":"C68845","definition":"An orally active acetate ester form of the steroidal compound abiraterone with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A714DC5-A5C1-9607-E050-BB89AD43167A","latestVersionIndicator":"Yes","beginDate":"2016-08-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-19","modifiedBy":"GDEEN","dateModified":"2022-07-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682DF2C6-77A1-47D7-E053-F662850A61D2","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Abemaciclib Verzenio","valueDescription":"Abemaciclib","ValueMeaning":{"publicId":"6148605","version":"1","preferredName":"Abemaciclib","longName":"6148605","preferredDefinition":"An orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. Abemaciclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abemaciclib","conceptCode":"C97660","definition":"An orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. Abemaciclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682DF2C6-77AE-47D7-E053-F662850A61D2","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682DF2C6-77C7-47D7-E053-F662850A61D2","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"9-AC 9-Aminocamptothecin","valueDescription":"Aminocamptothecin","ValueMeaning":{"publicId":"2576886","version":"1","preferredName":"Aminocamptothecin","longName":"2576886","preferredDefinition":"A water-insoluble camptothecin derivative.  Aminocamptothecin binds to the nuclear enzyme topoisomerase I, thereby inhibiting repair of single-strand DNA breakages.  Because the terminal lactone ring of aminocamptothecin required for the agent's antitumor activity spontaneously opens under physiological conditions to an inactive carboxy form, the drug must be administered over an extended period of time to achieve effective cytotoxicity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aminocamptothecin","conceptCode":"C1488","definition":"A water-insoluble camptothecin derivative.  Aminocamptothecin binds to the nuclear enzyme topoisomerase I, thereby inhibiting repair of single-strand DNA breakages.  Because the terminal lactone ring of aminocamptothecin required for the agent's antitumor activity spontaneously opens under physiological conditions to an inactive carboxy form, the drug must be administered over an extended period of time to achieve effective cytotoxicity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F963-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-09","modifiedBy":"ONEDATA","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682DF2C6-77DB-47D7-E053-F662850A61D2","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"776C85","valueDescription":"Eniluracil","ValueMeaning":{"publicId":"6148607","version":"1","preferredName":"Eniluracil","longName":"6148607","preferredDefinition":"An orally-active fluoropyrimidine analogue. Eniluracil inhibits dihydropyrimidine dehydrogenase, the rate-limiting enzyme that catabolizes and inactivates 5-fluorouracil (5-FU) in the liver. Co-administration of ethynyluracil permits the oral administration of 5-FU.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eniluracil","conceptCode":"C1773","definition":"An orally-active fluoropyrimidine analogue. Eniluracil inhibits dihydropyrimidine dehydrogenase, the rate-limiting enzyme that catabolizes and inactivates 5-fluorouracil (5-FU) in the liver. Co-administration of ethynyluracil permits the oral administration of 5-FU.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682DF2C6-77E8-47D7-E053-F662850A61D2","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682DF2C6-7801-47D7-E053-F662850A61D2","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"6-Thioguanine Lanvis","valueDescription":"Thioguanine","ValueMeaning":{"publicId":"2744957","version":"1","preferredName":"Thioguanine","longName":"2744957","preferredDefinition":"A synthetic guanosine analogue antimetabolite. Phosphorylated by hypoxanthine-guanine phosphoribosyltransferase, thioguanine incorporates into DNA and RNA, resulting in inhibition of DNA and RNA syntheses and cell death. This agent also inhibits glutamine-5-phosphoribosylpyrophosphate amidotransferase, thereby inhibiting purine synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thioguanine","conceptCode":"C876","definition":"A synthetic guanosine analogue antimetabolite. Phosphorylated by hypoxanthine-guanine phosphoribosyltransferase, thioguanine incorporates into DNA and RNA, resulting in inhibition of DNA and RNA syntheses and cell death. This agent also inhibits glutamine-5-phosphoribosylpyrophosphate amidotransferase, thereby inhibiting purine synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4BB4171E-80FC-21EC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-04-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682DF2C6-7815-47D7-E053-F662850A61D2","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"5-Azacytidine Azacitidine Vidaza","valueDescription":"Azacitidine","ValueMeaning":{"publicId":"3013054","version":"1","preferredName":"Azacitidine","longName":"3013054","preferredDefinition":"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity. Azacitidine is incorporated into DNA, where it reversibly inhibits DNA methyltransferase, thereby blocking DNA methylation.  Hypomethylation of DNA by azacitidine may activate tumor suppressor genes silenced by hypermethylation, resulting in an antitumor effect. This agent is also incorporated into RNA, thereby disrupting normal RNA function and impairing tRNA cytosine-5-methyltransferase activity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Azacitidine","conceptCode":"C288","definition":"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity. Azacitidine is incorporated into DNA, where it reversibly inhibits DNA methyltransferase, thereby blocking DNA methylation.  Hypomethylation of DNA by azacitidine may activate tumor suppressor genes silenced by hypermethylation, resulting in an antitumor effect. This agent is also incorporated into RNA, thereby disrupting normal RNA function and impairing tRNA cytosine-5-methyltransferase activity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7FF4D250-9950-4F75-E040-BB89AD434B4C","latestVersionIndicator":"Yes","beginDate":"2010-02-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-02-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682DF2C6-7829-47D7-E053-F662850A61D2","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"13-cis-retinoic acid Isotretinoin Accutane","valueDescription":"Isotretinoin","ValueMeaning":{"publicId":"3379087","version":"1","preferredName":"Isotretinoin","longName":"3379087","preferredDefinition":"A naturally-occurring retinoic acid with potential antineoplastic activity. Isotretinoin binds to and activates nuclear retinoic acid receptors (RARs); activated RARs serve as transcription factors that promote cell differentiation and apoptosis. This agent also exhibits immunomodulatory and anti-inflammatory responses and inhibits ornithine decarboxylase, thereby decreasing polyamine synthesis and keratinization.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Isotretinoin","conceptCode":"C603","definition":"A naturally-occurring retinoic acid with potential antineoplastic activity. Isotretinoin binds to and activates nuclear retinoic acid receptors (RARs); activated RARs serve as transcription factors that promote cell differentiation and apoptosis. This agent also exhibits immunomodulatory and anti-inflammatory responses and inhibits ornithine decarboxylase, thereby decreasing polyamine synthesis and keratinization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B915D7F9-5638-D77C-E040-BB89AD4330BD","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682DF2C6-783D-47D7-E053-F662850A61D2","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"10-EDAM Edatrexate","valueDescription":"Edatrexate","ValueMeaning":{"publicId":"6148609","version":"1","preferredName":"Edatrexate","longName":"6148609","preferredDefinition":"A polyglutamatable folate antagonist analogue of methotrexate with antineoplastic activity. Edatrexate inhibits dihydrofolate reductase, thereby increasing cellular levels of polyglutamates, inhibiting thymidylate synthase and glycinamide ribonucleotide formyl transferase, impairing synthesis of purine nucleotides and amino acids, and resulting in tumor cell death. Edatrexate may overcome tumor resistance to methotrexate, which loses its activity after it is polyglutamated. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Edatrexate","conceptCode":"C958","definition":"A polyglutamatable folate antagonist analogue of methotrexate with antineoplastic activity. Edatrexate inhibits dihydrofolate reductase, thereby increasing cellular levels of polyglutamates, inhibiting thymidylate synthase and glycinamide ribonucleotide formyl transferase, impairing synthesis of purine nucleotides and amino acids, and resulting in tumor cell death. Edatrexate may overcome tumor resistance to methotrexate, which loses its activity after it is polyglutamated. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682DF2C6-784A-47D7-E053-F662850A61D2","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682DF2C6-7863-47D7-E053-F662850A61D2","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"9-cis retinoic acid Panretin Alitretinoin","valueDescription":"Alitretinoin","ValueMeaning":{"publicId":"3378153","version":"1","preferredName":"Alitretinoin","longName":"3378153","preferredDefinition":"An orally- and topically-active naturally-occurring retinoic acid with antineoplastic, chemopreventive, teratogenic, and embryotoxic activities. Alitretinoin binds to and activates nuclear retinoic acid receptors (RAR) and retinoid X receptors (RXR); these activated receptors act as transcription factors, regulating gene expression that results in the inhibition of cell proliferation, induction of cell differentiation, and apoptosis of both normal cells and tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alitretinoin","conceptCode":"C1574","definition":"An orally- and topically-active naturally-occurring retinoic acid with antineoplastic, chemopreventive, teratogenic, and embryotoxic activities. Alitretinoin binds to and activates nuclear retinoic acid receptors (RAR) and retinoid X receptors (RXR); these activated receptors act as transcription factors, regulating gene expression that results in the inhibition of cell proliferation, induction of cell differentiation, and apoptosis of both normal cells and tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90390BA-6C8E-6B71-E040-BB89AD432BAA","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682DF2C6-7877-47D7-E053-F662850A61D2","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"AZD4547","valueDescription":"FGFR Inhibitor AZD4547","ValueMeaning":{"publicId":"6148619","version":"1","preferredName":"FGFR Inhibitor AZD4547","longName":"6148619","preferredDefinition":"An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. FGFR inhibitor AZD4547 binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways, and, so, the inhibition of tumor cell proliferation and tumor cell death. FGFR, up-regulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cellular proliferation, differentiation and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fexagratinib","conceptCode":"C88272","definition":"An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. fexagratinib binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways, and, so, the inhibition of tumor cell proliferation and tumor cell death. FGFR, up-regulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cellular proliferation, differentiation and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682E544B-84C4-22D2-E053-F662850A97FD","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E544B-84DD-22D2-E053-F662850A97FD","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"AZD2281 KU0059436 Olaparib","valueDescription":"Olaparib","ValueMeaning":{"publicId":"3377423","version":"1","preferredName":"Olaparib","longName":"3377423","preferredDefinition":"A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Olaparib","conceptCode":"C71721","definition":"A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DFB740-1C92-299D-E040-BB89AD430A5E","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"COOPERM","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E544B-84F1-22D2-E053-F662850A97FD","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"AZD2171 Recentin Cediranib","valueDescription":"Cediranib Maleate","ValueMeaning":{"publicId":"6148620","version":"1","preferredName":"Cediranib Maleate","longName":"6148620","preferredDefinition":"The maleate salt of an indole ether quinazoline derivative with antineoplastic activities. Competing with adenosine triphosphate, cediranib binds to and inhibits all three vascular endothelial growth factor receptor (VEGFR-1,-2,-3) tyrosine kinases, thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cediranib Maleate","conceptCode":"C48379","definition":"The maleate salt of an indole ether quinazoline derivative with antineoplastic activities. Competing with adenosine triphosphate, cediranib binds to and inhibits all three vascular endothelial growth factor receptor (VEGFR-1,-2,-3) tyrosine kinases, thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682E544B-84FD-22D2-E053-F662850A97FD","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E544B-8516-22D2-E053-F662850A97FD","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"AZD2014","valueDescription":"Vistusertib","ValueMeaning":{"publicId":"6148622","version":"1","preferredName":"Vistusertib","longName":"6148622","preferredDefinition":"An orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. Vistusertib inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase that is upregulated in a variety of tumors, plays an important role downstream in the PI3K/Akt/mTOR signaling pathway.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vistusertib","conceptCode":"C88329","definition":"An orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. Vistusertib inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase that is upregulated in a variety of tumors, plays an important role downstream in the PI3K/Akt/mTOR signaling pathway.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682E544B-8523-22D2-E053-F662850A97FD","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E544B-853C-22D2-E053-F662850A97FD","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"AZD1775 MK1775","valueDescription":"Adavosertib","ValueMeaning":{"publicId":"3718072","version":"1","preferredName":"Adavosertib","longName":"3718072","preferredDefinition":"A small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. Adavosertib selectively targets and inhibits WEE1, a tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (CDK1, CDC2) to inactivate the CDC2/cyclin B complex. Inhibition of WEE1 activity prevents the phosphorylation of CDC2 and impairs the G2 DNA damage checkpoint. This may lead to apoptosis upon treatment with DNA damaging chemotherapeutic agents. Unlike normal cells, most p53 deficient or mutated human cancers lack the G1 checkpoint as p53 is the key regulator of the G1 checkpoint and these cells rely on the G2 checkpoint for DNA repair to damaged cells. Annulment of the G2 checkpoint may therefore make p53 deficient tumor cells more vulnerable to antineoplastic agents and enhance their cytotoxic effect.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adavosertib","conceptCode":"C91725","definition":"A small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. Adavosertib selectively targets and inhibits WEE1, a tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (CDK1, CDC2) to inactivate the CDC2/cyclin B complex. Inhibition of WEE1 activity prevents the phosphorylation of CDC2 and impairs the G2 DNA damage checkpoint. This may lead to apoptosis upon treatment with DNA damaging chemotherapeutic agents. Unlike normal cells, most p53 deficient or mutated human cancers lack the G1 checkpoint as p53 is the key regulator of the G1 checkpoint and these cells rely on the G2 checkpoint for DNA repair to damaged cells. Annulment of the G2 checkpoint may therefore make p53 deficient tumor cells more vulnerable to antineoplastic agents and enhance their cytotoxic effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9A00243-390D-1772-E040-BB89AD43098A","latestVersionIndicator":"Yes","beginDate":"2013-04-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-04-05","modifiedBy":"COOPERM","dateModified":"2018-04-16","changeDescription":"Updated Long Name to current NCIt concept name.  Added previous Long Name as alternate VM. 4.16.18 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E544B-8550-22D2-E053-F662850A97FD","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"AZD0530 Saracatinib","valueDescription":"Saracatinib (AZD0530)","ValueMeaning":{"publicId":"3263353","version":"1","preferredName":"Saracatinib (AZD0530)","longName":"3263353","preferredDefinition":"An orally available 5-, 7-substituted anilinoquinazoline with anti-invasive and anti-tumor activities. Saracatinib is a dual-specific inhibitor of Src and Abl, protein tyrosine kinases that are overexpressed in chronic myeloid leukemia cells. This agent binds to and inhibits these tyrosine kinases and affects cell motility, cell migration, adhesion, invasion, proliferation, differentiation, and survival. Specifically, Saracatinib inhibits Src kinase-mediated osteoclast bone resorption.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Saracatinib","conceptCode":"C48378","definition":"An orally available 5-, 7-substituted anilinoquinazoline with anti-invasive and anti-tumor activities. Saracatinib is a dual-specific inhibitor of Src and Abl, protein tyrosine kinases that are overexpressed in chronic myeloid leukemia cells. This agent binds to and inhibits these tyrosine kinases and affects cell motility, cell migration, adhesion, invasion, proliferation, differentiation, and survival. Specifically, Saracatinib inhibits Src kinase-mediated osteoclast bone resorption.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AAC9BCD2-6B39-3AEE-E040-BB89AD4375B9","latestVersionIndicator":"Yes","beginDate":"2011-08-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-08-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E544B-8564-22D2-E053-F662850A97FD","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Axitinib, AG-013736","valueDescription":"Axitinib","ValueMeaning":{"publicId":"3107592","version":"1","preferredName":"Axitinib","longName":"3107592","preferredDefinition":"An orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Axitinib","conceptCode":"C38718","definition":"An orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8873406C-115B-C1CB-E040-BB89AD434472","latestVersionIndicator":"Yes","beginDate":"2010-06-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-06-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E544B-8578-22D2-E053-F662850A97FD","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Avelumab Bavencio","valueDescription":"Avelumab","ValueMeaning":{"publicId":"5799363","version":"1","preferredName":"Avelumab","longName":"5799363","preferredDefinition":"A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T-cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity. PD-L1, a transmembrane protein, is overexpressed on a variety of tumor cell types and is associated with poor prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Avelumab","conceptCode":"C116870","definition":"A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T-cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity. PD-L1, a transmembrane protein, is overexpressed on a variety of tumor cell types and is associated with poor prognosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E757D46-6B00-5282-E053-F662850AE968","latestVersionIndicator":"Yes","beginDate":"2017-05-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2017-05-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E544B-858C-22D2-E053-F662850A97FD","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Atezolizumab Tecentriq","valueDescription":"Atezolizumab","ValueMeaning":{"publicId":"5242662","version":"1","preferredName":"Atezolizumab","longName":"5242662","preferredDefinition":"A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, MPDL3280A also prevents binding of this ligand to B7.1 expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of MPDL3280A is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atezolizumab","conceptCode":"C106250","definition":"A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1; PDCD1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents binding of this ligand to B7.1 (CD80) expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of atezolizumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31F0A2DB-9907-9ED8-E050-BB89AD436E03","latestVersionIndicator":"Yes","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"COOPERM","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E544B-85A0-22D2-E053-F662850A97FD","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"AT9283","valueDescription":"Multikinase Inhibitor AT9283","ValueMeaning":{"publicId":"6148624","version":"1","preferredName":"Multikinase Inhibitor AT9283","longName":"6148624","preferredDefinition":"A small synthetic molecule and aurora kinase (AK) inhibitor with potential antineoplastic activity. AT9283 selectively binds to and inhibits AKs A and B, which are serine-threonine kinases that play essential roles in mitotic checkpoint control during mitosis. Inhibition of these kinases results in an inhibition of cellular division and proliferation in tumor cells that overexpress AKs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multikinase Inhibitor AT9283","conceptCode":"C66947","definition":"A small synthetic molecule and aurora kinase (AK) inhibitor with potential antineoplastic activity. AT9283 selectively binds to and inhibits AKs A and B, which are serine-threonine kinases that play essential roles in mitotic checkpoint control during mitosis. Inhibition of these kinases results in an inhibition of cellular division and proliferation in tumor cells that overexpress AKs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682E544B-85AD-22D2-E053-F662850A97FD","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E544B-85C6-22D2-E053-F662850A97FD","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"AT7519M","valueDescription":"CDKI AT7519","ValueMeaning":{"publicId":"6148626","version":"1","preferredName":"CDKI AT7519","longName":"6148626","preferredDefinition":"An orally bioavailable small molecule with potential antineoplastic activity. AT7519M selectively binds to and inhibits cyclin dependent kinases (CDKs), which may result in cell cycle arrest, induction of apoptosis, and inhibition of tumor cell proliferation. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some types of cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CDK Inhibitor AT7519","conceptCode":"C64761","definition":"An orally bioavailable small molecule with potential antineoplastic activity. AT7519M selectively binds to and inhibits cyclin dependent kinases (CDKs), which may result in cell cycle arrest, induction of apoptosis, and inhibition of tumor cell proliferation. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some types of cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682E544B-85D3-22D2-E053-F662850A97FD","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E544B-85EC-22D2-E053-F662850A97FD","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Asparaginase L-Asparaginase Elspar","valueDescription":"Asparaginase","ValueMeaning":{"publicId":"3377440","version":"1","preferredName":"Asparaginase","longName":"3377440","preferredDefinition":"An enzyme isolated from the bacterium Escherichia coli or the bacterium Erwinia carotovora with antileukemic activity. Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia in leukemic cells, resulting in the depletion of asparagine, inhibition of protein synthesis, cell cycle arrest in the G1 phase, and apoptosis in susceptible leukemic cell populations. Asparagine is critical to protein synthesis in leukemic cells; some leukemic cells cannot synthesize this amino acid de novo due to the absent or deficient expression of the enzyme asparagine synthase. The E. carotovora-derived form of asparaginase is typically reserved for cases of asparaginase hypersensitivity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Asparaginase","conceptCode":"C286","definition":"An enzyme isolated from the bacterium Escherichia coli or the bacterium Erwinia carotovora with antileukemic activity. Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia in leukemic cells, resulting in the depletion of asparagine, inhibition of protein synthesis, cell cycle arrest in the G1 phase, and apoptosis in susceptible leukemic cell populations. Asparagine is critical to protein synthesis in leukemic cells; some leukemic cells cannot synthesize this amino acid de novo due to the absent or deficient expression of the enzyme asparagine synthase. The E. carotovora-derived form of asparaginase is typically reserved for cases of asparaginase hypersensitivity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DF6309-A0D6-1E33-E040-BB89AD43040B","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E544B-8600-22D2-E053-F662850A97FD","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Interleukin-2 Proleukin","valueDescription":"Aldesleukin","ValueMeaning":{"publicId":"5127432","version":"1","preferredName":"Aldesleukin","longName":"5127432","preferredDefinition":"A recombinant analog of the endogenous cytokine interleukin-2 (IL-2) with immunoregulatory and antineoplastic activities. Aldesleukin binds to and activates the IL-2 receptor, followed by heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains; activation of the tyrosine kinase Jak3; and phosphorylation of tyrosine residues on the IL-2R beta chain, resulting in an activated receptor complex. Various cytoplasmic signaling molecules are recruited to the activated receptor complex and become substrates for regulatory enzymes that are associated with the receptor complex. This agent enhances lymphocyte mitogenesis; stimulates long-term growth of human IL-2 dependent cell lines; enhances lymphocyte cytotoxicity; induces lymphokine-activated killer (LAK) cell and natural killer (NK) cell activities; and induces expression of interferon-gamma. Aldesleukin may induce T cell-mediated tumor regression in some tumor types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aldesleukin","conceptCode":"C1498","definition":"A recombinant analog of the endogenous cytokine interleukin-2 (IL-2) with immunoregulatory and antineoplastic activities. Aldesleukin binds to and activates the IL-2 receptor, followed by heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains; activation of the tyrosine kinase Jak3; and phosphorylation of tyrosine residues on the IL-2R beta chain, resulting in an activated receptor complex. Various cytoplasmic signaling molecules are recruited to the activated receptor complex and become substrates for regulatory enzymes that are associated with the receptor complex. This agent enhances lymphocyte mitogenesis; stimulates long-term growth of human IL-2 dependent cell lines; enhances lymphocyte cytotoxicity; induces lymphokine-activated killer (LAK) cell and natural killer (NK) cell activities; and induces expression of interferon-gamma. Aldesleukin may induce T cell-mediated tumor regression in some tumor types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FB5B-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A768EF-15D2-2BEA-E053-F662850A8C5F","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Interleukin-12 IL12","valueDescription":"Interleukin-12","ValueMeaning":{"publicId":"2578188","version":"1","preferredName":"Interleukin-12","longName":"2578188","preferredDefinition":"Exhibiting a broad range of biological activities on T and natural killer cells, Interleukin-12 is a disulfide-bonded heterodimeric cytokine composed of a 35-kD IL12A subunit (IL-6 Superfamily) and a 40-kDa IL12B subunit (Type I Cytokine Receptor 3 Family). IL12 stimulates T-cell-independent production of IFN-gamma by PBMCs, enhances NK cell lytic activity, acts as a growth factor for T- and NK-cells, and is important for Th1 and Th2 cell differentiation. Lymphocyte responses to IL12 require NOS2A and are mediated by STAT4 activator of transcription. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interleukin-12","conceptCode":"C20514","definition":"Exhibiting a broad range of biological activities on T and natural killer cells, Interleukin-12 is a disulfide-bonded heterodimeric cytokine composed of a 35-kD IL12A subunit (IL-6 Superfamily) and a 40-kDa IL12B subunit (Type I Cytokine Receptor 3 Family). IL12 stimulates T-cell-independent production of IFN-gamma by PBMCs, enhances NK cell lytic activity, acts as a growth factor for T- and NK-cells, and is important for Th1 and Th2 cell differentiation. Lymphocyte responses to IL12 require NOS2A and are mediated by STAT4 activator of transcription. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE79-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A768EF-15E7-2BEA-E053-F662850A8C5F","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Interleukin-11 Neumega Oprelvekin RIL-11","valueDescription":"Oprelvekin","ValueMeaning":{"publicId":"2664856","version":"1","preferredName":"Oprelvekin","longName":"2664856","preferredDefinition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin 11 (IL-11). Secreted by bone marrow stromal cells and a number of mesenchymal cells, IL-11 binds to and activates its cell-surface receptor, promoting primary and secondary immune responses, modulating antigen-specific antibody reactions, and preventing apoptotic cell death.  This agent also stimulates the T-cell-dependent development of IgG-secreting B-cells in spleen cell cultures and may be an important regulator of megakaryocytopoiesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oprelvekin","conceptCode":"C1303","definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin 11 (IL-11). Secreted by bone marrow stromal cells and a number of mesenchymal cells, IL-11 binds to and activates its cell-surface receptor, promoting primary and secondary immune responses, modulating antigen-specific antibody reactions, and preventing apoptotic cell death.  This agent also stimulates the T-cell-dependent development of IgG-secreting B-cells in spleen cell cultures and may be an important regulator of megakaryocytopoiesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"35A00595-9C5C-3A15-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-07-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-07-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A768EF-15FB-2BEA-E053-F662850A8C5F","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Interferon-gamma","valueDescription":"Interferon Gamma","ValueMeaning":{"publicId":"2578177","version":"1","preferredName":"Interferon Gamma","longName":"2578177","preferredDefinition":"Interferon gamma (IFNg) is produced by activated T cells and is an important immunoregulatory molecule, particularly in allergic diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interferon Gamma","conceptCode":"C20496","definition":"Interferon gamma (166 aa, ~19 kDa) is encoded by the human IFNG gene. This protein is involved in antiviral activity, macrophage activation, antiproliferative activity and immunopotentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE6E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A768EF-160F-2BEA-E053-F662850A8C5F","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Interferon-beta","valueDescription":"Recombinant Interferon Beta","ValueMeaning":{"publicId":"6159845","version":"1","preferredName":"Recombinant Interferon Beta","longName":"6159845","preferredDefinition":"A recombinant protein which is chemically identical to or similar to endogenous interferon beta with antiviral and anti-tumor activities. Endogenous interferons beta are cytokines produced by nucleated cells (predominantly natural killer cells) upon exposure to live or inactivated virus, double-stranded RNA or bacterial products. These agents bind to specific cell-surface receptors, resulting in the transcription and translation of genes with an interferon-specific response element. The proteins so produced mediate many complex effects, including antiviral (the most important being inhibition of viral protein synthesis), antiproliferative and immune modulating effects. The recombinant therapeutic forms of interferon beta are interferon beta 1-a and interferon beta 1-b. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Interferon Beta","conceptCode":"C495","definition":"A recombinant protein which is chemically identical to or similar to endogenous interferon beta with antiviral and anti-tumor activities. Endogenous interferons beta are cytokines produced by nucleated cells (predominantly natural killer cells) upon exposure to live or inactivated virus, double-stranded RNA or bacterial products. These agents bind to specific cell-surface receptors, resulting in the transcription and translation of genes with an interferon-specific response element. The proteins so produced mediate many complex effects, including antiviral (the most important being inhibition of viral protein synthesis), antiproliferative and immune modulating effects. The recombinant therapeutic forms of interferon beta are interferon beta 1-a and interferon beta 1-b. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A768EF-161C-2BEA-E053-F662850A8C5F","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A768EF-1635-2BEA-E053-F662850A8C5F","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Inotuzumab ozogamicin Besponsa","valueDescription":"Inotuzumab Ozogamicin","ValueMeaning":{"publicId":"5577157","version":"1","preferredName":"Inotuzumab Ozogamicin","longName":"5577157","preferredDefinition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inotuzumab Ozogamicin","conceptCode":"C71542","definition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"415CA911-09D6-28BD-E053-F662850AAA2B","latestVersionIndicator":"Yes","beginDate":"2016-11-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2016-11-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A768EF-1649-2BEA-E053-F662850A8C5F","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Ifosfamide IFO Holoxan Holeren Ifex","valueDescription":"Ifosfamide","ValueMeaning":{"publicId":"2739548","version":"1","preferredName":"Ifosfamide","longName":"2739548","preferredDefinition":"A synthetic analogue of the nitrogen mustard cyclophosphamide with antineoplastic activity. Ifosfamide alkylates and forms DNA crosslinks, thereby preventing DNA strand separation and DNA replication.  This agent is a prodrug that must be activated through hydroxylation by hepatic microsomal enzymes. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ifosfamide","conceptCode":"C564","definition":"A synthetic analogue of the nitrogen mustard cyclophosphamide with antineoplastic activity. Ifosfamide alkylates and forms DNA crosslinks, thereby preventing DNA strand separation and DNA replication.  This agent is a prodrug that must be activated through hydroxylation by hepatic microsomal enzymes. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A7528ED-01A4-5EF5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A768EF-165D-2BEA-E053-F662850A8C5F","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Idelalisib Zydelig CAL101","valueDescription":"Idelalisib","ValueMeaning":{"publicId":"5096863","version":"1","preferredName":"Idelalisib","longName":"5096863","preferredDefinition":"An orally bioavailable, small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities.  Idelalisib inhibits the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), preventing the activation of the PI3K signaling pathway and inhibiting tumor cell proliferation, motility, and survival. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Idelalisib","conceptCode":"C78825","definition":"An orally bioavailable, small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities.  Idelalisib inhibits the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), preventing the activation of the PI3K signaling pathway and inhibiting tumor cell proliferation, motility, and survival. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28ACEAFB-479D-6667-E050-BB89AD432DA7","latestVersionIndicator":"Yes","beginDate":"2016-01-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-01-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A768EF-1671-2BEA-E053-F662850A8C5F","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Idarubicin HCL","valueDescription":"Idarubicin Hydrochloride","ValueMeaning":{"publicId":"3379135","version":"1","preferredName":"Idarubicin Hydrochloride","longName":"3379135","preferredDefinition":"The hydrochloride salt of the anthracycline antineoplastic antibiotic idarubicin.  Idarubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.  Due to its high lipophilicity, idarubicin penetrates cell membranes more efficiently than other anthracycline antibiotic compounds","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Idarubicin Hydrochloride","conceptCode":"C1587","definition":"The hydrochloride salt of the anthracycline antineoplastic antibiotic idarubicin.  Idarubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.  Due to its high lipophilicity, idarubicin penetrates cell membranes more efficiently than other anthracycline antibiotic compounds","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B917C4ED-E9AE-F265-E040-BB89AD435210","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A768EF-1685-2BEA-E053-F662850A8C5F","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Ibrutinib, Imbruvica","valueDescription":"Ibrutinib","ValueMeaning":{"publicId":"5588944","version":"1","preferredName":"Ibrutinib","longName":"5588944","preferredDefinition":"An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon oral administration, ibrutinib binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is required for B cell receptor signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies. The expression of BTK in tumor cells is also associated with increased proliferation and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ibrutinib","conceptCode":"C81934","definition":"An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon oral administration, ibrutinib binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is required for B cell receptor signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies. The expression of BTK in tumor cells is also associated with increased proliferation and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42B08557-93BA-6CD6-E053-F662850A558E","latestVersionIndicator":"Yes","beginDate":"2016-12-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-12-02","modifiedBy":"COOPERM","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A768EF-1699-2BEA-E053-F662850A8C5F","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Ibritumomab tiuxetan Zevalin","valueDescription":"Ibritumomab Tiuxetan","ValueMeaning":{"publicId":"2741549","version":"1","preferredName":"Ibritumomab Tiuxetan","longName":"2741549","preferredDefinition":"ZEVALIN (Ibritumomab Tiuxetan) is the immunoconjugate resulting from a stable thiourea covalent bond between the monoclonal antibody Ibritumomab and the linker-chelator tiuxetan.  This linker-chelator provides a high affinity, conformationally restricted chelation site for Indium-111 or Yttrium-90.  The ZEVALIN therapeutic regimen is administered in two steps: Step 1 includes one infusion of Rituximab preceding In-111 ZEVALIN. Step 2 follows Step 1 by seven to nine days and consists of a second infusion of Rituximab followed by Y-90 ZEVALIN.  ZEVALIN is supplied as two separate and distinctly labeled kits that contain all of the non-radioactive ingredients necessary to produce a single dose of In-111 ZEVALIN and a single dose of Y-90 ZEVALIN, both essential components of the ZEVALIN therapeutic regimen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ibritumomab Tiuxetan","conceptCode":"C29981","definition":"An immunoconjugate of the monoclonal antibody ibritumomab conjugated with the linker-chelator tiuxetan, a high affinity, conformationally restricted chelation site for radioisotopes. When bound to indium In 111 or yttrium Y 90, ibritumomab tiuxetan, targeting the CD20 antigen on B cell surfaces, specifically delivers a potentially cytotoxic dose of radiation to B lymphocytes. Ibritumomab is a murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AEC075A-461A-26F2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A768EF-16AD-2BEA-E053-F662850A8C5F","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"I131 Iodine-131 Radioiodine Radioactive iodine","valueDescription":"Iodine I 131","ValueMeaning":{"publicId":"2939366","version":"1","preferredName":"Iodine I 131","longName":"2939366","preferredDefinition":"A radioactive isotope of iodine with an atomic mass of 131, a half life of eight days, and potential antineoplastic activity. Selectively accumulating in the thyroid gland, iodine I 131 emits beta and gamma particles, thereby killing thyroid cells and decreasing thyroid hormone production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Iodine I-131","conceptCode":"C1639","definition":"A radioactive isotope of iodine with an atomic mass of 131, a half life of eight days, and potential antineoplastic activity. Selectively accumulating in the thyroid gland, iodine I 131 emits beta and gamma particles, thereby killing thyroid cells and decreasing thyroid hormone production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7339449B-399C-92A9-E040-BB89AD435E25","latestVersionIndicator":"Yes","beginDate":"2009-09-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-09-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A768EF-16C1-2BEA-E053-F662850A8C5F","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Hydroxyurea Hydrea Hydroxycarbamide","valueDescription":"Hydroxyurea","ValueMeaning":{"publicId":"2578118","version":"1","preferredName":"Hydroxyurea","longName":"2578118","preferredDefinition":"A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle.  This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydroxyurea","conceptCode":"C560","definition":"A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle.  This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE33-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A768EF-16D5-2BEA-E053-F662850A8C5F","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Hexamethylmelamine HXM HMM Altretamine Hexalen","valueDescription":"Hexamethylmelamine (Altretamine)","ValueMeaning":{"publicId":"2576918","version":"1","preferredName":"Hexamethylmelamine (Altretamine)","longName":"2576918","preferredDefinition":"A synthetic cytotoxic s-triazine derivative similar in structure to alkylating agent triethylenemelamin with antineoplastic activity.  Although the precise mechanism by which altretamine exerts its cytotoxic effect is unknown, N-demethylation of altretamine may produce reactive intermediates which covalently bind to DNA, resulting in DNA damage. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Altretamine","conceptCode":"C544","definition":"A synthetic cytotoxic s-triazine derivative similar in structure to alkylating agent triethylenemelamin with antineoplastic activity.  Although the precise mechanism by which altretamine exerts its cytotoxic effect is unknown, N-demethylation of altretamine may produce reactive intermediates which covalently bind to DNA, resulting in DNA damage. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F983-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"REEVESD","dateModified":"2012-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A768EF-16E9-2BEA-E053-F662850A8C5F","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"HCG Chorionic gonadotropin Pregnyl","valueDescription":"Recombinant Human Chorionic Gonadotropin","ValueMeaning":{"publicId":"6159847","version":"1","preferredName":"Recombinant Human Chorionic Gonadotropin","longName":"6159847","preferredDefinition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous glycoprotein hormone human chorionic gonadotropin (HCG).  HCG binds to cells of the corpus luteum, thereby stimulating progesterone production and helping to maintain a secretory endometrium. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Human Chorionic Gonadotropin","conceptCode":"C528","definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous glycoprotein hormone human chorionic gonadotropin (HCG).  HCG binds to cells of the corpus luteum, thereby stimulating progesterone production and helping to maintain a secretory endometrium. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A768EF-16F6-2BEA-E053-F662850A8C5F","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A768EF-170F-2BEA-E053-F662850A8C5F","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"LY335979 Zosuquidar trihydrochloride","valueDescription":"Zosuquidar Trihydrochloride","ValueMeaning":{"publicId":"6159863","version":"1","preferredName":"Zosuquidar Trihydrochloride","longName":"6159863","preferredDefinition":"A difluorocyclopropyl quinoline. Zosuquidar trihydrochloride binds with high affinity to P-glycoprotein and inhibits P-glycoprotein-mediated multidrug resistance (MDR). P-glycoprotein, encoded by the MDR-1 gene, is a member of the ATP-binding cassette superfamily of transmembrane transporters and prevents the intracellular accumulation of many natural product-derived cytotoxic agents. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zosuquidar Trihydrochloride","conceptCode":"C2225","definition":"A difluorocyclopropyl quinoline. Zosuquidar trihydrochloride binds with high affinity to P-glycoprotein and inhibits P-glycoprotein-mediated multidrug resistance (MDR). P-glycoprotein, encoded by the MDR-1 gene, is a member of the ATP-binding cassette superfamily of transmembrane transporters and prevents the intracellular accumulation of many natural product-derived cytotoxic agents. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A7818A-0E99-654B-E053-F662850ADDB3","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A7818A-0EB2-654B-E053-F662850ADDB3","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"LY293111","valueDescription":"Etalocib","ValueMeaning":{"publicId":"6159865","version":"1","preferredName":"Etalocib","longName":"6159865","preferredDefinition":"A second-generation selective leukotriene B4 receptor (LTB4R) antagonist with potential antineoplastic activity. Although the exact underlying mechanism through which LY293111 exerts its effects has not been fully elucidated, this agent selectively binds to and blocks LTB4Rs, thereby inhibiting the downstream signalling pathway. LY29311 has been shown to induce apoptosis and inhibits cellular proliferation in LTB4R expressing cells, such as pancreatic cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etalocib","conceptCode":"C1626","definition":"A second-generation selective leukotriene B4 receptor (LTB4R) antagonist with potential antineoplastic activity. Although the exact underlying mechanism through which LY293111 exerts its effects has not been fully elucidated, this agent selectively binds to and blocks LTB4Rs, thereby inhibiting the downstream signalling pathway. LY29311 has been shown to induce apoptosis and inhibits cellular proliferation in LTB4R expressing cells, such as pancreatic cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A7818A-0EBF-654B-E053-F662850ADDB3","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A7818A-0ED8-654B-E053-F662850ADDB3","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Prednisone Deltasone Apo-prednisone Novo-prednisone","valueDescription":"Prednisone","ValueMeaning":{"publicId":"2568547","version":"1","preferredName":"Prednisone","longName":"2568547","preferredDefinition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prednisone","conceptCode":"C770","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8D0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"ALAIS","dateModified":"2007-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AD6E55-A870-3C96-E053-F662850A17E8","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Prednisolone","valueDescription":"Prednisolone","ValueMeaning":{"publicId":"3305273","version":"1","preferredName":"Prednisolone","longName":"3305273","preferredDefinition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisolone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prednisolone","conceptCode":"C769","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisolone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1F1A4B8-0CFE-8518-E040-BB89AD435A01","latestVersionIndicator":"Yes","beginDate":"2011-11-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AD6E55-A87A-3C96-E053-F662850A17E8","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Ponatinib hydrochloride Iclusig","valueDescription":"Ponatinib Hydrochloride","ValueMeaning":{"publicId":"6159896","version":"1","preferredName":"Ponatinib Hydrochloride","longName":"6159896","preferredDefinition":"The hydrochloride salt form of an orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ponatinib Hydrochloride","conceptCode":"C78194","definition":"The hydrochloride salt form of an orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68AD6E55-A887-3C96-E053-F662850A17E8","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AD6E55-A8A0-3C96-E053-F662850A17E8","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Pomalidomide Pomalyst","valueDescription":"Pomalidomide","ValueMeaning":{"publicId":"3944871","version":"1","preferredName":"Pomalidomide","longName":"3944871","preferredDefinition":"An orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). In addition, pomalidomide may inhibit tumor angiogenesis, promote cell cycle arrest in susceptible tumor cell populations, and stimulate erythropoeisis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pomalidomide","conceptCode":"C72560","definition":"An orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). In addition, pomalidomide may inhibit tumor angiogenesis, promote cell cycle arrest in susceptible tumor cell populations, and stimulate erythropoeisis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA60336B-F055-AE12-E040-BB89AD435C63","latestVersionIndicator":"Yes","beginDate":"2013-11-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-11-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AD6E55-A8B4-3C96-E053-F662850A17E8","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Placebo","valueDescription":"Placebo","ValueMeaning":{"publicId":"3228305","version":"1","preferredName":"Placebo","longName":"3228305","preferredDefinition":"An inactive substance, treatment or procedure that is intended to mimic as closely as possible a therapy in a clinical trial.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Placebo","conceptCode":"C753","definition":"An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A15C7F84-4B5D-4B63-E040-BB89AD432192","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"MAESKEB","dateCreated":"2011-04-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AD6E55-A8E1-3C96-E053-F662850A17E8","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Pidilizumab","valueDescription":"Pidilizumab","ValueMeaning":{"publicId":"6159899","version":"1","preferredName":"Pidilizumab","longName":"6159899","preferredDefinition":"A humanized monoclonal antibody directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities. Pidilizumab blocks interaction between the receptor PD-1 with its ligands, PD-1 ligand 1 (PD-1L1) and PD-1 ligand 2 (PD-1L2), resulting in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells, and the augmentation of the anti-tumor activities of NK cells. PD-1 is an inhibitory receptor belonging to the B7-receptor family that is expressed on lymphocytes and myeloid cells; its ligands, PD-1L1 and PD-1L2, are expressed not only by hematopoietic cells but also by cells in non-lymphoid tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pidilizumab","conceptCode":"C71014","definition":"A humanized monoclonal antibody directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities. Pidilizumab blocks interaction between the receptor PD-1 with its ligands, PD-1 ligand 1 (PD-1L1) and PD-1 ligand 2 (PD-1L2), resulting in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells, and the augmentation of the anti-tumor activities of NK cells. PD-1 is an inhibitory receptor belonging to the B7-receptor family that is expressed on lymphocytes and myeloid cells; its ligands, PD-1L1 and PD-1L2, are expressed not only by hematopoietic cells but also by cells in non-lymphoid tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68AD6E55-A912-3C96-E053-F662850A17E8","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AD6E55-A92B-3C96-E053-F662850A17E8","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"AS-703026 Pimasertib","valueDescription":"Pimasertib","ValueMeaning":{"publicId":"6024061","version":"1","preferredName":"Pimasertib","longName":"6024061","preferredDefinition":"An orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity. Pimasertib selectively binds to and inhibits the activity of MEK1/2, preventing the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK1/2 (MAP2K1/K2) are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pimasertib","conceptCode":"C84864","definition":"An orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity. Pimasertib selectively binds to and inhibits the activity of MEK1/2, preventing the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK1/2 (MAP2K1/K2) are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5D19D58D-9E06-66C6-E053-F662850A0684","latestVersionIndicator":"Yes","beginDate":"2017-11-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-11-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E544B-8614-22D2-E053-F662850A97FD","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Arsenic trioxide Trisenox","valueDescription":"Arsenic Trioxide","ValueMeaning":{"publicId":"3377438","version":"1","preferredName":"Arsenic Trioxide","longName":"3377438","preferredDefinition":"A small-molecule arsenic compound with antineoplastic activity.  The mechanism of action of arsenic trioxide is not completely understood. This agent causes damage to or degradation of the promyelocytic leukemia protein/retinoic acid receptor-alpha (PML/RARa) fusion protein; induces apoptosis in acute promyelocytic leukemia (APL) cells and in many other tumor cell types; promotes cell differentiation and suppresses cell proliferation in many different tumor cell types; and is pro-angiogenic. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Arsenic Trioxide","conceptCode":"C1005","definition":"A small-molecule arsenic compound with antineoplastic activity.  The mechanism of action of arsenic trioxide is not completely understood. This agent causes damage to or degradation of the promyelocytic leukemia protein/retinoic acid receptor-alpha (PML/RARa) fusion protein; induces apoptosis in acute promyelocytic leukemia (APL) cells and in many other tumor cell types; promotes cell differentiation and suppresses cell proliferation in many different tumor cell types; and is pro-angiogenic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DF6309-A0B0-1E33-E040-BB89AD43040B","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E544B-8628-22D2-E053-F662850A97FD","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"ARRY-162 Binimetinib","valueDescription":"Binimetinib","ValueMeaning":{"publicId":"4828187","version":"1","preferredName":"Binimetinib","longName":"4828187","preferredDefinition":"An orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. Inhibition of MEK1/2 prevents the activation of MEK1/2 dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling. This may eventually lead to an inhibition of tumor cell proliferation and an inhibition in production of various inflammatory cytokines including interleukin-1, -6 and tumor necrosis factor. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Binimetinib","conceptCode":"C84865","definition":"An orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. Inhibition of MEK1/2 prevents the activation of MEK1/2 dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling. This may eventually lead to an inhibition of tumor cell proliferation and an inhibition in production of various inflammatory cytokines including interleukin-1, -6 and tumor necrosis factor. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"16717093-49B7-6644-E050-BB89AD434C5B","latestVersionIndicator":"Yes","beginDate":"2015-05-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-05-19","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E544B-863C-22D2-E053-F662850A97FD","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"ARN-509 Apalutamide","valueDescription":"Apalutamide","ValueMeaning":{"publicId":"5811375","version":"1","preferredName":"Apalutamide","longName":"5811375","preferredDefinition":"A small molecule and androgen receptor (AR) antagonist with potential antineoplastic activity. Apalutamide binds to AR in target tissues thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes. This ultimately inhibits the expression of genes that regulate prostate cancer cell proliferation and may lead to an inhibition of cell growth in AR-expressing tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Apalutamide","conceptCode":"C92574","definition":"A small molecule and androgen receptor (AR) antagonist with potential antineoplastic activity. Apalutamide binds to AR in target tissues thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes. This ultimately inhibits the expression of genes that regulate prostate cancer cell proliferation and may lead to an inhibition of cell growth in AR-expressing tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F2E845A-26D5-6A9B-E053-F662850ACCDA","latestVersionIndicator":"Yes","beginDate":"2017-05-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-05-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E544B-8650-22D2-E053-F662850A97FD","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Arimidex Anastrozole","valueDescription":"Anastrozole","ValueMeaning":{"publicId":"3145842","version":"1","preferredName":"Anastrozole","longName":"3145842","preferredDefinition":"A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure.  As a third-generation aromatase inhibitor, anastrozole selectively and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.  In estrogen-dependent breast cancers, ananstrozole may inhibit tumor growth. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anastrozole","conceptCode":"C1607","definition":"A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure.  As a third-generation aromatase inhibitor, anastrozole selectively binds to and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.  In estrogen-dependent breast cancers, ananstrozole may inhibit tumor growth. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91CFFC87-A37F-4714-E040-BB89AD4352D5","latestVersionIndicator":"Yes","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E544B-8664-22D2-E053-F662850A97FD","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Aplidine Dehydrodidemnin B","valueDescription":"Plitidepsin","ValueMeaning":{"publicId":"6148628","version":"1","preferredName":"Plitidepsin","longName":"6148628","preferredDefinition":"A cyclic depsipeptide isolated from the marine tunicate Aplidium albicans. Plitidepsin displays a broad spectrum of antitumor activities, inducing apoptosis by triggering mitochondrial cytochrome c release, initiating the Fas/DC95, JNK pathway and activating caspase 3 activation. This agent also inhibits elongation factor 1-a, thereby interfering with protein synthesis, and induces G1 arrest and G2 blockade, thereby inhibiting tumor cell growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plitidepsin","conceptCode":"C1689","definition":"A cyclic depsipeptide isolated from the marine tunicate Aplidium albicans. Plitidepsin displays a broad spectrum of antitumor activities, inducing apoptosis by triggering mitochondrial cytochrome c release, initiating the Fas/DC95, JNK pathway and activating caspase 3 activation. This agent also inhibits elongation factor 1-a, thereby interfering with protein synthesis, and induces G1 arrest and G2 blockade, thereby inhibiting tumor cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682E544B-8671-22D2-E053-F662850A97FD","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E544B-868A-22D2-E053-F662850A97FD","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Androlone Nandrolone Durabolin","valueDescription":"Nandrolone Decanoate","ValueMeaning":{"publicId":"6148630","version":"1","preferredName":"Nandrolone Decanoate","longName":"6148630","preferredDefinition":"The decanoate salt form of nandrolone, an anabolic steroid analog of testosterone with androgenic, anabolic, and erythropoietin stimulating effects. Nandrolone enters the cell and binds to and activates specific nuclear androgen receptors in responsive tissue, including the prostate, seminal vesicles, scrotum, penis, larynx, hair follicles, muscle, and bone. The resulting activated hormone receptor complex translocates into the nucleus and binds to androgen response elements (ARE) in the promoter region of targeted genes, where the complex promotes gene expression necessary for maintaining male sex characteristics. Mimicking the negative feedback mechanism of testosterone, nandrolone decanoate also suppresses the secretion of luteinizing hormone (LH). Furthermore, this agent also stimulates erythropoietin production by enhancing the production of erythropoietic stimulating factors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nandrolone Decanoate","conceptCode":"C1172","definition":"The decanoate salt form of nandrolone, an anabolic steroid analog of testosterone with androgenic, anabolic, and erythropoietin stimulating effects. Nandrolone enters the cell and binds to and activates specific nuclear androgen receptors in responsive tissue, including the prostate, seminal vesicles, scrotum, penis, larynx, hair follicles, muscle, and bone. The resulting activated hormone receptor complex translocates into the nucleus and binds to androgen response elements (ARE) in the promoter region of targeted genes, where the complex promotes gene expression necessary for maintaining male sex characteristics. Mimicking the negative feedback mechanism of testosterone, nandrolone decanoate also suppresses the secretion of luteinizing hormone (LH). Furthermore, this agent also stimulates erythropoietin production by enhancing the production of erythropoietic stimulating factors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682E544B-8697-22D2-E053-F662850A97FD","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"682E544B-86B0-22D2-E053-F662850A97FD","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"ONEDATA","dateModified":"2018-03-24","deletedIndicator":"No"},{"value":"Fulvestrant Faslodex","valueDescription":"Fulvestrant","ValueMeaning":{"publicId":"2575943","version":"1","preferredName":"Fulvestrant","longName":"2575943","preferredDefinition":"A synthetic estrogen receptor antagonist.  Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fulvestrant","conceptCode":"C1379","definition":"A synthetic estrogen receptor antagonist.  Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F5B4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-15","modifiedBy":"REEVESD","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A69E62-799D-30F2-E053-F662850A32BD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Fostriecin","valueDescription":"Fostriecin","ValueMeaning":{"publicId":"6159808","version":"1","preferredName":"Fostriecin","longName":"6159808","preferredDefinition":"An anti-tumor antibiotic isolated from the bacterium Streptomyces pulveraceus. Fostriecin inhibits topoisomerase II catalytic activity, resulting in impaired DNA and RNA synthesis in various malignant cell types.  This agent also inhibits serine/threonine protein phosphatase type 2A in some tumor cell types, thereby interfering with cellular proliferation and differentiation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fostriecin","conceptCode":"C1372","definition":"An anti-tumor antibiotic isolated from the bacterium Streptomyces pulveraceus. Fostriecin inhibits topoisomerase II catalytic activity, resulting in impaired DNA and RNA synthesis in various malignant cell types.  This agent also inhibits serine/threonine protein phosphatase type 2A in some tumor cell types, thereby interfering with cellular proliferation and differentiation. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A69E62-79AA-30F2-E053-F662850A32BD","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A69E62-79C3-30F2-E053-F662850A32BD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Fosamax Alendronate","valueDescription":"Alendronate Sodium","ValueMeaning":{"publicId":"2576907","version":"1","preferredName":"Alendronate Sodium","longName":"2576907","preferredDefinition":"A bisphosphonate with increased antiresorption activity (100x-1000x that of etidronate).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alendronate Sodium","conceptCode":"C973","definition":"The sodium salt of alendronate, a second generation bisphosphonate and synthetic analog of pyrophosphate with bone anti-resorption activity. Alendronate sodium binds to and inhibits the activity of geranyltranstransferase (farnesyl pyrophosphate synthetase), an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which is important in the process of osteoclast turnover. As a result, osteoclast activity is inhibited and bone resorption and turnover are reduced.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A69E62-79D7-30F2-E053-F662850A32BD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Foretinib, GSK1363089, XL880","valueDescription":"Multitargeted Tyrosine Kinase Inhibitor GSK1363089","ValueMeaning":{"publicId":"3124282","version":"1","preferredName":"Multitargeted Tyrosine Kinase Inhibitor GSK1363089","longName":"3124282","preferredDefinition":"An orally bioavailable small molecule with potential antineoplastic activity. MET/VEGFR2 inhibitor GSK1363089 binds to and selectively inhibits hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), which may result in the inhibition of tumor angiogenesis, tumor cell proliferation and metastasis. The proto-oncogene c-MET has been found to be over-expressed in a variety of cancers. VEGFR2 is found on endothelial and hematopoietic cells and mediates the development of the vasculature and hematopoietic cells through VEGF signaling.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Foretinib","conceptCode":"C80058","definition":"An orally bioavailable small molecule with potential antineoplastic activity. Foretinib binds to and selectively inhibits hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), which may result in the inhibition of tumor angiogenesis, tumor cell proliferation and metastasis. The proto-oncogene c-MET has been found to be over-expressed in a variety of cancers. VEGFR2 is found on endothelial and hematopoietic cells and mediates the development of the vasculature and hematopoietic cells through VEGF signaling.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C0EAA9F-D66C-4F99-E040-BB89AD435CFD","latestVersionIndicator":"Yes","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A69E62-79EB-30F2-E053-F662850A32BD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Fluorouracil 5-Fluorouracil Adrucil","valueDescription":"Fluorouracil","ValueMeaning":{"publicId":"5567087","version":"1","preferredName":"Fluorouracil","longName":"5567087","preferredDefinition":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluorouracil","conceptCode":"C505","definition":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"40CFD039-BC2F-556D-E053-F662850AED1E","latestVersionIndicator":"Yes","beginDate":"2016-11-08","endDate":null,"createdBy":"PATELV","dateCreated":"2016-11-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A69E62-79FF-30F2-E053-F662850A32BD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Fludarabine phosphate Fludara","valueDescription":"Fludarabine Phosphate","ValueMeaning":{"publicId":"5044412","version":"1","preferredName":"Fludarabine Phosphate","longName":"5044412","preferredDefinition":"The phosphate salt of a fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fludarabine Phosphate","conceptCode":"C1102","definition":"The phosphate salt of a fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"245B5ACF-1B83-A2B9-E050-BB89AD43722C","latestVersionIndicator":"Yes","beginDate":"2015-11-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2015-11-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A69E62-7A13-30F2-E053-F662850A32BD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Floxuridine FUDR","valueDescription":"Floxuridine","ValueMeaning":{"publicId":"3379039","version":"1","preferredName":"Floxuridine","longName":"3379039","preferredDefinition":"A fluorinated pyrimidine monophosphate analogue of 5-fluoro-2'-deoxyuridine-5'-phosphate (FUDR-MP) with antineoplastic activity. As an antimetabolite, floxuridine inhibits thymidylate synthase, resulting in disruption of DNA synthesis and cytotoxicity. This agent is also metabolized to fluorouracil and other metabolites that can be incorporated into RNA and inhibit the utilization of preformed uracil in RNA synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Floxuridine","conceptCode":"C504","definition":"A fluorinated pyrimidine monophosphate analogue of 5-fluoro-2'-deoxyuridine-5'-phosphate (FUDR-MP) with antineoplastic activity. As an antimetabolite, floxuridine inhibits thymidylate synthase, resulting in disruption of DNA synthesis and cytotoxicity. This agent is also metabolized to fluorouracil and other metabolites that can be incorporated into RNA and inhibit the utilization of preformed uracil in RNA synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914931D-1F1F-28A3-E040-BB89AD437288","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A69E62-7A27-30F2-E053-F662850A32BD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Flavopiridol HMR-1275","valueDescription":"Flavopiridol","ValueMeaning":{"publicId":"2576859","version":"1","preferredName":"Flavopiridol","longName":"2576859","preferredDefinition":"A synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, flavopiridol induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (cdk) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis.  This agent is also a competitive inhibitor of adenosine triphosphate activity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alvocidib Hydrochloride","conceptCode":"C1571","definition":"A synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (CDKs) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis. This agent is also a competitive inhibitor of adenosine triphosphate activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F948-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A69E62-7A3B-30F2-E053-F662850A32BD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Flavone acetic acid FAA","valueDescription":"Mitoflaxone","ValueMeaning":{"publicId":"6159810","version":"1","preferredName":"Mitoflaxone","longName":"6159810","preferredDefinition":"A synthetic flavonoid with vascular targeting properties. Flavone acetic acid exhibits an antiproliferative effect on endothelial cells as a result of a superoxide-dependent mechanism, which induces changes in permeability of the vasculature of the tumor. This agent may stimulate tumor necrosis and promote shunting of blood flow to viable regions of the tumor, increasing their oxygenation and rendering them more susceptible to the antitumor effects of hyperthermia and ionizing radiation.  (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mitoflaxone","conceptCode":"C1101","definition":"A synthetic flavonoid with vascular targeting properties. Flavone acetic acid exhibits an antiproliferative effect on endothelial cells as a result of a superoxide-dependent mechanism, which induces changes in permeability of the vasculature of the tumor. This agent may stimulate tumor necrosis and promote shunting of blood flow to viable regions of the tumor, increasing their oxygenation and rendering them more susceptible to the antitumor effects of hyperthermia and ionizing radiation.  (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A69E62-7A48-30F2-E053-F662850A32BD","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A69E62-7A61-30F2-E053-F662850A32BD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Finasteride Proscar","valueDescription":"Finasteride","ValueMeaning":{"publicId":"2576856","version":"1","preferredName":"Finasteride","longName":"2576856","preferredDefinition":"A synthetic azasteroid compound.  Finasteride binds to and inhibits 5-alpha-reductase, thereby interfering with the enzymatic conversion of testosterone to 5-dihydrotestosterone, ultimately interfering with prostate growth. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Finasteride","conceptCode":"C1099","definition":"A synthetic 4-azasteroid compound. Finasteride competitively binds to and inhibits steroid type II 5-alpha-reductase in the prostate gland, liver, and skin, thereby interfering with the enzymatic conversion of testosterone to 5-dihydrotestosterone (DHT) and reducing serum DHT levels. The reduction in serum DHT levels results in diminished stimulation of androgen receptors in the nuclei of prostate cells and, so, diminished prostate cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F945-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A69E62-7A75-30F2-E053-F662850A32BD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Femara Letrozole","valueDescription":"Letrozole","ValueMeaning":{"publicId":"2921027","version":"1","preferredName":"Letrozole","longName":"2921027","preferredDefinition":"A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure.  As a third-generation aromatase inhibitor, letrozole selectively and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.  In estrogen-dependent breast cancers, ananstrozole may inhibit tumor growth. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Letrozole","conceptCode":"C1527","definition":"A nonsteroidal inhibitor of estrogen synthesis with antineoplastic activity. As a third-generation aromatase inhibitor, letrozole selectively and reversibly inhibits aromatase, which may result in growth inhibition of estrogen-dependent breast cancer cells. Aromatase, a cytochrome P-450 enzyme localized to the endoplasmic reticulum of the cell and found in many tissues including those of the premenopausal ovary, liver, and breast, catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6F2A9285-CD52-5F08-E040-BB89AD435BDA","latestVersionIndicator":"Yes","beginDate":"2009-07-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A69E62-7A89-30F2-E053-F662850A32BD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Exemestane","valueDescription":"Exemestane","ValueMeaning":{"publicId":"2563643","version":"1","preferredName":"Exemestane","longName":"2563643","preferredDefinition":"A synthetic androgen analogue.  Exemestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Exemestane","conceptCode":"C1097","definition":"An irreversible steroidal aromatase inhibitor, with antiestrogen and antineoplastic activities. Upon oral administration, exemestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the peripheral aromatization of androgens, including androstenedione and testosterone, to estrogens. This lowers estrogen levels in the blood circulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C5A8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-12-05","endDate":null,"createdBy":"CVALMONT","dateCreated":"2002-12-05","modifiedBy":"COOPERM","dateModified":"2016-08-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A69E62-7A93-30F2-E053-F662850A32BD","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Pertuzumab, Perjeta, Omnitarg","valueDescription":"Pertuzumab","ValueMeaning":{"publicId":"3378887","version":"1","preferredName":"Pertuzumab","longName":"3378887","preferredDefinition":"A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pertuzumab","conceptCode":"C38692","definition":"A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90729CF-405F-B0E0-E040-BB89AD436B58","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AD6E55-A93F-3C96-E053-F662850A17E8","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Perifosine D-21266","valueDescription":"Perifosine","ValueMeaning":{"publicId":"3379467","version":"1","preferredName":"Perifosine","longName":"3379467","preferredDefinition":"An orally active alkyl-phosphocholine compound with potential antineoplastic activity.  Targeting cellular membranes, perifosine modulates membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth.  This agent also inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis.  Perifosine has a lower gastrointestinal toxicity profile than the related agent miltefosine. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Perifosine","conceptCode":"C1727","definition":"An orally active alkyl-phosphocholine compound with potential antineoplastic activity.  Targeting cellular membranes, perifosine modulates membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth.  This agent also inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis.  Perifosine has a lower gastrointestinal toxicity profile than the related agent miltefosine. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-244B-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AD6E55-A953-3C96-E053-F662850A17E8","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Pepcid Famotidine","valueDescription":"Famotidine","ValueMeaning":{"publicId":"2576843","version":"1","preferredName":"Famotidine","longName":"2576843v1.00","preferredDefinition":"A propanimidamide and histamine H2-receptor antagonist with antacid activity. As a competitive inhibitor of histamine H2-receptors located on the basolateral membrane of the parietal cell, famotidine reduces basal and nocturnal gastric acid secretion, resulting in a reduction in gastric volume, acidity, and amount of gastric acid released in response to various stimuli.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Famotidine","conceptCode":"C29045","definition":"A propanimidamide and histamine H2-receptor antagonist with antacid activity. As a competitive inhibitor of histamine H2-receptors located on the basolateral membrane of the parietal cell, famotidine reduces basal and nocturnal gastric acid secretion, resulting in a reduction in gastric volume, acidity, and amount of gastric acid released in response to various stimuli.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F938-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"KUMMEROA","dateModified":"2023-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AD6E55-A967-3C96-E053-F662850A17E8","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Pembrolizumab MK3475 Keytruda","valueDescription":"Pembrolizumab","ValueMeaning":{"publicId":"5076693","version":"1","preferredName":"Pembrolizumab","longName":"5076693v1.00","preferredDefinition":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pembrolizumab","conceptCode":"C106432","definition":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2653AD7D-EB81-5B33-E050-BB89AD437FF5","latestVersionIndicator":"Yes","beginDate":"2015-12-07","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AD6E55-A97B-3C96-E053-F662850A17E8","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Peginterferon alpha-2B Sylatron Pegetron","valueDescription":"Peginterferon Alfa-2b","ValueMeaning":{"publicId":"3379406","version":"1","preferredName":"Peginterferon Alfa-2b","longName":"3379406","preferredDefinition":"A covalent conjugate of recombinant interferon alpha, subtype 2b, and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha-2b protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha-2b, thereby extending the duration of its therapeutic effects, but may also reduce the interferon-mediated stimulation of an immune response. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Peginterferon Alfa-2b","conceptCode":"C1845","definition":"A covalent conjugate of recombinant interferon alpha, subtype 2b, and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha-2b protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha-2b, thereby extending the duration of its therapeutic effects, but may also reduce the interferon-mediated stimulation of an immune response. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-1E77-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AD6E55-A98F-3C96-E053-F662850A17E8","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Pazopanib Votrient","valueDescription":"Pazopanib Hydrochloride","ValueMeaning":{"publicId":"3380354","version":"1","preferredName":"Pazopanib Hydrochloride","longName":"3380354","preferredDefinition":"The hydrochloride salt of a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pazopanib Hydrochloride","conceptCode":"C60779","definition":"The hydrochloride salt of a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A6A5-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AD6E55-A9A3-3C96-E053-F662850A17E8","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Panobinostat Farydak","valueDescription":"Panobinostat","ValueMeaning":{"publicId":"3379455","version":"1","preferredName":"Panobinostat","longName":"3379455","preferredDefinition":"A cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein expression, cell cycle arrest in the G2/M phase and apoptosis. In addition, this agent appears to modulate the expression of angiogenesis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1a) and vascular endothelial growth factor (VEGF), thus impairing endothelial cell chemotaxis and invasion. HDAC is an enzyme that deacetylates chromatin histone proteins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Panobinostat","conceptCode":"C66948","definition":"A cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein expression, cell cycle arrest in the G2/M phase and apoptosis. In addition, this agent appears to modulate the expression of angiogenesis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1a) and vascular endothelial growth factor (VEGF), thus impairing endothelial cell chemotaxis and invasion. HDAC is an enzyme that deacetylates chromatin histone proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-2334-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AD6E55-A9B7-3C96-E053-F662850A17E8","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Panitumumab, Vectibix","valueDescription":"Panitumumab","ValueMeaning":{"publicId":"3379440","version":"1","preferredName":"Panitumumab","longName":"3379440","preferredDefinition":"A human monoclonal antibody produced in transgenic mice that attaches to the transmembrane epidermal growth factor (EGF) receptor. Panitumumab may inhibit autocrine EGF stimulation of tumor cells that express the EGF receptor, thereby inhibiting tumor cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Panitumumab","conceptCode":"C1857","definition":"A human IgG2kappa monoclonal antibody specific for the epidermal growth factor receptor (EGFR). Monoclonal antibody E7.6.3 binds to the EGFR, blocking the binding of epidermal growth factor and transforming growth factor alpha to EGFR-expressing cancer cells and ultimately inhibiting EGFR-dependent cell activation and proliferation. (NCI)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-2183-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AD6E55-A9CB-3C96-E053-F662850A17E8","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Pamidronate Aredia","valueDescription":"Osimertinib","ValueMeaning":{"publicId":"5305951","version":"1","preferredName":"Osimertinib","longName":"5305951","preferredDefinition":"A third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, osimertinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. AZD9291 preferentially inhibits mutated forms of EGFR including T790M, a secondarily-acquired resistance mutation, and may have enhanced anti-tumor effects in tumors with T790M-mediated resistance when compared to other EGFR tyrosine kinase inhibitors. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Osimertinib","conceptCode":"C116377","definition":"A third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, osimertinib covalently binds to and inhibits the activity of numerous mutant forms of EGFR, including the secondarily-acquired resistance mutation T790M, L858R, and exon 19 deletions, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"35DFF1EC-FEBB-8034-E050-BB89AD435383","latestVersionIndicator":"Yes","beginDate":"2016-06-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-06-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AD6E55-A9DF-3C96-E053-F662850A17E8","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Palbociclib  PD0332991","valueDescription":"PD-0332991","ValueMeaning":{"publicId":"3564160","version":"1","preferredName":"PD-0332991","longName":"3564160","preferredDefinition":"An orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. PD-0332991 selectively inhibits cyclin-dependent kinases (particularly Cdk4/cyclin D1 kinase), which may inhibit retinoblastoma (Rb) protein phosphorylation; inhibition of Rb phosphorylation prevents Rb-positive tumor cells from entering the S phase of the cell cycle (arrest in the G1 phase), resulting in suppression of DNA replication and decreased tumor cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Palbociclib","conceptCode":"C49176","definition":"An orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7DBA78C-8B81-5111-E040-BB89AD4317C1","latestVersionIndicator":"Yes","beginDate":"2012-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-22","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68AD6E55-A9F3-3C96-E053-F662850A17E8","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Rituximab and hyaluronidase Rituxan Hycela","valueDescription":"Rituximab and Hyaluronidase Human","ValueMeaning":{"publicId":"6159901","version":"1","preferredName":"Rituximab and Hyaluronidase Human","longName":"6159901","preferredDefinition":"A combination preparation of rituximab, a genetically engineered chimeric murine/human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against the CD20 antigen, and the recombinant form of the human enzyme hyaluronidase, with antineoplastic activity. Upon subcutaneous administration of rituximab and hyaluronidase human, the hyaluronidase reversibly depolymerizes the polysaccharide hyaluronan in the subcutaneous tissue. This increases the permeability of the subcutaneous tissue and enhances the absorption of rituximab into the systemic circulation. In turn, rituximab targets and binds to CD20 expressed on tumor cells, and induces tumor cell lysis primarily through the induction of complement dependent cytotoxicity (CDC) and antibody-dependent cell mediated cytotoxicity (ADCC).  When administered subcutaneously, hyaluronidase, an endoglycosidase, increases the dispersion and absorption of co-administered drugs.  CD20 is expressed on the surface of pre-B and mature B-lymphocytes, and is overexpressed in a variety of B-cell malignancies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rituximab and Hyaluronidase Human","conceptCode":"C136821","definition":"A combination preparation of rituximab, a genetically engineered chimeric murine/human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against the CD20 antigen, and the recombinant form of the human enzyme hyaluronidase, with antineoplastic activity. Upon subcutaneous administration of rituximab and hyaluronidase human, the hyaluronidase reversibly depolymerizes the polysaccharide hyaluronan in the subcutaneous tissue. This increases the permeability of the subcutaneous tissue and enhances the absorption of rituximab into the systemic circulation. In turn, rituximab targets and binds to CD20 expressed on tumor cells, and induces tumor cell lysis primarily through the induction of complement dependent cytotoxicity (CDC) and antibody-dependent cell mediated cytotoxicity (ADCC).  When administered subcutaneously, hyaluronidase, an endoglycosidase, increases the dispersion and absorption of co-administered drugs.  CD20 is expressed on the surface of pre-B and mature B-lymphocytes, and is overexpressed in a variety of B-cell malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A6D7EC-5A6F-2303-E053-F662850A11B7","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A6D7EC-5A88-2303-E053-F662850A11B7","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Ribociclib Kisqali","valueDescription":"Ribociclib","ValueMeaning":{"publicId":"6072178","version":"1","preferredName":"Ribociclib","longName":"6072178","preferredDefinition":"An orally available cyclin-dependent kinase (CDK) inhibitor targets at cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. Ribociclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ribociclib","conceptCode":"C95701","definition":"An orally available cyclin-dependent kinase (CDK) inhibitor targets at cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. Ribociclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65344B1A-4E61-24A6-E053-F662850A121F","latestVersionIndicator":"Yes","beginDate":"2018-02-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-02-14","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A6D7EC-5A9C-2303-E053-F662850A11B7","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Revlimid Lenalidomide Revimid CC-5013 CDC-501","valueDescription":"Lenalidomide","ValueMeaning":{"publicId":"3379210","version":"1","preferredName":"Lenalidomide","longName":"3379210","preferredDefinition":"A thalidomide analog with potential antineoplastic activity.  Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis.  This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lenalidomide","conceptCode":"C2668","definition":"A thalidomide analog with potential antineoplastic activity.  Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis.  This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B918227F-B2FA-6EA7-E040-BB89AD434A76","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A6D7EC-5AB0-2303-E053-F662850A11B7","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Regorafenib, BAY 73-4506, Stivarga","valueDescription":"Regorafenib","ValueMeaning":{"publicId":"3729312","version":"1","preferredName":"Regorafenib","longName":"3729312","preferredDefinition":"An orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Regorafenib","conceptCode":"C78204","definition":"The anhydrous form of regorafenib, an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB0A510A-06A5-547A-E040-BB89AD436C02","latestVersionIndicator":"Yes","beginDate":"2013-04-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-04-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A6D7EC-5AC4-2303-E053-F662850A11B7","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"RDEA119 Refametinib","valueDescription":"Refametinib","ValueMeaning":{"publicId":"6159903","version":"1","preferredName":"Refametinib","longName":"6159903","preferredDefinition":"An orally bioavailable selective MEK inhibitor with potential antineoplastic activity. Refametinib specifically inhibits mitogen-activated protein kinase kinase 1 (MAP2K1 or MAPK/ERK kinase 1), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a dual specificity threonine/tyrosine kinase, is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Refametinib","conceptCode":"C74059","definition":"An orally bioavailable selective MEK inhibitor with potential antineoplastic activity. Refametinib specifically inhibits mitogen-activated protein kinase kinase 1 (MAP2K1 or MAPK/ERK kinase 1), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a dual specificity threonine/tyrosine kinase, is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A6D7EC-5AD1-2303-E053-F662850A11B7","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A6D7EC-5AEA-2303-E053-F662850A11B7","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Trelstar Triptorelin Decapeptyl","valueDescription":"Triptorelin Triptorelin Pamoate","ValueMeaning":{"publicId":"6161759","version":"1","preferredName":"Triptorelin Triptorelin Pamoate","longName":"6161759","preferredDefinition":"A drug that is used to treat advanced prostate cancer, and is being studied in the treatment of breast cancer. It belongs to the family of hormonal drugs called gonadotropin-releasing hormone analogs.: The pamoate salt of triptorelin, a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH).  Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion after prolonged administration.  After chronic, continuous administration, a sustained decrease in LH, FSH and testicular and ovarian steroidogenesis is observed.  The serum testosterone concentration may fall to levels typically seen in surgically castrated men. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Triptorelin","conceptCode":"C1267","definition":"A synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH).  Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Triptorelin Pamoate","conceptCode":"C29523","definition":"The pamoate salt of triptorelin, a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH).  Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion after prolonged administration.  After chronic, continuous administration, a sustained decrease in LH, FSH and testicular and ovarian steroidogenesis is observed.  The serum testosterone concentration may fall to levels typically seen in surgically castrated men. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"692D5C1A-12D3-1A2C-E053-F662850AD20F","latestVersionIndicator":"Yes","beginDate":"2018-04-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-06","modifiedBy":"ONEDATA","dateModified":"2018-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"692D5C1A-12EC-1A2C-E053-F662850AD20F","beginDate":"2018-04-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-06","modifiedBy":"ONEDATA","dateModified":"2018-04-06","deletedIndicator":"No"},{"value":"Vinorelbine Navelbine","valueDescription":"Vinorelbine Tartrate Vinorelbine","ValueMeaning":{"publicId":"6161757","version":"1","preferredName":"Vinorelbine Tartrate Vinorelbine","longName":"6161757","preferredDefinition":"The ditartrate salt of a semisynthetic vinca alkaloid derived from the leaves of the periwinkle plant (Vinca rosea) with antineoplastic properties.  Vinorelbine binds to tubulin, thereby inhibiting tubulin polymerization into microtubules and spindle formation and resulting in apoptosis of susceptible cancer cells. Inhibition of mitotic microtubules correlates with antitumor activity, whereas inhibition of axonal microtubules seems to correlate with vinorelbine's neurotoxicity. Compared to related vinca alkaloids, vinorelbine is more selective against mitotic than axonal microtubules in vitro, which may account for its decreased neurotoxicity.  This agent is also a radiation-sensitizing agent. (NCI04): A semisynthetic vinca alkaloid. Vinorelbine binds to tubulin and prevents formation of the mitotic spindle, resulting in the arrest of tumor cell growth in metaphase. This agent may also interfere with amino acid, cyclic AMP. and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vinorelbine Tartrate","conceptCode":"C1395","definition":"The ditartrate salt of a semisynthetic vinca alkaloid derived from the leaves of the periwinkle plant (Vinca rosea) with antineoplastic properties.  Vinorelbine binds to tubulin, thereby inhibiting tubulin polymerization into microtubules and spindle formation and resulting in apoptosis of susceptible cancer cells. Inhibition of mitotic microtubules correlates with antitumor activity, whereas inhibition of axonal microtubules seems to correlate with vinorelbine's neurotoxicity. Compared to related vinca alkaloids, vinorelbine is more selective against mitotic than axonal microtubules in vitro, which may account for its decreased neurotoxicity.  This agent is also a radiation-sensitizing agent. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Vinorelbine","conceptCode":"C1275","definition":"A semisynthetic vinca alkaloid. Vinorelbine binds to tubulin and prevents formation of the mitotic spindle, resulting in the arrest of tumor cell growth in metaphase. This agent may also interfere with amino acid, cyclic AMP. and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"692D5C1A-12AC-1A2C-E053-F662850AD20F","latestVersionIndicator":"Yes","beginDate":"2018-04-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-06","modifiedBy":"ONEDATA","dateModified":"2018-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"692D5C1A-12C5-1A2C-E053-F662850AD20F","beginDate":"2018-04-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-06","modifiedBy":"ONEDATA","dateModified":"2018-04-06","deletedIndicator":"No"},{"value":"Procrit Erythropoietin Eprex Epogen","valueDescription":"Erythropoietin Epoetin Alfa","ValueMeaning":{"publicId":"6161760","version":"1","preferredName":"Erythropoietin Epoetin Alfa","longName":"6161760","preferredDefinition":"Glycoprotein hormone, secreted chiefly by the kidney in the adult and the liver in the fetus, that acts on erythroid stem cells of the bone marrow to stimulate proliferation and differentiation.: A substance that is made in the laboratory and stimulates the bone marrow to make red blood cells. It is a type of antianemic and a type of recombinant human erythropoietin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Erythropoietin","conceptCode":"C20429","definition":"Erythropoietin (193 aa, ~21 kDa) is encoded by the human EPO gene. This protein plays a role in both erythropoiesis and the maintenance of red blood cell volume.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Epoetin Alfa","conceptCode":"C2695","definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine human erythropoietin (EPO). Produced primarily by cells of the peritubular capillary endothelium of the kidney in response to hypoxia, circulating EPO binds to EPO receptors on the surface of committed erythroid progenitors in the bone marrow resulting in their replication and maturation into functional erythrocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"692D5C1A-12F9-1A2C-E053-F662850AD20F","latestVersionIndicator":"Yes","beginDate":"2018-04-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-06","modifiedBy":"ONEDATA","dateModified":"2018-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"692D5C1A-1312-1A2C-E053-F662850AD20F","beginDate":"2018-04-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-06","modifiedBy":"ONEDATA","dateModified":"2018-04-06","deletedIndicator":"No"},{"value":"Niraparib MK-4827 Zejula","valueDescription":"Niraparib Tosylate Monohydrate Niraparib","ValueMeaning":{"publicId":"6161762","version":"1","preferredName":"Niraparib Tosylate Monohydrate Niraparib","longName":"6161762","preferredDefinition":"An orally bioavailable, hydrated, tosylate salt form of niraparib, an inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2 (PARP-1 and -2), with antineoplastic activity. Upon administration, niraparib binds to and inhibits the activity of PARP-1 and -2, thereby inhibiting PARP-1 and -2-mediated DNA repair, enhancing the accumulation of DNA strand breaks, promoting genomic instability and resulting in apoptosis. The PARP family of proteins catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks.: An orally bioavailable inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2 (PARP-1 and -2), with antineoplastic activity. Upon administration, niraparib binds to and inhibits the activity of PARP-1 and -2, thereby inhibiting PARP-1 and -2-mediated DNA repair, enhancing the accumulation of DNA strand breaks, promoting genomic instability and resulting in apoptosis. The PARP family of proteins catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Niraparib Tosylate Monohydrate","conceptCode":"C133238","definition":"An orally bioavailable, hydrated, tosylate salt form of niraparib, an inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2 (PARP-1 and -2), with antineoplastic activity. Upon administration, niraparib binds to and inhibits the activity of PARP-1 and -2, thereby inhibiting PARP-1 and -2-mediated DNA repair, enhancing the accumulation of DNA strand breaks, promoting genomic instability and resulting in apoptosis. The PARP family of proteins catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Niraparib","conceptCode":"C80059","definition":"An orally bioavailable inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2 (PARP-1 and -2), with antineoplastic activity. Upon administration, niraparib binds to and inhibits the activity of PARP-1 and -2, thereby inhibiting PARP-1 and -2-mediated DNA repair, enhancing the accumulation of DNA strand breaks, promoting genomic instability and resulting in apoptosis. The PARP family of proteins catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"692D5C1A-1320-1A2C-E053-F662850AD20F","latestVersionIndicator":"Yes","beginDate":"2018-04-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-06","modifiedBy":"ONEDATA","dateModified":"2018-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"692D5C1A-1339-1A2C-E053-F662850AD20F","beginDate":"2018-04-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-06","modifiedBy":"ONEDATA","dateModified":"2018-04-06","deletedIndicator":"No"},{"value":"Gemcitabine Gemzar","valueDescription":"Gemcitabine Gemcitabine Hydrochloride","ValueMeaning":{"publicId":"6161763","version":"1","preferredName":"Gemcitabine Gemcitabine Hydrochloride","longName":"6161763","preferredDefinition":"A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in \"masked termination\" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.: The hydrochloride salt of an analogue of the antimetabolite nucleoside deoxycytidine with antineoplastic activity. Gemcitabine is converted intracellularly to the active metabolites difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP). dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP is incorporated into DNA, resulting in DNA strand termination and apoptosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gemcitabine","conceptCode":"C66876","definition":"A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in \"masked termination\" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Gemcitabine Hydrochloride","conceptCode":"C961","definition":"The hydrochloride salt of an analogue of the antimetabolite nucleoside deoxycytidine with antineoplastic activity. Gemcitabine is converted intracellularly to the active metabolites difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP). dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP is incorporated into DNA, resulting in DNA strand termination and apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"692D5C1A-1346-1A2C-E053-F662850AD20F","latestVersionIndicator":"Yes","beginDate":"2018-04-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-06","modifiedBy":"ONEDATA","dateModified":"2018-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"692D5C1A-135F-1A2C-E053-F662850AD20F","beginDate":"2018-04-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-06","modifiedBy":"ONEDATA","dateModified":"2018-04-06","deletedIndicator":"No"},{"value":"Thiotepa Thioplex","valueDescription":"Thiotepa","ValueMeaning":{"publicId":"5810420","version":"1","preferredName":"Thiotepa","longName":"Thiopeta","preferredDefinition":"A polyfunctional, organophosphorus alkylating agent and a stable derivative of N,N',N''-triethylenephosphoramide (TEPA), with antineoplastic activity. Upon administration, thiotepa is converted into highly reactive ethylenimine groups, which covalently bind to nucleophilic groups in DNA and demonstrate a preference for the N7 position of guanine bases. This induces crosslinking of alkylated guanine bases in double-stranded DNA, interferes with both DNA replication and cell division, and results in both the induction of apoptosis and the inhibition of cell growth.","context":"NHLBI","contextVersion":"1","Concepts":[{"longName":"Thiotepa","conceptCode":"C875","definition":"A polyfunctional, organophosphorus alkylating agent and a stable derivative of N,N',N''-triethylenephosphoramide (TEPA), with antineoplastic activity. Upon administration, thiotepa is converted into highly reactive ethylenimine groups, which covalently bind to nucleophilic groups in DNA and demonstrate a preference for the N7 position of guanine bases. This induces crosslinking of alkylated guanine bases in double-stranded DNA, interferes with both DNA replication and cell division, and results in both the induction of apoptosis and the inhibition of cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F02410F-4E09-4DC7-E053-F662850A8F88","latestVersionIndicator":"Yes","beginDate":"2017-05-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-05-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"692D5C1A-1373-1A2C-E053-F662850AD20F","beginDate":"2018-04-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-06","modifiedBy":"ONEDATA","dateModified":"2018-04-06","deletedIndicator":"No"},{"value":"Raloxifene Evista","valueDescription":"Raloxifene Hydrochloride","ValueMeaning":{"publicId":"3379522","version":"1","preferredName":"Raloxifene Hydrochloride","longName":"3379522","preferredDefinition":"The hydrochloride salt form of raloxifene, a selective benzothiophene estrogen receptor modulator (SERM) with lipid lowering effects and activity against osteoporosis. Raloxifene hydrochloride specifically binds to estrogen receptors in responsive tissue, including liver, bone, breast, and endometrium. The resulting ligand-receptor complex is translocated to the nucleus where, depending on the tissue type, it promotes or suppresses the transcription of estrogen-regulated genes, thereby exerting its agonistic or antagonistic effects. This agent functions as an estrogen agonist in lipid metabolism, thereby decreasing total and LDL cholesterol levels. In tissue like bone, it decreases bone resorption and bone turnover and increases bone mineral density. Raloxifene hydrochloride acts as an estrogen antagonist in uterine and breast tissue. This agent also exerts an anti-proliferative effect on estrogen-sensitive breast cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Raloxifene Hydrochloride","conceptCode":"C1762","definition":"The hydrochloride salt form of raloxifene, a selective benzothiophene estrogen receptor modulator (SERM) with lipid lowering effects and activity against osteoporosis. Raloxifene hydrochloride specifically binds to estrogen receptors in responsive tissue, including liver, bone, breast, and endometrium. The resulting ligand-receptor complex is translocated to the nucleus where, depending on the tissue type, it promotes or suppresses the transcription of estrogen-regulated genes, thereby exerting its agonistic or antagonistic effects. This agent functions as an estrogen agonist in lipid metabolism, thereby decreasing total and LDL cholesterol levels. In tissue like bone, it decreases bone resorption and bone turnover and increases bone mineral density. Raloxifene hydrochloride acts as an estrogen antagonist in uterine and breast tissue. This agent also exerts an anti-proliferative effect on estrogen-sensitive breast cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-3249-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A6D7EC-5B38-2303-E053-F662850A11B7","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Ranitidine Zantac","valueDescription":"Ranitidine Hydrochloride","ValueMeaning":{"publicId":"6159905","version":"1","preferredName":"Ranitidine Hydrochloride","longName":"6159905","preferredDefinition":"A member of the class of histamine H2-receptor antagonists with antacid activity. Ranitidine is a competitive and reversible inhibitor of the action of histamine, released by enterochromaffin-like (ECL) cells, at the histamine H2-receptors on parietal cells in the stomach, thereby inhibiting the normal and meal-stimulated secretion of stomach acid. In addition, other substances that promote acid secretion have a reduced effect on parietal cells when the H2 receptors are blocked.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ranitidine Hydrochloride","conceptCode":"C66506","definition":"A member of the class of histamine H2-receptor antagonists with antacid activity. Ranitidine is a competitive and reversible inhibitor of the action of histamine, released by enterochromaffin-like (ECL) cells, at the histamine H2-receptors on parietal cells in the stomach, thereby inhibiting the normal and meal-stimulated secretion of stomach acid. In addition, other substances that promote acid secretion have a reduced effect on parietal cells when the H2 receptors are blocked.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A6D7EC-5AF7-2303-E053-F662850A11B7","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A6D7EC-5B10-2303-E053-F662850A11B7","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Ramucirumab, Cyramza","valueDescription":"Ramucirumab","ValueMeaning":{"publicId":"3553252","version":"1","preferredName":"Ramucirumab","longName":"3553252","preferredDefinition":"A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity. Ramucirumab specifically binds to and inhibits VEGFR-2, which may result in an in inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ramucirumab","conceptCode":"C70792","definition":"A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity. Ramucirumab specifically binds to and inhibits VEGFR-2, which may result in an inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6BB9C1D-7980-2974-E040-BB89AD430E5E","latestVersionIndicator":"Yes","beginDate":"2012-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A6D7EC-5B24-2303-E053-F662850A11B7","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Radium 223 dichloride Xofigo","valueDescription":"Radium Chloride Ra-223","ValueMeaning":{"publicId":"3788420","version":"1","preferredName":"Radium Chloride Ra-223","longName":"3788420","preferredDefinition":"A radiopharmaceutic of short-lived radium-223 with potential anti-tumor activity. Radium preferentially binds to and accumulates in bone tissue. The radioisotope radium-223 may kill bone cancer cells through the local emission of high energy alpha particles, thereby potentially decreasing tumor progression in the skeleton.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radium Ra 223 Dichloride","conceptCode":"C62535","definition":"A radiopharmaceutical composed of the dichloride salt of the alpha-emitting isotope radium Ra 223, with antineoplastic activity. Like calcium, radium targets bone tissue and preferentially accumulates in osteoblastic lesions, such as those seen in areas of bone metastases. Radium Ra 223 forms complexes with hydroxyapatite and becomes incorporated into the bone matrix. The radioisotope Ra 223 kills bone cancer cells through local emission of high energy alpha particles, causing DNA double-strand breaks and tumor regression in the skeleton. The short range effects of alpha emission allows for localized DNA damage with limited toxicity to nearby healthy bone tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF80A1B1-CB3D-E6C9-E040-BB89AD4332B0","latestVersionIndicator":"Yes","beginDate":"2013-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A6D7EC-5B4C-2303-E053-F662850A11B7","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"PSC-833 Valspodar","valueDescription":"Valspodar","ValueMeaning":{"publicId":"3379420","version":"1","preferredName":"Valspodar","longName":"3379420","preferredDefinition":"An analogue of cyclosporin-A. Valspodar inhibits p-glycoprotein, the multidrug resistance efflux pump, thereby restoring the retention and activity of some drugs in some drug-resistant tumor cells. This agent also induces caspase-mediated apoptosis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Valspodar","conceptCode":"C1405","definition":"An analogue of cyclosporin-A. Valspodar inhibits p-glycoprotein, the multidrug resistance efflux pump, thereby restoring the retention and activity of some drugs in some drug-resistant tumor cells. This agent also induces caspase-mediated apoptosis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-1FB8-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A6D7EC-5B86-2303-E053-F662850A11B7","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"PS341 Bortezomib Velcade","valueDescription":"Bortezomib","ValueMeaning":{"publicId":"5127395","version":"1","preferredName":"Bortezomib","longName":"5127395","preferredDefinition":"A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bortezomib","conceptCode":"C1851","definition":"A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FA1B-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A6D7EC-5B9A-2303-E053-F662850A11B7","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Prostvac Rilimogene glafolivec","valueDescription":"Rilimogene Galvacirepvec","ValueMeaning":{"publicId":"6159909","version":"1","preferredName":"Rilimogene Galvacirepvec","longName":"6159909","preferredDefinition":"A vaccine formulation consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA) and recombinant vaccinia virus encoding three co-stimulatory molecule transgenes B7.1, ICAM-1, and LFA-3 (TRICOM). Vaccination with PSA in combination with TRICOM may enhance antigen presentation, resulting in the augmentation of a cytotoxic T cell (CTL) immune response against tumor cells expressing PSA.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rilimogene Galvacirepvec","conceptCode":"C38681","definition":"A vaccine formulation consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA) and recombinant vaccinia virus encoding three co-stimulatory molecule transgenes B7.1, ICAM-1, and LFA-3 (TRICOM). Vaccination with PSA in combination with TRICOM may enhance antigen presentation, resulting in the augmentation of a cytotoxic T cell (CTL) immune response against tumor cells expressing PSA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A6D7EC-5BA8-2303-E053-F662850A11B7","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"HARTLEYG","dateModified":"2022-02-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A6D7EC-5BC1-2303-E053-F662850A11B7","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Propantheline Pro-banthine","valueDescription":"Propantheline","ValueMeaning":{"publicId":"6159911","version":"1","preferredName":"Propantheline","longName":"6159911","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Propantheline","conceptCode":"C78077","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A6D7EC-5BCE-2303-E053-F662850A11B7","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A6D7EC-5BE7-2303-E053-F662850A11B7","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Progesterone Prometrium","valueDescription":"Therapeutic Progesterone","ValueMeaning":{"publicId":"6159913","version":"1","preferredName":"Therapeutic Progesterone","longName":"6159913","preferredDefinition":"A synthetic form of the endogenous hormone progesterone.  Progesterone binds to the progesterone receptor, resulting in dissociation of heat shock proteins, receptor phosphorylation, and transcription activation through direct or indirect interaction with transcription factors.  This agent exerts inhibitory effects on estrogens by decreasing the number of estrogen receptors and increasing its metabolism to inactive metabolites.  Progesterone induces secretory changes in the endometrium, decreases uterine contractility during pregnancy, and maintains pregnancy. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Progesterone","conceptCode":"C777","definition":"The therapeutic form of the naturally occurring hormone progesterone.  Progesterone binds to the progesterone receptor, resulting in dissociation of heat shock proteins, receptor phosphorylation, and transcription activation through direct or indirect interaction with transcription factors.  This agent exerts inhibitory effects on estrogens by decreasing the number of estrogen receptors and increasing its metabolism to inactive metabolites.  Progesterone induces secretory changes in the endometrium, decreases uterine contractility during pregnancy, and maintains pregnancy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A6D7EC-5BF4-2303-E053-F662850A11B7","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A6D7EC-5C0D-2303-E053-F662850A11B7","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Procarbazine HCL Methylhydrazine Natulan Matulane","valueDescription":"Procarbazine Hydrochloride","ValueMeaning":{"publicId":"6159914","version":"1","preferredName":"Procarbazine Hydrochloride","longName":"6159914","preferredDefinition":"The hydrochloride salt of a methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Procarbazine Hydrochloride","conceptCode":"C773","definition":"The hydrochloride salt of a methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A6D7EC-5C17-2303-E053-F662850A11B7","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68A6D7EC-5C30-2303-E053-F662850A11B7","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","deletedIndicator":"No"},{"value":"Furosemide Lasix","valueDescription":"Furosemide","ValueMeaning":{"publicId":"2576880","version":"1","preferredName":"Furosemide","longName":"2576880","preferredDefinition":"A sulfamyl saluretic and diuretic. It has a fast onset and short duration of action and is used in edema and chronic renal insufficiency.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Furosemide","conceptCode":"C515","definition":"A sulfamoylanthranilic acid derivative, also known as frusemide, and potent loop diuretic. Furosemide is widely used to treat hypertension and edema. This agent is highly bound to albumin and is largely excreted unchanged in the urine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F95D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D7428F-DF4E-5951-E053-F662850A688B","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","deletedIndicator":"No"},{"value":"Halotestin Fluoxymesterone","valueDescription":"Fluoxymesterone","ValueMeaning":{"publicId":"2576869","version":"1","preferredName":"Fluoxymesterone","longName":"2576869","preferredDefinition":"An anabolic steroid that has been used in the treatment of male hypogonadism, delayed puberty in males, and in the treatment of breast neoplasms in women.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluoxymesterone","conceptCode":"C507","definition":"A halogenated derivative of 17-alpha-methyltestosterone.  Similar to testosterone, fluoxymesterone binds to and activates specific nuclear receptors, resulting in an increase in protein anabolism, a decrease in amino acid catabolism, and retention of nitrogen, potassium, and phosphorus.  This agent also may competitively inhibit prolactin receptors and estrogen receptors, thereby inhibiting the growth of hormone-dependent tumor lines. Fluoxymesterone is approximately five times more potent than methyltestosterone. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F952-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D7428F-DF62-5951-E053-F662850A688B","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","deletedIndicator":"No"},{"value":"Interleukin-21 Recombinant human interleukin-21 RIL-21","valueDescription":"Wildtype","ValueMeaning":{"publicId":"2581323","version":"1","preferredName":"Wildtype","longName":"2581323","preferredDefinition":"The naturally-occuring, normal, non-mutated version of a gene or genome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Denenicokin","conceptCode":"C62492","definition":"A recombinant peptide similar to or identical to endogenous human cytokine interleukin-21 (IL-21) with potential antineoplastic activity. Denenicokin binds to and activates IL-21 receptors, expressed on T-cells, B-cells, dendritic cells (DC), and natural killer (NK) cells, modulating the proliferation and/or differentiation of T and B cells, promoting T cell survival, and increasing the cytolytic activity of cytotoxic T lymphocytes (CTLs) and NK cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0AB8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-10","endDate":null,"createdBy":"UMLLOADER_CGOM","dateCreated":"2006-10-20","modifiedBy":"CURTIST","dateModified":"2006-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D7428F-DF76-5951-E053-F662850A688B","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","deletedIndicator":"No"},{"value":"Interleukin-3 IL3","valueDescription":"Interleukin-3","ValueMeaning":{"publicId":"2578189","version":"1","preferredName":"Interleukin-3","longName":"2578189","preferredDefinition":"Human interleukin-3 (152 aa, 17 kDa precursor) is encoded by the human interleukin-3 (IL3) gene. This protein is a potent growth-promoting cytokine that enhances the ability of the immune system to fight tumor cells. IL-3 supports proliferation of many hematopoietic cell types. It is involved in cell growth, differentiation and apoptosis in addition to possessing neurotrophic activity. Abnormalities in this protein may be associated with neurologic disorders.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interleukin-3","conceptCode":"C20439","definition":"Interleukin-3 (152 aa, ~17 kDa) is encoded by the human IL3 gene. This protein plays a role in neurotrophic activity and the proliferation of several types of hematopoietic lineage cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE7A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D7428F-DF8A-5951-E053-F662850A688B","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","deletedIndicator":"No"},{"value":"Interleukin-4 IL4","valueDescription":"Interleukin-4","ValueMeaning":{"publicId":"6159861","version":"1","preferredName":"Interleukin-4","longName":"6159861","preferredDefinition":"Interleukin-4 (153 aa, ~17 kDa) is encoded by the human IL4 gene. This protein is involved in the regulation of the expression of class II MHC molecules, Fc receptors and cell surface-bound immunoglobulins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interleukin-4","conceptCode":"C20508","definition":"Interleukin-4 (153 aa, ~17 kDa) is encoded by the human IL4 gene. This protein is involved in the regulation of the expression of class II MHC molecules, Fc receptors and cell surface-bound immunoglobulins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A77B6F-531E-2619-E053-F662850A3197","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D7428F-DF9E-5951-E053-F662850A688B","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","deletedIndicator":"No"},{"value":"Nilutamide Anandron Nilandron","valueDescription":"Nilutamide","ValueMeaning":{"publicId":"2573402","version":"1","preferredName":"Nilutamide","longName":"2573402","preferredDefinition":"A drug that blocks the effects of male hormones in the body. It is a type of antiandrogen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nilutamide","conceptCode":"C1173","definition":"A synthetic, nonsteroidal agent with antiandrogenic properties. Nilutamide preferentially binds to androgen receptors and blocks androgen receptor activation by testosterone and other androgens; this agent may inhibit androgen-dependent growth of normal and neoplastic prostate cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EBC7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-11","modifiedBy":"COOPERM","dateModified":"2016-08-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D7428F-DFB2-5951-E053-F662850A688B","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","deletedIndicator":"No"},{"value":"Nozinan Methotrimeprazine Levoprome","valueDescription":"Levomepromazine","ValueMeaning":{"publicId":"6159886","version":"1","preferredName":"Levomepromazine","longName":"6159886","preferredDefinition":"A phenothiazine and typical antipsychotic agent, with sedative/hypnotic, anxiolytic, antiemetic, analgesic and antipsychotic activities. Although the exact mechanism of action of levomepromazine is not fully known, upon administration, this agent appears to act as an antagonist for a variety of receptors in the central nervous system (CNS), including adrenergic, dopamine, histamine, cholinergic and serotonin (5-hydroxytryptamine; 5-HT) receptors. Blocking these receptors results in levomepromazine's pharmacologic effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Levomepromazine","conceptCode":"C66118","definition":"A phenothiazine and typical antipsychotic agent, with sedative/hypnotic, anxiolytic, antiemetic, analgesic and antipsychotic activities. Although the exact mechanism of action of levomepromazine is not fully known, upon administration, this agent appears to act as an antagonist for a variety of receptors in the central nervous system (CNS), including adrenergic, dopamine, histamine, cholinergic and serotonin (5-hydroxytryptamine; 5-HT) receptors. Blocking these receptors results in levomepromazine's pharmacologic effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A540C7-4BF7-0CA2-E053-F662850A07D0","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D7428F-DFC6-5951-E053-F662850A688B","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","deletedIndicator":"No"},{"value":"Ofatumumab Arzerra","valueDescription":"Ofatumumab","ValueMeaning":{"publicId":"3243442","version":"1","preferredName":"Ofatumumab","longName":"3243442","preferredDefinition":"A fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. Ofatumumab binds specifically to CD20 on the surfaces of B cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B cells overexpressing CD20. The CD20 antigen, found on over 90% of B cells, B cell lymphomas, and other B cells of lymphoid tumors of B cell origin, is a non-glycosylated cell surface phosphoprotein that acts a calcium ion channel; it is exclusively expressed on B cells during most stages of B cell development.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ofatumumab","conceptCode":"C66952","definition":"A fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. Ofatumumab binds specifically to CD20 on the surfaces of B cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B cells overexpressing CD20. The CD20 antigen, found on over 90% of B cells, B cell lymphomas, and other B cells of lymphoid tumors of B cell origin, is a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel; it is exclusively expressed on B cells during most stages of B cell development.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A55A32E7-3256-D7C0-E040-BB89AD437508","latestVersionIndicator":"Yes","beginDate":"2011-06-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-06-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D7428F-DFDA-5951-E053-F662850A688B","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","deletedIndicator":"No"},{"value":"Piperazine","valueDescription":"Piperazine","ValueMeaning":{"publicId":"6159898","version":"1","preferredName":"Piperazine","longName":"6159898","preferredDefinition":"A cyclic organic compound possessing two nitrogen atoms in opposite positions within a 6-member heterocyclic ring that serves as a backbone for piperazine derivatives and acts as a gamma-amino-butyric acid (GABA) receptor agonist in nematodes, with potential anti-helminthic activity. Upon administration, piperazine binds to the GABA inhibitory receptors in susceptible nematodes, thereby inducing chloride channel opening and hyperpolarization. This results in paralysis of the worm musculature and allows normal peristalsis to dislodge the worm from the intestinal lumen, which causes the worm to be expelled from the body. Unlike vertebrates where GABA is restricted to the central nervous system (CNS), the GABA receptors in helminths are also expressed in the peripheral nervous system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Piperazine","conceptCode":"C61892","definition":"A cyclic organic compound possessing two nitrogen atoms in opposite positions within a 6-member heterocyclic ring that serves as a backbone for piperazine derivatives and acts as a gamma-amino-butyric acid (GABA) receptor agonist in nematodes, with potential anti-helminthic activity. Upon administration, piperazine binds to the GABA inhibitory receptors in susceptible nematodes, thereby inducing chloride channel opening and hyperpolarization. This results in paralysis of the worm musculature and allows normal peristalsis to dislodge the worm from the intestinal lumen, which causes the worm to be expelled from the body. Unlike vertebrates where GABA is restricted to the central nervous system (CNS), the GABA receptors in helminths are also expressed in the peripheral nervous system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68AD6E55-A8ED-3C96-E053-F662850A17E8","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D7428F-DFEE-5951-E053-F662850A688B","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","deletedIndicator":"No"},{"value":"Plasmapheresis","valueDescription":"Plasmapheresis","ValueMeaning":{"publicId":"6159897","version":"1","preferredName":"Plasmapheresis","longName":"6159897","preferredDefinition":"The process of separating certain cells from the plasma in the blood by a machine; only the cells are returned to the person. Plasmapheresis can be used to remove excess antibodies from the blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plasmapheresis","conceptCode":"C15304","definition":"A procedure that collects plasma from the peripheral blood while returning the rest to the donor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68AD6E55-A8BE-3C96-E053-F662850A17E8","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D7428F-E002-5951-E053-F662850A688B","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","deletedIndicator":"No"},{"value":"Sirolimus, Rapamycin, Rapamune","valueDescription":"Sirolimus","ValueMeaning":{"publicId":"5127411","version":"1","preferredName":"Sirolimus","longName":"5127411","preferredDefinition":"A drug used to keep the body from rejecting organ and bone marrow transplants. Rapamune blocks certain white blood cells that can reject foreign tissues and organs. It also blocks a protein that is involved in cell division. It is a type of antibiotic, a type of immunosuppressant, and a type of serine/threonine kinase inhibitor. Rapamune was previously called rapamycin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sirolimus","conceptCode":"C1212","definition":"A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FA4E-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D7428F-E016-5951-E053-F662850A688B","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","deletedIndicator":"No"},{"value":"Teniposide VM26 Vumon","valueDescription":"Teniposide","ValueMeaning":{"publicId":"2739552","version":"1","preferredName":"Teniposide","longName":"2739552","preferredDefinition":"An anticancer drug that is a podophyllotoxin derivative and belongs to the family of drugs called mitotic inhibitors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Teniposide","conceptCode":"C857","definition":"A semisynthetic derivative of podophyllotoxin with antineoplastic activity. Teniposide forms a ternary complex with the enzyme topoisomerase II and DNA, resulting in dose-dependent single- and double-stranded breaks in DNA, DNA: protein cross-links, inhibition of DNA strand religation, and cytotoxicity. This agent acts in the late S or early G phase of the cell cycle. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A7528ED-026F-5EF5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D7428F-E02A-5951-E053-F662850A688B","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","deletedIndicator":"No"},{"value":"Topotecan Hycamtin","valueDescription":"Topotecan","ValueMeaning":{"publicId":"3380233","version":"1","preferredName":"Topotecan","longName":"3380233","preferredDefinition":"A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata. Topotecan inhibits topoisomerase I activity by stabilizing the topoisomerase I-DNA covalent complexes during S phase of cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Topotecan","conceptCode":"C1413","definition":"A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata. Topotecan inhibits topoisomerase I activity by stabilizing the topoisomerase I-DNA covalent complexes during S phase of cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97B8401-1648-113F-E040-BB89AD431AAC","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D7428F-E03E-5951-E053-F662850A688B","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","deletedIndicator":"No"},{"value":"Tositumomab Bexxar Iodine I131 tositumomab","valueDescription":"Iodine I 131 Tositumomab","ValueMeaning":{"publicId":"3377416","version":"1","preferredName":"Iodine I 131 Tositumomab","longName":"3377416","preferredDefinition":"A monoclonal antibody (tositumomab) that has been chemically changed by adding radioactive iodine, and that is used in the treatment of certain types of non-Hodgkin lymphoma. It belongs to the family of drugs called radioconjugated monoclonal antibodies. When iodine I 131 tositumomab and tositumomab are given together, the combination is called the Bexxar regimen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Iodine I 131 Tositumomab","conceptCode":"C2444","definition":"A monoclonal antibody directed against the CD20 protein expressed on the surface of B-lymphocytes and radiolabeled with the radioisotope iodine I 131 with potential antineoplastic activity. Iodine I 131 tositumomab binds to and selectively delivers cyctotoxic radiation to CD20-expressing B-lymphocytes, thereby minimizing systemic radiotoxicity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DFB740-1BC8-299D-E040-BB89AD430A5E","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D7428F-E052-5951-E053-F662850A688B","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","deletedIndicator":"No"},{"value":"Zoledronate Zoledronic acid Zometa","valueDescription":"Zoledronic Acid","ValueMeaning":{"publicId":"5709612","version":"1","preferredName":"Zoledronic Acid","longName":"5709612","preferredDefinition":"A drug used to treat patients with hypercalcemia (high blood levels of calcium) caused by cancer. It is also used together with other drugs to treat multiple myeloma and to prevent bone fractures and reduce bone pain in people who have cancer that has spread to the bone. It is a type of bisphosphonate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zoledronic Acid","conceptCode":"C1699","definition":"A synthetic imidazole bisphosphonate analog of pyrophosphate with anti-bone-resorption activity. A third-generation bisphosphonate, zoledronic acid binds to hydroxyapatite crystals in the bone matrix, slowing their dissolution and inhibiting the formation and aggregation of these crystals. This agent also inhibits farnesyl pyrophosphate synthase, an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids, donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which are important in the process of osteoclast turnover. Decreased bone turnover and stabilization of the bone matrix contribute to the analgesic effect of zoledronic acid with respect to painful osteoblastic lesions. The agent also reduces serum calcium concentrations associated with hypercalcemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AA0A7DB-1D43-7C8E-E053-F662850A3136","latestVersionIndicator":"Yes","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"COLBERTM","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":"1/2/24 Added Zometa as alt name for PCDC. mr","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68D7428F-E066-5951-E053-F662850A688B","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","deletedIndicator":"No"},{"value":"Melphalan Alkeran Phenylalanine mustard","valueDescription":"Melphalan Hydrochloride Melphalan","ValueMeaning":{"publicId":"6160035","version":"1","preferredName":"Melphalan Hydrochloride Melphalan","longName":"6160035","preferredDefinition":"A bifunctional alkylating agent and phenylalanine derivative of nitrogen mustard. Melphalan hydrochloride is converted into highly reactive ethylenimmonium intermediates that induce covalent guanine N7-N7 intra- and inter-crosslinks and alkylation of adenine N3 of DNA. This agent also alkylates RNA and protein structures. As a result RNA transcription and protein synthesis are inhibited, ultimately leading to cell growth arrest and/or death.: A phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melphalan Hydrochloride","conceptCode":"C48002","definition":"A bifunctional alkylating agent and phenylalanine derivative of nitrogen mustard. Melphalan hydrochloride is converted into highly reactive ethylenimmonium intermediates that induce covalent guanine N7-N7 intra- and inter-crosslinks and alkylation of adenine N3 of DNA. This agent also alkylates RNA and protein structures. As a result RNA transcription and protein synthesis are inhibited, ultimately leading to cell growth arrest and/or death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Melphalan","conceptCode":"C633","definition":"A phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68E3D2BE-CC7E-3F5E-E053-F662850A05E0","latestVersionIndicator":"Yes","beginDate":"2018-04-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68E3D2BE-CC97-3F5E-E053-F662850A05E0","beginDate":"2018-04-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","deletedIndicator":"No"},{"value":"LY231514 TS inhibitor MTA Pemetrexed Alimta","valueDescription":"Pemetrexed Disodium Pemetrexed","ValueMeaning":{"publicId":"6160037","version":"1","preferredName":"Pemetrexed Disodium Pemetrexed","longName":"6160037","preferredDefinition":"The disodium salt of a synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS) which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.: A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pemetrexed Disodium","conceptCode":"C1533","definition":"The disodium salt of a synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS) which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pemetrexed","conceptCode":"C61614","definition":"A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68E3D2BE-CCA5-3F5E-E053-F662850A05E0","latestVersionIndicator":"Yes","beginDate":"2018-04-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68E3D2BE-CCBE-3F5E-E053-F662850A05E0","beginDate":"2018-04-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","deletedIndicator":"No"},{"value":"L-throxine Levothroxine sodium Synthroid Levoxyl Unithroid Levothroid","valueDescription":"Levothyroxine Sodium Levothyroxine","ValueMeaning":{"publicId":"6160038","version":"1","preferredName":"Levothyroxine Sodium Levothyroxine","longName":"6160038","preferredDefinition":"The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.: A synthetic levoisomer of thyroxine (T4), similar to the endogenous hormone produced by the thyroid gland. Thyroxine is de-iodinated to form triiodothyronine (T3) in the peripheral tissues. T3 enters the cell and binds to nuclear thyroid hormone receptors, and the hormone-receptor complex in turn triggers gene expression and produces proteins required in the regulation of cellular respiration, thermogenesis, cellular growth and differentiation, and metabolism of proteins, carbohydrates and lipids. T4 and T3 also possess cardiac stimulatory effect.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Levothyroxine Sodium","conceptCode":"C888","definition":"The sodium salt of levothyroxine, a synthetic levoisomer of thyroxine (T4) that is similar to the endogenous hormone produced by the thyroid gland. In peripheral tissues, levothyroxine is deiodinated by 5'-deiodinase to form triiodothyronine (T3). T3 enters the cell and binds to nuclear thyroid hormone receptors; the activated hormone-receptor complex in turn triggers gene expression and produces proteins required in the regulation of cellular respiration; thermogenesis; cellular growth and differentiation; and the metabolism of proteins, carbohydrates and lipids. T3 also exhibits cardiostimulatory effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Levothyroxine","conceptCode":"C62080","definition":"A synthetic levoisomer of thyroxine (T4), similar to the endogenous hormone produced by the thyroid gland. Thyroxine is de-iodinated to form triiodothyronine (T3) in the peripheral tissues. T3 enters the cell and binds to nuclear thyroid hormone receptors, and the hormone-receptor complex in turn triggers gene expression and produces proteins required in the regulation of cellular respiration, thermogenesis, cellular growth and differentiation, and metabolism of proteins, carbohydrates and lipids. T4 and T3 also possess cardiac stimulatory effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68E3D2BE-CCCB-3F5E-E053-F662850A05E0","latestVersionIndicator":"Yes","beginDate":"2018-04-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68E3D2BE-CCE4-3F5E-E053-F662850A05E0","beginDate":"2018-04-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","deletedIndicator":"No"},{"value":"Interleukin - type unknown","valueDescription":"Interleukin Type Unknown","ValueMeaning":{"publicId":"6160039","version":"1","preferredName":"Interleukin Type Unknown","longName":"6160039","preferredDefinition":"Interleukin is the generic name for a group of well-characterized cytokines that are produced by leukocytes and other cell types.  They have a broad spectrum of functional activities that regulate the activities and capabilities of a wide variety of cell types.  They are particularly important as members of the cytokine networks that regulate inflammatory and immune responses.: Something distinguishable as an identifiable class based on common qualities.: Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interleukin","conceptCode":"C20497","definition":"Interleukin is the generic name for a group of well-characterized cytokines that are produced by leukocytes and other cell types.  They have a broad spectrum of functional activities that regulate the activities and capabilities of a wide variety of cell types.  They are particularly important as members of the cytokine networks that regulate inflammatory and immune responses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68E3D2BE-CCF2-3F5E-E053-F662850A05E0","latestVersionIndicator":"Yes","beginDate":"2018-04-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68E3D2BE-CD0B-3F5E-E053-F662850A05E0","beginDate":"2018-04-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","deletedIndicator":"No"},{"value":"Interferon-alfa Roferon-A Intron A","valueDescription":"Interferon Alpha Recombinant Interferon Alfa-2a Recombinant Interferon Alfa-2b","ValueMeaning":{"publicId":"6160042","version":"1","preferredName":"Interferon Alpha Recombinant Interferon Alfa-2a Recombinant Interferon Alfa-2b","longName":"6160042","preferredDefinition":"A class of interferon (leukocyte interferon) produced predominantly by B lymphocytes.  Located in a cluster on 9p22 there are at least 13 functional genes and 1 pseudogene.: A non-glycosylated recombinant human alpha interferon, subtype 2a, produced in the bacterium E. coli.  Interferon alpha-2a binds to its specific cell-surface receptor, resulting in the transcription and translation of genes whose protein products have antiviral, antiproliferative, anticancer, and immune modulating effects. (NCI04): A non-glycosylated recombinant interferon with antiviral and antineoplastic activities. Alfa interferons bind to specific cell-surface receptors, resulting in the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interferon Alpha","conceptCode":"C20494","definition":"A class of interferon (leukocyte interferon) produced predominantly by B lymphocytes.  Located in a cluster on 9p22 there are at least 13 functional genes and 1 pseudogene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Recombinant Interferon Alfa-2a","conceptCode":"C1952","definition":"A non-glycosylated recombinant human alpha interferon, subtype 2a, produced in the bacterium E. coli.  Interferon alpha-2a binds to its specific cell-surface receptor, resulting in the transcription and translation of genes whose protein products have antiviral, antiproliferative, anticancer, and immune modulating effects. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Recombinant Interferon Alfa-2b","conceptCode":"C1953","definition":"A non-glycosylated recombinant interferon with antiviral and antineoplastic activities. Alfa interferons bind to specific cell-surface receptors, resulting in the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68E3D2BE-CD1B-3F5E-E053-F662850A05E0","latestVersionIndicator":"Yes","beginDate":"2018-04-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68E3D2BE-CD34-3F5E-E053-F662850A05E0","beginDate":"2018-04-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","deletedIndicator":"No"},{"value":"Interferon - type unknown","valueDescription":"Interferon Type Unknown","ValueMeaning":{"publicId":"6160043","version":"1","preferredName":"Interferon Type Unknown","longName":"6160043","preferredDefinition":"Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570): Something distinguishable as an identifiable class based on common qualities.: Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interferon","conceptCode":"C20493","definition":"Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68E3D2BE-CD42-3F5E-E053-F662850A05E0","latestVersionIndicator":"Yes","beginDate":"2018-04-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68E3D2BE-CD5B-3F5E-E053-F662850A05E0","beginDate":"2018-04-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3629877","version":"1","preferredName":"Therapeutic Procedure Name","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.:The words or language units by which a thing is known.","longName":"C49236:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CEF54A49-4A73-0AB2-E040-BB89AD431994","latestVersionIndicator":"Yes","beginDate":"2012-11-20","endDate":null,"createdBy":"KNUTSOND","dateCreated":"2012-11-20","modifiedBy":"ONEDATA","dateModified":"2012-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CES-D:Center for Epidemiologic Studies Depression Scale. Radloff, L.S., Applied Psychological Measurement, 1:385-401, 1977.","workflowStatus":"RELEASED","registrationStatus":"Application","id":"682DF2C6-76F7-47D7-E053-F662850A61D2","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"CLOHNES","dateModified":"2023-05-22","changeDescription":"11/26/18 TT released/CWinch. 3/24/27 tt/MA39.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"TRT_NAM","type":"USED_BY","context":"CCTG"},{"name":"CM_CMDECOD_NEWTX","type":"OID, CCTG","context":"CCTG"}],"ReferenceDocuments":[{"name":"CCTG - 1","type":"Alternate Question Text","description":"If systemic therapy, treatment name","url":null,"context":"CCTG"},{"name":"Drug/Agent Name","type":"Preferred Question Text","description":"Drug/Agent Name","url":null,"context":"CCTG"},{"name":"CCTG_02","type":"Alternate Question Text","description":"Treatment Name","url":null,"context":"CCTG"},{"name":"CCTG_03","type":"Alternate Question Text","description":"Treatment name","url":null,"context":"CCTG"}],"origin":"CCTG: Canadian Cancer Trials Group","workflowStatus":"RELEASED","registrationStatus":"Application","id":"692F102C-902F-2A09-E053-F662850A9C0C","latestVersionIndicator":"Yes","beginDate":"2018-04-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-06","modifiedBy":"CLOHNES","dateModified":"2023-02-23","changeDescription":"11/26/18 TT released/CWinch. 4/6/18 tt/MA39.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}